This edition of Forum examines network effects in the electric vehicle market, the collapse of Silicon Valley Bank, and the future of survey evidence after the US Supreme Court’s Jack Daniel’s decision.
Writing with Professor Giuseppe Colangelo (University of Basilicata), Analysis Group Senior Advisor Eliana Garcés has published a white paper on “Markets, Competition, and Fairness” on SSRN.
Professor Hart is a leading expert in contract theory, the theory of the firm, and corporate finance. In 2016, he and Professor Bengt Holmström were awarded the Nobel Prize in Economics for their work in contract theory. Professor Hart’s research centers on the roles that ownership structure and contractual arrangements play in the governance and boundaries of corporations. His recent work involves determining how parties can write better contracts, as well as how a new model of corporate governance can better incorporate the importance shareholders place on nonfinancial criteria.
Professor Hart has consulted to businesses and government entities, and provided expert testimony on contract and governance disputes in which he has evaluated the business purpose and economic substance of special purpose entities. As an expert on behalf of Qualcomm in Apple v. Qualcomm, he provided guidance on the optimal structure of contracts, and why and when they should be enforced. His book Firms, Contracts, and Financial Structure is a leading work in the fields of contract theory and corporate finance. He has published widely in peer-reviewed journals and contributed to the Financial Times and The Wall Street Journal. Professor Hart is a member of the IGM (Initiative on Global Markets) Economics Experts Panel of The University of Chicago Booth School of Business, and is affiliated with the Program on Corporate Governance at Harvard Law School’s John M. Olin Center for Law, Economics, and Business. He is a past president of the American Law and Economics Association.
)Professor Baker is an expert in health care economics, including the effects of regulation on health care markets, physician market structure, the effects of managed care and insurance market competition on health care delivery and spending, and the determinants and impact of medical technology adoption. He has served as a consultant and advisor to health plans, government programs and public initiatives, and firms providing health care services and developing new health care products. Professor Baker’s research has been published in leading academic journals, including JAMA, The New England Journal of Medicine, American Economic Review, and the Journal of Health Economics. He is an elected member of the National Academy of Medicine and the recipient of the American Society of Health Economists’ ASHEcon Medal, which recognizes the top American health economists age 40 or under. Professor Baker’s studies of the relationships between area characteristics and health care delivery have twice won the NIHCM Foundation Health Care Research Award.
)Ms. Comeaux specializes in the application of finance and economics to complex business litigation and damages estimation. She has led teams across a broad range of matters involving commercial disputes, antitrust and competition, and securities and finance. Her clients include leading media and technology companies, financial institutions, global manufacturers, and life sciences companies. Ms. Comeaux has provided assistance through all phases of pretrial and trial practice, including expert search, fact discovery, class certification, quantification and rebuttal of damages, expert testimony, trial preparation, and settlement negotiations. She has also assisted clients in mass arbitration proceedings, regulatory investigations, and strategy engagements.
Ms. Comeaux has experience with a wide range of empirical methodologies, particularly within the context of damages analyses. Her work regularly involves critical examination of theories of liability, development of models to quantify damages, and both quantitative and qualitative analyses in response to allegations of negligence or punitive damages. She has worked with a wide variety of academic and industry experts to assess organizational, industry, and market conditions in order to contextualize analyses of damages. Ms. Comeaux has particular expertise in organizational assessments that address theories of liability, including reviewing and responding to the results of assessments conducted by regulators and third parties.
)Professor Reuter specializes in examining the behavior of individual investors and financial institutions, including mutual fund families, investment banks, rating agencies, financial advisors, and the financial media. His work focuses on the value of financial advice, the strategic behavior of target-date retirement funds, and portfolio management outsourcing in the mutual fund industry. In addition to his academic experience, Professor Reuter has served as an expert in a mutual fund fee litigation, filing an expert report and testifying at deposition. He has also provided testimony to the US Department of Labor (DOL), which summarized his research on the behavior of brokers and broker-sold mutual funds.
Professor Reuter has published a number of articles on topics such as mutual fund performance, the effect of pension design on employer costs and employee retirement choices, and the effect of advertising on product reviews. This research has been published in leading academic journals, including The Journal of Finance and The Quarterly Journal of Economics; mentioned in media outlets such as The New York Times and The Wall Street Journal; and cited by the President’s Council of Economic Advisers and the DOL. Professor Reuter also serves as an editorial board member of the Journal of Pension Economics and Finance. He is a research associate at the National Bureau of Economic Research (NBER) and a fellow at the TIAA Institute.
)Dr. Chapsal is an economist who specializes in empirical and theoretical industrial organization. He has provided economic expertise in a large number of high-profile cases involving mergers, cartels, information exchanges, abuses of dominant positions, regulation, intellectual property matters, and damages quantifications. Recent examples include the Lafarge/Holcim and Fnac/Darty mergers, as well as airfreight, cathode ray tube, and elevator cartel cases. Dr. Chapsal has also assisted various firms in designing optimized pricing strategies and dealing with policy issues. His reports have been presented to the competition authorities of France, Germany, Austria, and South Africa; the European Commission; the Higher Regional Court of Düsseldorf; and the Court of Appeals, Conseil d’Etat, Conseil constitutionnel, and Tribunal of Commerce of Paris.
Prior to joining Analysis Group, Dr. Chapsal founded MAPP, a Paris- and Brussels-based economic consultancy, which was acquired by KPMG in 2018. Previously, he worked in a US competition economics consultancy. Dr. Chapsal regularly publishes articles on competition economics, on subjects ranging from the econometric analysis of cartels to geographic market delineation and exclusionary strategies. He is an affiliated professor at the Sciences Po Department of Economics and a member of the CESifo academic research network.
)Mr. Malinak specializes in financial economics, with particular expertise in damages estimation, applied finance theory, and business and asset valuation. He has provided deposition, arbitration, and trial testimony on economic damages and valuation issues, and has testified on financial integrity, the cost of capital, and economic issues in utility rate hearings and at a Federal Energy Regulatory Commission (FERC) hearing. Mr. Malinak has directed litigation projects in many industries on issues related to securities (including derivative securities), antitrust, breach of contract, taxation, regulatory economics, and intellectual property claims. He has frequently addressed class certification and damages issues in securities fraud cases, as well as the myriad economic, financial, and accounting issues common to most damages calculations, such as cost of capital and prejudgment interest. Mr. Malinak has significant experience in tax-related work, including leading Analysis Group teams in Black & Decker, Inc. v. United States and Chemtech Royalty Associates L.P. v. United States, as well as in financial institutions and risk management, having led consulting teams supporting experts in the Winstar savings and loan litigations. He also completed a major project on the risk of Fannie Mae, resulting in a white paper authored by an academic affiliate. He has served as treasurer, head of the audit and finance committee, and a member of the executive committee and board of directors of the Meridian International Center, an international leadership organization that works with partners in the government, private, NGO, and educational sectors to create lasting international partnerships through leadership programs and cultural exchanges. Prior to joining Analysis Group, Mr. Malinak was a principal at Putnam, Hayes & Bartlett.
)Dr. Brackley is board certified in internal medicine and an expert in patient and medical safety. Her deep knowledge of clinical trial management includes clinical events committees and safety event reviews, as well as pharmacovigilance, post-market processes, field actions, and risk management. She has consulted on these issues to medical device, diagnostic, and pharmaceutical companies for over a decade. Dr. Brackley’s expert experience includes providing medical insight, post-market surveillance, and pharmacovigilance expertise in complex legal matters, in which she has submitted expert reports and testified at deposition; supporting legal teams in their review and understanding of complex medical and epidemiological issues; and reviewing medical records, complaints, and regulatory submissions. She has provided safety oversight and medical review expertise in clinical studies, and developed processes for clinical trial adjudication and data safety monitoring boards. In addition, Dr. Brackley has created strategies for developing and optimizing medical safety groups in the medical device, diagnostic, and pharmaceutical industries, including processes, procedures, organizational structure, implementation, and rollout. Earlier in her career, as a vice president and medical safety officer at Boston Scientific, she provided safety oversight and safety vigilance throughout the product life cycle and was involved in strategic decision making across all products worldwide. Prior to her roles in industry, Dr. Brackley completed a residency in internal medicine. She is a member of the American Medical Association, the Massachusetts Medical Society, and the Regulatory Affairs Professionals Society.
)Ms. Comstock has extensive experience applying economic and financial analyses to litigation and other complex business situations. She has assisted clients in all phases of the litigation process, including fact and expert discovery, trial preparation, and settlement negotiations. Ms. Comstock’s case work has involved litigation related to the high-profile bankruptcies of several firms. She has provided consulting support and supported experts in cases related to the alleged manipulation of different benchmark rates, including evaluations of the effects of alleged manipulation on the value of different derivatives and securities. She has also provided consulting and expert support in matters involving alleged violations of Rule 10b-5 and Section 11, and on matters related to mortgage-backed securities. Ms. Comstock has supported experts in ERISA-related litigations, alleged breach of contract matters, and other business and valuation disputes.
)Mr. Beach has more than 30 years of experience valuing businesses; rendering fairness opinions; and negotiating, structuring, and closing mergers and acquisitions (M&A), financings, strategic alliances, and joint ventures. During his career, he has closed over 100 M&A transactions and over 100 financings for companies in the technology, health care, consumer products, and financial services industries. He has frequently served as an expert witness in complex litigation matters involving shareholder rights and valuation, and has testified several times in Delaware Chancery Court. As founder and president of Business Consulting Group, LLC, Mr. Beach oversees the firm’s valuation and advisory work for corporate transactions. Earlier in his career, Mr. Beach was head of corporate finance for KPMG and head of investment banking at Advest, Inc. In addition, he was president and co-founder of Boston Corporate Finance, a boutique investment banking firm focused on providing M&A, capital-raising, and general advisory services to global companies in the technology sector. He has served on the board of numerous companies and organizations, and has advised many companies on their strategic development and direction. Mr. Beach has been a guest lecturer at Harvard Business School, Cornell University, and Dartmouth College. He has been a certified public accountant and is a registered principal with the Financial Industry Regulatory Authority (FINRA).
)Mr. Hille has more than 30 years of experience in investment management. In his former role as chief investment officer at Texas Christian University (TCU), he was responsible for the day-to-day management of its multibillion-dollar investment program, which includes the operation and fiduciary oversight of the university’s endowment assets. His responsibilities also included implementing approved investment policies; developing investment processes and procedures for risk management and asset allocation, monitoring, and evaluation; investment manager selection and termination; and identifying management strategies to improve the program’s investment performance and efficiency. Prior to joining TCU, Mr. Hille was chief investment officer of the Teacher Retirement System of Texas, the state’s largest public pension plan. Earlier in his career, he managed portfolios for the Employees Retirement System of Texas. He currently serves on the investment advisory and trustee boards of the Employees Retirement System of Texas and the Texas Treasury Safekeeping Trust Company, as well as on the board of trustees of the Communities Foundation of Texas. Mr. Hille has served as president of the Austin Society of Financial Analysts and as an adjunct professor of finance at the University of Texas McCombs School of Business. He is a Chartered Financial Analyst (CFA) and Chartered Alternative Investment Analyst (CAIA) charterholder.
)
Mr. Richard has more than 20 years of experience in institutional money management. He was a founder of Taurus Horizon Fund, where he was a managing partner and fund manager for the strategy. Previously, he served at State Street Global Advisors as a senior fixed-income portfolio manager. The assets under his management exceeded $15 billion dollars. Mr. Richard's investment expertise spans a variety of security types, including unsecured corporate credit and securitized structures (such as ABS, MBS, CMBS, and CDO). Over his career, Mr. Richard has also taken an active role in trading securities and performing due-diligence credit work on underlying collateral.
Mr. Richard has provided expert reports, rebuttal reports, deposition testimony, and trial testimony in a number of securities-related cases, opining on issues related to valuation, portfolio manager due diligence, investment suitability, and market conditions, among others. He has served as an expert witness in securities litigation in which he analyzed structured investment vehicles (SIV) on behalf of a large investment bank, and has opined on issues related to the residential mortgage-backed security (RMBS) market. He has also provided consulting services on matters related to auction-rate securities and embedded swap agreements within structured finance instruments. He is a Chartered Financial Analyst and a member of the Boston Security Analysts Society.
)For more than 25 years, Mr. Christensen has worked on high-stakes litigation matters with world-class experts, supporting their testimony at both bench and jury trials. His work has focused on valuation and appraisal matters, private equity disputes, antitrust and consent decree litigations, bankruptcy, and tax and transfer pricing dispute resolutions. Through his extensive experience, he has developed a deep understanding of the high-tech, digital advertising, pharmaceutical, media and entertainment, and finance industries. In addition to his litigation work, Mr. Christensen has also assisted in the preparation of numerous impact studies in the high-tech space on issues such as cloud computing and storage, broadband availability, virtual and augmented reality, artificial intelligence, and the metaverse. His clients have included Meta/Facebook, Google, GSK, AstraZeneca, JAB Holding Company, Bank of America, BNP, and Fidelity. Among his engagements are high-tech antitrust matters, a GSK transfer pricing dispute, the Nortel Networks bankruptcy, Delaware appraisal trial victories involving PetSmart and Panera, and rate-setting trials for BMI. Mr. Christensen is a CFA charterholder.
)Professor Christoffersen’s research focuses on mutual funds, hedge funds, and the role of financial institutions in capital markets. She has been retained as an expert in litigation matters to address topics such as mutual fund market timing and trading strategy issues. She has published in a number of finance journals, and her work has been cited in The New York Times, the International Herald Tribune, Bloomberg News, and The Wall Street Journal. Professor Christoffersen has received grants from Canada’s Social Sciences and Humanities Research Council, the Montreal Financial Mathematics Institute, and the Quebec Research Funds, as well as research awards from Q Group, the Bank of Canada, the BSI Gamma Foundation, INQUIRE, and the Swiss Finance Institute. Prior to joining the faculty at the University of Toronto, she held positions at McGill University, Copenhagen Business School, and the Department of Finance Canada.
)Mr. McLean specializes in applying finance and economics to problems in complex business litigation, including securities, valuation, tax, and intellectual property (IP) matters. His experience spans several industries, from banking, insurance, and high tech to telecommunications and health care. He has served as an expert witness, and has provided assistance in many phases of litigation, including development, presentation, and review of pretrial discovery; preparation of testimony; and critique of analyses of opposing experts.
Mr. McLean’s case work has included general damages analyses, lost profit and reasonable royalty calculations related to IP misappropriation, and assessments of fiduciary duties and investment management. In addition, he has evaluated the economic characteristics and risk transfer of a range of financial instruments, such as private mortgage insurance, subprime loans, and preferred equity in a new venture. He has led large case teams in a number of high-profile matters, including consulting to the US Department of Justice (DOJ) regarding the financial issues involved in tribal trust fund disputes, and supporting counsel for a large electronics manufacturer in litigation associated with features on smartphones and tablets.
In addition, Mr. McLean has presented on topics related to damages assessment and patents. He has also worked with entrepreneurial companies, helping to develop financial projections, business plans, and marketing strategies.
)Professor Hubbard is a leading expert in public economics, corporate and institutional finance, macroeconomics, antitrust, and industrial organization. He has provided trial and deposition testimony in numerous litigation matters, including more than a dozen cases in the Delaware Chancery Court. He has also served as a testifying expert in several high-profile finance- and securities-related cases, as well as on damages issues in antitrust matters. Professor Hubbard has consulted to several government and international agencies, including the US Department of the Treasury, the US International Trade Commission, the US Securities and Exchange Commission, the World Bank, the Board of Governors of the Federal Reserve System, the Federal Reserve Bank of New York, and the Congressional Budget Office. From 2001 to 2003, he served as chairman of the President’s Council of Economic Advisers.
Professor Hubbard has published more than 100 scholarly articles and coauthored several books, including the widely used textbook Money, the Financial System, and the Economy. His commentaries have appeared in Businessweek, The Wall Street Journal, The New York Times, the Financial Times, and The Washington Post, as well as on PBS television and NPR radio business programs. A frequent speaker, Professor Hubbard has presented his research at economic conferences throughout the world.
)Ms. Cotton has extensive experience conducting complex quantitative and qualitative analyses of data in both mergers and litigation matters. She has supported experts from leading universities and managed case teams in a broad range of industries on matters related to antitrust, bankruptcy, class certification, intellectual property, securities, survey design, tax, and transfer pricing. Her recent case work has included assessing competitive effects in major antitrust matters and mergers; analyzing Federal Trade Commission (FTC), US Department of Justice (DOJ), and Canadian Competition Bureau (CCB) merger compliance, including assistance with Hart-Scott-Rodino (HSR) filings, second requests, divestiture analysis, advocacy, and merger trial testimony; managing the independent evaluation of large-scale transaction and customer datasets in major antitrust matters; examining damages issues in a data breach context; and determining arm’s-length pricing in a large US transfer pricing matter. Ms. Cotton also has substantial experience evaluating questions of commonality and typicality in the context of privacy, technology, data breach, pharmaceutical, medical device, and overcharge class actions.
)Professor Blanchard’s research combines experiments with observational data analyses to study how consumers make complex decisions about finance and technology. He serves as a marketing and research expert in commercial litigation and advises financial services and technology companies on business strategies and research. Professor Blanchard is the director of Georgetown’s M.B.A. Certificate in Consumer Analytics and Insights program, and he teaches courses on research design, surveys, and quantitative analyses to undergraduate, graduate, and executive education program students. He has been named among the best 40 business professors under 40 by Poets&Quants, and a Young Scholar by the Marketing Science Institute.
Professor Blanchard is an associate editor of the Journal of Marketing Research, the Journal of Consumer Research, and the International Journal of Research in Marketing, and he has published articles in a number of prominent marketing journals. Professor Blanchard’s research and perspectives on consumer finances and technology have been featured in media outlets such as Forbes, Fortune, Harvard Business Review, NerdWallet, The New York Times, Marketplace, and NBC News. Prior to joining the Georgetown faculty, he served as a member of the American Marketing Association’s Academic Council, and held visiting positions at Dartmouth College and Columbia University.
)Mr. Richardson has more than 30 years of experience as a senior executive at institutional asset management firms, most recently as executive director of client service and business development and member of the global management team at Impax Asset Management Group. Throughout his career, Mr. Richardson has been responsible for overseeing the management of institutional investment portfolios of fixed-income, listed equity, and private securities. During the final decade of his tenure as head of Impax’s North American business, these portfolios were managed with a particular focus on the role of environmental, social, and governance (ESG) factors in investment management decisions. He has consulted to public and private companies in numerous industries, including financial services and insurance, on investment, governance, and compliance matters. Mr. Richardson has had oversight of a full range of investment portfolios offered through different fund vehicles, including 40 Act funds, commingled funds, collective trust funds, limited partnerships, and segregated accounts. He has been responsible for client, asset, and revenue growth, as well as new product initiatives and M&A. Mr. Richardson testified at deposition and trial, and has contributed to articles on sustainable investments for media outlets such as the Financial Times, The New York Times, and CNBC. Prior to his work with Impax, he co-founded Global Energy Investors, a private equity infrastructure firm, and Dwight Asset Management, an institutional fixed-income investment firm that was subsequently acquired by Goldman Sachs. He serves as a member of the Global Leadership Council for the World Resources Institute, and as a member of the President’s Council for Ceres. Mr. Richardson is a CFA charterholder.
)Dr. Cliff is a financial economist with expertise in a range of topics, including asset valuation, mergers and acquisitions (M&A), tax shelters, stock analysts’ recommendations, IPOs, REITs, derivatives, and hedge funds. He has extensive experience with large financial datasets, sophisticated econometric models, and simulations. In his consulting engagements, Dr. Cliff has addressed damages modeling, class certification, business and asset valuation, analysis of complex financial structures, analysis of solvency and debt covenants, evaluation of investment strategies, and assessment of due diligence practices. In these assignments, he has managed large case teams, designed and performed analyses in support of expert reports, critiqued opposing expert reports, and assisted with preparation for depositions and trial. Dr. Cliff has also served as an expert on cases involving valuation, damages, and liquidity discounts. Prior to joining Analysis Group, Dr. Cliff was a finance professor for nine years at Purdue University and Virginia Tech, where he taught a variety of courses at the undergraduate, M.B.A., and Ph.D. levels. His academic research has been published in leading journals such as the Journal of Finance, the Journal of Business, and Financial Management.
)Professor Eden is an expert on transfer pricing and multinational enterprises (MNEs), with decades of experience consulting to MNEs, governments, and international organizations on transfer pricing and MNE strategies and structures. In transfer pricing matters, she has served as an expert witness – in cases that include Coca-Cola Co. v. Commissioner and In re: Nortel Networks – and filed numerous expert reports. Professor Eden has taught courses on transfer pricing, MNEs, and the economics of international business, and founded the Transfer Pricing Aggies program at Texas A&M University, which has trained hundreds of graduate students. She has extensive research experience in areas such as transfer pricing and MNE strategies in the digital economy, and her work has been widely published in management and international business journals. Professor Eden has authored several books, including Taxing Multinationals: Transfer Pricing and Corporate Income Taxation in North America, Multinationals in North America, The Economics of Transfer Pricing, and Research Methods in International Business. She is a frequent speaker at transfer pricing and tax conferences, as well as dean of the Fellows of the Academy of International Business, where she formerly served as president.
)Dr. Mortimer specializes in health economics, industrial organization, microeconomic theory, and econometrics. He has extensive experience with issues involving competition, intellectual property, marketing, pricing, and valuation with a focus on the health care industry. He has evaluated questions of class certification, damages, liability, and market definition in antitrust matters. He also has provided economic analyses and expert testimony on causation and damages in a variety of health care cases, including cases involving allegations of False Claims Act (FCA) and Anti-Kickback Statute (AKS) violations. In addition to his work in litigation, Dr. Mortimer has assisted pharmaceutical and medical device manufacturers on pricing and contracting issues and authored several public policy studies related to legislation establishing a biosimilar approval pathway, biosimilar competition, pharmaceutical pricing, generic drug competition and the role of authorized generic entry, and paragraph IV abbreviated new drug application (ANDA) filings. His research has been published in leading peer-reviewed journals, including Health Affairs, Nature Reviews Drug Discovery, The Journal of Industrial Economics, and the Journal of Medical Economics.
)Professor Jena is a health economist, practicing internal medicine physician, and professor of health care policy. His work involves several areas of health economics and policy, including the economics of medical innovation, the economics of physician behavior and the physician workforce, medical malpractice, and the economics of health care productivity. Professor Jena has been retained as an expert in several pharmaceutical and health care industry matters.
A prolific author, Professor Jena has contributed to more than 150 peer-reviewed articles and articles intended to increase patient understanding, published in outlets including the New England Journal of Medicine and The New York Times. He is a faculty research fellow at the National Bureau of Economic Research and serves on Harvard Medical School's Standing Committee on Health Policy. Professor Jena is a recipient of the NIH Director's Early Independence Award to fund research on the physician determinants of health care spending, quality, and patient outcomes, and a recipient of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) New Investigator Award. In 2018, he was listed among 100 great leaders in health care by Becker's Hospital Review.
)Dr. Dawson specializes in applying economics and finance to complex problems in business litigation, including intellectual property (IP), false advertising, securities, and finance matters. Her experience spans several industries, from medical devices and high tech to telecommunications and accounting. Dr. Dawson has consulted to counsel in all phases of the litigation process, including understanding complex claims, assisting with fact and expert discovery, and providing trial support. She has served as an expert witness on matters involving false advertising, breach of contract, and copyright infringement. Dr. Dawson’s case work has involved complex data analysis, development of financial models, general damages assessment, evaluation of lost profits, royalty, and other damages remedies in IP and false advertising matters, ascertainment of loss causation and damages in securities fraud matters, and financial statement analyses. She has spoken at various conferences and served as a panelist on the topics of platform economics and IP damages.
)Mr. Bodington specializes in the business and finance aspects of the electric power industry. He is the founder of a boutique investment banking firm that has provided M&A, financing, and restructuring advisory services to the energy sector for more than 25 years. Mr. Bodington has played a key role in more than 100 transactions with an aggregate value of more than $7 billion. In these engagements, he has led the purchase and sale of interests in power projects; arranged debt and equity financing for energy projects in development, construction, and operation; and advised owners and lenders on various capitalization, value, repayment, restructuring, and management issues. His clients include industrial companies, independent power companies, equity investors, lenders, utility affiliates, and regulated utilities.
Mr. Bodington is also a seasoned expert witness who has provided testimony for clients on finance and damages issues. Prior to founding Bodington & Company, he spent eight years with Bechtel Group and four years with an international management consulting firm. Mr. Bodington is the author of more than 50 articles on a variety of economic and financial topics relevant to the energy sector. He holds Financial Industry Regulatory Authority (FINRA) Series 7, 24, 63, 79, and 99 licenses.
)Dr. Robbins is a pharmaceutical and biotech executive with over 40 years of broad-based industry experience. In his role at Kodiak Strategic Consultants, he consults to a diverse group of pharmaceutical and biotech companies on clinical, regulatory, business development, and licensing issues. Dr. Robbins served as a CEO in residence at the University of Minnesota’s Office for Technology Commercialization and co-founded several biotech ventures. He is actively involved with a number of startups, including GigaMune, Neuropharma Meds, and Diastol Therapeutics. He served as the COO of Bullet Biotechnology, regulatory strategic advisor to GigaGen, and acting CEO of GigaMune, all of which have focused on novel immunotherapies targeting cancer and autoimmune diseases. Dr. Robbins has served as an expert in multiple antitrust matters, intellectual property cases, and contract disputes, and provided testimony at deposition, trial, and arbitration. Prior to his consulting career, he held several senior-level positions at brand and generic pharmaceutical companies, where he was responsible for the development of regulatory and clinical strategies that led to numerous new drug application (NDA), biologics license application (BLA), and abbreviated new drug application (ANDA) approvals by the US Food and Drug Administration (FDA). He has conducted analyses in therapeutic areas that include cardiology, oncology, endocrine/metabolic, women’s health, infectious diseases, radiology, and nuclear medicine and diagnostics. In addition, Dr. Robbins has experience assisting biotech startups with strategy and financing. He holds adjunct professorships in pharmacology at the University of Minnesota Medical School and the University of Minnesota College of Pharmacy, and his work has been published in numerous peer-reviewed scientific journals. Dr. Robbins serves on the Antitrust Council of the Minnesota State Bar Association.
)Mr. Cohen has over 30 years’ experience as an expert in international arbitration, valuation, antitrust, intellectual property, and securities, and has testified in arbitration and federal courts on many aspects of economic damages. He specializes in fields that are intensive in intangible assets such as patents, copyrights, trademarks, and trade secrets. He has worked across a wide range of industries, including health care, software and technology, financial services, energy, transportation, and entertainment.
Mr. Cohen has worked with significant corporations including Apple, Microsoft, Oracle, Wells Fargo, State Street, Wachovia, SoundExchange, ASCAP, Liberty Mutual, Allstate Insurance, Johnson & Johnson, AstraZeneca, Astellas, United Airlines, TWA, DaimlerChrysler, Mitsubishi, and Anheuser-Busch. He also has experience in matters related to the US Federal Trade Commission, the US International Trade Commission, the Tax and Antitrust Divisions of the US Department of Justice, the Republic of Uruguay, and the Commonwealth of Australia.
Mr. Cohen is the author of Intangible Assets: Valuation and Economic Benefit and a contributor to the American Bar Association publication Proving Antitrust Damages. He has been a guest lecturer at both Northwestern University and The University of Chicago. He is also a prolific songwriter.
)Professor Hylton has over 30 years of experience researching legal issues in antitrust, merger, and intellectual property cases. He is an expert on tort law, labor law, civil procedure, and empirical legal analysis. A prolific author, Professor Hylton has published 5 books and more than 100 scholarly articles on topics such as oligopoly pricing, the intersection of antitrust and intellectual property, and damages in patent infringement cases. He is an associate editor of the International Review of Law and Economics, a former contributing editor of the Antitrust Law Journal, coeditor of Competition Policy International, and editor of the Social Science Research Network’s Torts & Products Liability Law eJournal. Professor Hylton is a past president of the American Law and Economics Association, and previously served as the organization’s secretary-treasurer and vice president. He is a member of the American Law Institute and serves on the board of directors of the Pioneer Institute. Prior to joining Boston University, Professor Hylton was awarded tenure as a faculty member at Northwestern University School of Law and served as a research fellow at the American Bar Foundation.
)Professor Knittel’s research focuses on industrial organization, applied econometrics, and energy and environmental economics. He has provided trial and deposition testimony in a number of litigation matters, including valuing product features in smartphones, PCs, and contact lenses. He has also consulted to Delta Airlines, Ford Motor Company, the US Energy Information Administration, and Korea Electric Power Company. Professor Knittel has authored or coauthored numerous articles on topics such as market structure and product pricing, tacit collusion, and challenges in merger simulation analysis. Examples of his research include articles on the spurious correlation between ethanol production and gasoline prices, unilateral market power in the electricity reserves market, and tacit collusion in credit card markets. His research has appeared in the American Economic Review, the American Economic Journal: Macroeconomics, the American Economic Journal: Economic Policy, The Review of Economics and Statistics, The Journal of Industrial Economics, and The Energy Journal, among other academic publications. He is a former coeditor of the Journal of Public Economics and serves or has served as an associate editor for several other scholarly journals, including the American Economic Journal: Economic Policy, The Journal of Industrial Economics, the Journal of Transport Economics and Policy, and The Journal of Energy Markets. Professor Knittel is a research associate at the National Bureau of Economic Research (NBER) in the Productivity, Innovation, and Entrepreneurship and Industrial Organization programs, and he co-directs the Environment and Energy Economics program.
)Dr. Duh, Chief Epidemiologist at Analysis Group, specializes in real-world evidence (RWE) generation for product registration, post-approval safety studies, and health economics and outcomes research (HEOR) of pharmaceuticals, vaccines, and regenerative biotherapeutics. She has led multiple projects for new molecular entity approvals and product label expansion applications to the US Food and Drug Administration (FDA) and European Medicines Agency (EMA), as well as health technology assessment (HTA) research for submissions to national payers such as the Centers for Medicare and Medicaid Services (CMS) in the US and the UK’s National Institute for Health and Care Excellence (NICE). Her extensive research has appeared in over 250 peer-reviewed publications.
Her work also extends to pharmaceutical liability litigation and securities fraud litigation related to adverse drug events that allegedly led to product recalls, market withdrawals, black box warnings, and FDA limited access programs.
Dr. Duh is also an adjunct in the biostatistics department at the Harvard T.H. Chan School of Public Health. She served as a chairperson of drug safety and epidemiology for the Drug Information Association (DIA) and was an adjunct assistant professor of pharmacoeconomics and pharmacoepidemiology at Massachusetts College of Pharmacy and Allied Health Sciences. Dr. Duh was appointed to an expert panel convened by the Foundation for the National Institutes of Health’s (FNIH’s) Observational Medical Outcomes Partnership (OMOP). She has served as a peer reviewer for several journals, including PharmacoEconomics, the American Journal of Health-System Pharmacy, Chest, Pharmacoepidemiology and Drug Safety, the American Journal of Kidney Diseases, and Therapeutics and Clinical Risk Management. Dr. Duh is also an elected member of the American Society of Hematology and a member of the American Society of Clinical Oncology, the International Society of Pharmacoepidemiology, and the International Society of Pharmacoeconomics and Outcomes Research (ISPOR).
View Dr. Duh's selected publications on the Harvard Catalyst website
)Pierre Cremieux, President of Analysis Group, has a broad range of expertise in health economics, antitrust, statistics, and labor economics. He has consulted to numerous clients in the US and Canada and testified in bench and jury trials, arbitrations, and administrative proceedings.
Dr. Cremieux has served as an expert and supported other experts in both litigation and non-litigation matters on antitrust issues; general commercial claims; contractual disputes; and a number of labor-related matters in a variety of industries, including high tech, pharmaceuticals, biotech, financial products, consumer products, and commodities. He has assessed the evaluation of damages on a class-wide basis in some of the largest class action matters in recent years.
His scientific research in antitrust economics, class certification, health economics, and statistics has been published in numerous peer-reviewed journals including the George Mason Law Review, the American Bar Association Economics Committee Newsletter, The Review of Economics and Statistics, the Journal of Health Economics, Industrial and Labor Relations Review, the Journal of Clinical Oncology, and the American Journal of Managed Care. Dr. Cremieux's research has been cited in leading media outlets including The Wall Street Journal and Forbes.
Dr. Cremieux has frequently presented at leading legal, health care, and economics seminars on topics such as antitrust, class certification, health economics, and statistics, in both the United States and Canada. He has also been invited to teach courses on economics, statistics, health care, and antitrust at various schools including McGill University, Boston University, Harvard Medical School, and Yale's School of Management.
Prior to joining Analysis Group in 1997, Dr. Cremieux spent five years as a professor at the University du Québec à Montréal, and served as an adjunct professor from 1997 to 2018.
)Dr. Rice is an economist with a range of expertise in health economics, industrial organization, statistics, and econometrics. He has extensive experience applying economic theory and statistical methods in complex litigation and research settings. Dr. Rice has led analyses related to government investigations and litigation matters, where he has supported counsel and been retained as an expert on alleged Anti-Kickback Statute and False Claims Act violations, as well as on antitrust, cryptocurrency, insider trading, misappropriation of trade secrets, and breach of contract issues. In matters related to liability and damages, he conducts empirical analyses involving large-scale databases on a range of topics, including causal inference, merger simulation, and budget impact. Dr. Rice’s case experience has involved providing assistance in the preparation of expert reports, testimony, and rebuttal analyses and arguments; developing sophisticated interactive models enabling real-time damages assessments under alternative scenarios; and presenting analyses to US Attorney’s Office investigators. In addition to his litigation work, he has provided econometric and statistical consulting on matters such as economic research questions, risk management, fair market valuation, and compliance. Dr. Rice is adjunct faculty in the Harvard University Department of Economics and has taught undergraduate courses on econometrics, health economics, industrial organization, and regulatory economics. He has published extensively in numerous peer-reviewed journals, and presented at conferences and seminars.
)Mr. Jenson has extensive experience managing complex high tech capital equipment businesses for public and private equity companies. He has more than 30 years of experience in global manufacturing focusing on general management, marketing, sales, and product development. His experience includes automation systems, robotics, thin-film process equipment, material handling equipment, industrial equipment, and analytical instrumentation. Mr. Jenson has participated in numerous mergers and acquisitions (M&As), as part of both the acquiring firm and the acquired firm. His M&A experience includes investment target identification, valuation, due diligence, integration, and management of acquired companies. In his position as general manager of core technologies for Ocean Insight – a spectroscopy and imaging technology company – Mr. Jenson leads the global sales, marketing, and product development teams. Prior to his work with Ocean Insight, he led the $200 million waterjet cutting systems business segment of SHAPE Technologies Group, managed the $250 million compound semiconductor equipment business unit of Veeco Instruments, and served as a senior leader in automation solutions for the semiconductor and flat panel display industries at Brooks Automation. Mr. Jenson is also a veteran submarine officer of the US Navy.
)Ms. Glowka is a chartered accountant who specializes in the assessment of damages and forensic analysis arising in the context of dispute resolution. She has served as an expert and led consulting teams on complex UK and international assignments, including litigation and international arbitration matters before the High Court of Justice in London, the Scottish Court of Session, the UK Competition Appeal Tribunal, and all the major international arbitration forums.
Ms. Glowka has acted on a broad range of litigation and arbitration matters across the automotive, oil and gas, pharmaceutical, telecommunications, software, and consumer products industries, among others. Her litigation and arbitration work has involved the evaluation of damages arising in the context of contractual and shareholder disputes, as well as post-transaction disputes such as breach of warranty claims. Ms. Glowka’s forensic accounting work has spanned analysis and tracing of funds and transactions, as well as evaluation of fraud and accounting irregularities, including allegations of accounts manipulation for inflating performance-related bonuses and purchase consideration. She has also evaluated complex financial reporting issues under a variety of accounting standard-setting regimes, including UK generally accepted accounting principles (GAAP) and International Financial Reporting Standards (IFRS). Ms. Glowka is a member of Chartered Accountants Australia and New Zealand.
)Professor Rock is an expert in corporate law and corporate governance. He coauthored the book The Anatomy of Corporate Law: A Comparative and Functional Approach, and has published numerous articles on topics such as poison pills, politics and corporate law, hedge funds, corporate voting, proxy access, corporate federalism, and mergers and acquisitions. Prior to joining the NYU faculty, Professor Rock taught at the University of Pennsylvania Law School, where at various times he served as co-director of the Institute for Law and Economics, associate dean, senior advisor to the president, and provost and director of open course initiatives. He has held visiting professorships at NYU and Columbia University, and was a Fulbright Senior Scholar at Hebrew University. Prior to his academic career, Professor Rock worked as an attorney specializing in complex antitrust, corporate, and securities litigation. In January 2019, the American Law Institute named him Reporter for the Restatement of the Law, Corporate Governance.
)Professor Levinsohn is an expert in antitrust, industrial organization, and econometrics. He has provided expert reports and testimony in several landmark antitrust and regulatory matters, including In re: TFT-LCD (Flat Panel) Antitrust Litigation, In re: Vitamins Antitrust Litigation, In re: New Motor Vehicles Canadian Export Antitrust Litigation, and the Tobacco Master Settlement Agreement proceedings. He has also consulted to numerous foreign governments and international organizations.
Professor Levinsohn conducts research in industrial organization, applied econometrics, international economics, and development economics. He has served on the editorial boards of American Economic Review, The Review of Economics and Statistics, the Journal of International Economics, and the Journal of Economic Literature. Prior to joining the Yale faculty, Professor Levinsohn was the J. Ira and Nicki Harris Family Professor of Public Policy at the Gerald R. Ford School of Public Policy at the University of Michigan.
)Dr. Garces is an economist with deep public- and private-sector antitrust policy and regulation experience in the US and Europe, including serving in the European Commission’s Directorate-General for Competition (DG COMP) and Directorate-General for Internal Market and Industry. Her consulting and case work experience includes mergers and conduct cases in the telecommunications, media, industrial, consumer staples, and technology sectors. She has corporate experience at a large technology company and is widely recognized as an expert on the economic analysis of new digital business models, as well as on regulation in innovative sectors. Dr. Garces has published extensively on topics such as the antitrust analysis of commercial practices, the assessment of conglomerate mergers, the interaction between antitrust and privacy, value creation processes in platform businesses, and behavioral economics. She is also a coauthor of the widely used book Quantitative Techniques for Competition and Antitrust Analysis.
)Professor Keller is an expert on marketing management, branding, and brand equity. His research focuses on improving marketing strategies through an understanding of consumer behavior, as well as on the design, implementation, and evaluation of integrated marketing communication programs. Professor Keller has served as brand advisor to a number of large corporations, including Accenture, American Express, Disney, Ford, Intel, Levi-Strauss, L.L. Bean, Nike, Procter & Gamble, and Samsung. He has published over 120 papers in peer-reviewed journals such as the Journal of Marketing, the Journal of Marketing Research, and the Journal of Consumer Research. He also authored the widely used textbooks Marketing Management (with Philip Kotler) and Strategic Brand Management. Professor Keller has received numerous awards for his research accomplishments, and has conducted marketing seminars for executives in a variety of forums. He previously held faculty positions at the University of California, Berkeley; Stanford University; and the University of North Carolina at Chapel Hill.
)A former chief economist at the Federal Communications Commission (FCC), Professor Rogerson focuses his research on applied microeconomic theory, industrial organization, regulation, cost accounting, telecommunications, and defense procurement. He has been an active participant in media transactions before the FCC, including Comcast/NBCUniversal and News Corp./DirecTV, as well as various rulemaking proceedings. Professor Rogerson was also the FCC’s senior economist, supervising its economic analyses of the Comcast/Time Warner Cable, AT&T/DirecTV, and Charter Communications/Time Warner Cable transactions. He has also served as an economic expert for the US Department of Justice, Federal Trade Commission, and the National Association of Attorneys General in various antitrust cases in the telecommunications, media, and defense industries. Professor Rogerson has published a number of articles and book chapters on topics such as vertical mergers in the video programming and distribution industry, and incentives for investment and innovation as related to the regulation of broadband telecommunications. He is a former editor of Economic Inquiry and Defense and Peace Economics, and a former member of the editorial boards of both the Review of Accounting Studies and The Journal of Industrial Economics. He served two terms as chair of Northwestern University’s Department of Economics, and currently holds several leadership roles at Northwestern, including research director of the Program on Antitrust Economics and Competition Policy at the Searle Center on Law, Regulation, and Economic Growth; director of the Center for Business Institutions; and co-director of the Center for the Study of Industrial Organization.
)Professor Haas-Wilson is an expert in health care antitrust, including the competitive effects of hospital mergers and commercial health insurer mergers, the effects of vertical consolidation in health care markets, and the implications of physician networks on competition in the health care industry. She recently testified in Federal District Court in Idaho on behalf of plaintiffs, in an antitrust lawsuit alleging competitive harm from St. Luke’s Health System’s acquisition of a large independent physician practice. She has served as a consultant on antitrust issues to the Federal Trade Commission, the Massachusetts Attorney General, the California Department of Corporations, and numerous private entities. She also testified on behalf of the Federal Trade Commission in the matter of Evanston Northwestern Healthcare Corporation. Professor Haas-Wilson is the author of Managed Care and Monopoly Power: The Antitrust Challenge and coeditor of Uncertain Times: Kenneth Arrow and the Changing Economics of Health Care. Her research has appeared in the Journal of Political Economy, the Journal of Economic Perspectives, the Journal of Law and Economics, the Review of Economics and Statistics, and the Journal of Health Economics, among others.
)Dr. Rothman specializes in the economic analysis of antitrust and competition issues. He is retained by private parties to present analyses to the US Department of Justice (DOJ) and the US Federal Trade Commission (FTC). He is also retained by and has testified for the FTC as an expert witness in merger litigation. In addition to his merger work, Dr. Rothman has worked on multiple joint conduct and unilateral conduct matters.
Dr. Rothman is a senior editor of the Antitrust Law Journal. He has published research in outlets including Antitrust Law Journal, The Antitrust Source, Journal of Health Economics, Journal of Competition Law & Economics, and Concurrences: Competition Law Journal. Dr. Rothman has taught a course on the economics of merger analysis in the economics department at Harvard University. Prior to joining Analysis Group, he was an assistant professor at Columbia University.
)Professor Pindyck is a leading industrial organization economist and testifying witness in the areas of antitrust and intellectual property. His research and writing have covered topics in microeconomics and industrial organization, the behavior of resource and commodity markets, financial markets, and econometric modeling and forecasting. His recent work in economics and finance has examined the determinants of market structure and market power, the dynamics of commodity spot and futures markets, criteria for investing in risky projects, the role of R&D, and the value of patents. He has received many academic honors, including several awards for outstanding teaching, and holds senior editorial positions with a number of publications. Professor Pindyck has consulted to dozens of public and private organizations, including the Federal Trade Commission, IBM, and AT&T, and has been deposed and/or testified in over a dozen cases in diverse industries such as food, energy, software, medical devices, and airlines. He has worked with Analysis Group on many of these cases, including the Lotus v. Borland litigation, in which Professor Pindyck used econometric modeling techniques to identify the economic value of various attributes and isolated the value of the infringing features. He also worked with Analysis Group in a major litigation matter involving price-fixing allegations, in which he examined allegations of accumulation of buying power and the resulting effects on negotiations with suppliers.
)Ms. Guérin is an economist who specializes in the application of statistics and econometrics to health economics and outcomes research (HEOR) and epidemiology. Her areas of expertise include retrospective database analyses such as medical claims, electronic health records, and clinical trial data; economic modeling, such as cost-effectiveness and budget impact models; and design of chart review studies, surveys, and other prospective studies. She has participated in the development of large clinical data registries and in the design of real-world evidence (RWE) studies to support regulatory submissions. Ms. Guérin has broad research and analytical experience in areas such as comparative effectiveness and cost effectiveness, development of prediction algorithms, assessment of disease prevalence and incidence, evaluation of burden of illness, productivity loss, treatment patterns, analysis of patient-reported outcomes (PROs), safety/tolerability analyses, discrete choice experiments, and patient experience studies. She has also supported many pharmaceutical companies in the development of HEOR planning and RWE generation plans. Ms. Guérin has conducted health care research across many therapeutic areas, including oncology, hematology, dermatology, gastroenterology, rheumatology, neurology, psychiatry, endocrinology, cardiology and circulatory diseases, and respiratory diseases. She publishes frequently and is the coauthor of over 100 research papers published in numerous peer-reviewed journals and presented at a variety of scientific conferences.
)Dr. Cain is an expert in securities litigation, corporate disclosures, M&A litigation, private equity, valuation, insider trading, and corporate governance. He has provided economic analysis, consulting, and expert witness testimony on a variety of finance topics for investigations, settlement negotiations, and trials. He has estimated event studies and trading profits in relation to allegations of insider trading, improper trading behavior, corporate misrepresentations and disclosures, and unregistered stock sales on behalf of the US Securities and Exchange Commission (SEC), US Department of Justice (DOJ), Commodity Futures Trading Commission (CFTC), and other clients. Dr. Cain worked for several years at the SEC, where he was an advisor to Commissioner Jackson and a financial economist in the Office of Litigation Economics. Prior to joining the SEC, Dr. Cain was an assistant professor of finance at the University of Notre Dame Mendoza College of Business. He has published research in numerous journals on topics that include investment banking and fairness opinion valuations, merger contracts and terminations, corporate governance and shareholder activism, hostile takeovers, earnout clauses, merger-related litigation, and management buyouts. Dr. Cain’s research has been cited in forums such as the US Chamber Institute for Legal Reform, amicus briefs to the US Supreme Court, trial verdicts of the Supreme Court of the State of New York and the Delaware Chancery Court, and The International Comparative Legal Guide to Mergers and Acquisitions. His research has also been highlighted in media outlets such as The Wall Street Journal, The New York Times, the Financial Times, and Forbes.
)Professor Kinch, a drug development expert specializing in cancer, immunological, and infectious diseases, focuses on combining cutting-edge science and entrepreneurship to improve public health. At Washington University in St. Louis, Professor Kinch founded and directs the Center for Research Innovation in Biotechnology (CRIB), which assesses trends that guide the research and development of novel medicines. He also helped create the Center for Drug Discovery (CDD) to identify and underwrite the university’s most promising drug discovery projects. Professor Kinch has been issued more than a dozen US patents, published more than 100 patent applications, and written several books and book chapters on the commercialization of biopharmaceutical innovation, as well as other aspects of drug development. He has published widely in peer-reviewed journals, including Drug Discovery Today, Science, Cell Chemical Biology, and Biotechnology Law Report, and his research has been profiled in media outlets such as The Wall Street Journal, NPR, CBS News, and The New York Times. Before joining Washington University, he was the managing director of the Yale Center for Molecular Discovery. He has also taught at Johns Hopkins University and Purdue University, and held senior research positions at Functional Genetics and MedImmune. Professor Kinch serves on the board of the American Cancer Society and on scientific advisory boards (SABs) for several biopharmaceutical companies.
)Professor Rossiter is an expert in health economics who has testified or served as an expert in the following areas: competition in the financing and delivery of health services; reimbursement economics, especially for Medicare, Medicare Advantage, and Medicaid; managed care organizations; prescription medicines; survey research; and health information analytics. Professor Rossiter is the former secretary of health and human resources for the Commonwealth of Virginia. In that role, he was responsible for over 15,000 employees in 13 agencies (including 10 state mental hospitals), brought major information technology projects in the Secretariat to national prominence, and made major reforms in Virginia Medicaid. He also served as deputy for policy to the Administrator of the Centers for Medicare and Medicaid Services (CMS). As deputy, he created and directed a new payment system for US hospitals under Medicare, was responsible for the CMS strategic plan, and formulated all agency policy initiatives through the federal legislative process.
Prior to joining the William & Mary faculty, Professor Rossiter was a professor of health administration at Virginia Commonwealth University. He served on the board of regents of the National Library of Medicine, National Institutes of Health; on the board of directors of AcademyHealth; and as chair of the board of directors of the Coalition for Health Services Research, the lobbying arm of AcademyHealth, during the passage of the Affordable Care Act. He has also served on numerous advisory groups, including the National Advisory Council for Healthcare Research and Quality, and is currently a trustee and chair of the Williamsburg Health Foundation. Professor Rossiter is the author or editor of 15 books, and the author of over 50 journal articles on health economics and the role of competition in the financing and delivery of health services.
)Mr. Darling consults to clients and provides expert testimony to address litigation, strategy, regulatory, and policy questions in a wide range of antitrust and competition, class certification, health care, energy, and environmental matters. He has submitted and supported expert testimony before US district and appellate courts, state utility commissions, siting boards, and federal agencies. He has also assisted clients with responses to government investigations and presented findings before US Attorneys’ Offices, state attorneys general, and the US Drug Enforcement Administration.
In the areas of health care and antitrust, Mr. Darling has extensive experience supporting clients on issues related to discovery and data production, class certification, patent infringement, market definition and market power, and competitive effects in pharmaceutical and life sciences matters involving patent infringement issues, reverse payment settlements, and product hop allegations. He has also designed and implemented customized suspicious order monitoring (SOM) and loss prevention programs for controlled substances, and has experience in False Claims Act and Anti-Kickback Statute litigation cases, including analyses of causation and damages calculations.
Mr. Darling is also an expert on electricity, oil, and natural gas pricing, markets, and infrastructure. His consulting work on behalf of utilities, state and regional organizations, and global companies includes projects related to cost/benefit analyses of new plant construction and retirements; ratepayer and bill impacts; environmental effects of emissions and pollution controls; economic impacts of energy projects, mergers, and policies; natural gas, biomass, and other market studies; and climate change matters including decarbonization policy proposals and quantification of the impacts of greenhouse gas emissions. He has conducted and overseen numerous economic and bill impact assessments in support of projects and policy proposals, ranging from new power plants and transportation facilities to electric, petroleum, and natural gas transmission infrastructure.
)Ms. Hitscherich specializes in corporate acquisitions, leveraged buyouts, exclusive sales and divestitures, takeover defenses, and restructurings. She has served as an expert witness in several complex securities litigations, including matters involving deal structure, valuation, due diligence, custom and usage in the finance industry, and financing alternatives.
Ms. Hitscherich has extensive experience in investment banking and corporate law practice, including as a managing director in mergers and acquisitions with Banc of America Securities, where she was secretary of the Fairness Opinion Review Committee; vice president in mergers and acquisitions with J.P. Morgan & Co., where she was a founding member of the takeover defense team and a senior member of the acquisitions fairness Advisory Review Committee; and as a mergers and acquisitions attorney with Skadden, Arps, Slate, Meagher & Flom.
At Columbia Business School, Ms. Hitscherich teaches corporate finance, advanced corporate finance, business law, and mergers and acquisitions in the M.B.A. and Executive M.B.A. programs.)Dr. Royer applies a broad range of quantitative tools to address client needs in data science, statistics, HEOR, finance, intellectual property, competition policy, and antitrust cases in the United States, Canada, and the EU. His recent work includes predicting the potential future onset of rare or undiagnosed conditions with machine learning models; predicting whether patents would be considered essential to technological standards if challenged in courts; valuing patents in the communications industry; evaluating damages related to product defects; analyzing investment guidelines in securities lending suits; addressing allegations of monopolization in major antitrust cases involving high tech firms; and supporting many academic experts on mutual fund market timing and excess fee cases. In addition, Dr. Royer has conducted extensive academic research and coauthored books and papers on topics such as using new AI advances in HEOR; predicting treatment resistance in tuberculosis, using machine learning algorithms in propensity score models; measuring the impact of ESO backdating on shareholders’ wealth; analyzing mutual fund pricing; analyzing antitrust limit pricing; valuing private investments for hospitals in Canada; determining the impact of hypertension therapies on mortality; and comparing unemployment compensation in different countries.
)Professor Reibstein’s research focuses on competitive marketing strategies, metrics, and product line decisions, among other topics. He has provided marketing management education and consulting research to companies in the consumer goods, pharmaceutical, and oil and gas industries, among others. His consulting activities have included numerous applications of conjoint analysis and other survey techniques in engagements spanning a wide range of products. Professor Reibstein has submitted expert reports and provided testimony on marketing and marketing research in several litigation matters, including analyses of smartphone features in a patent dispute, health claims in a false advertising dispute, and pharmaceutical detailing in a co-marketing dispute.
His recent work includes assessing strategies to address competitors’ reactions to marketing actions and developing metrics that link marketing decisions to financial consequences, which was published in his book, Marketing Metrics: The Definitive Guide to Measuring Marketing Performance. Professor Reibstein is also the author or coauthor of numerous books and chapters in books on subjects including competitive marketing strategy, global branding, and marketing performance measurement. Professor Reibstein has also written several papers on conjoint analysis and its validity and reliability. His research has been published in leading academic journals, including Marketing Science, the Journal of Marketing Research, and the International Journal of Research in Marketing. Â
Professor Reibstein has been honored with more than 30 teaching and publishing awards, including the John S. Day Distinguished Alumni Academic Service Award from Purdue University’s Krannert School of Management. He has served as the chairman of the American Marketing Association board of directors and as the executive director of the Marketing Science Institute.
)Professor Carlson specializes in the marketing management implications of consumer decision-making processes, including the development of brand preferences and the influence of emerging preferences on the decision making process. Though much of Professor Carlson's research explores consumer decision making, he also studies how voters, jurors, and managers make decisions. Over the last 20 years, he has run thousands of surveys, sampling U.S. and international populations.
Professor Carlson has served as an expert in evaluating a survey in a class action matter, consulted on a high profile class action settlement involving consumer deception, and testified before the SEC in an equity trust matter. Professor Carlson's published research can be found in top marketing, psychology, and management journals. He is also the coauthor of Contemporary Brand Management. He blogs for Psychology Today and Forbes, and maintains an active Twitter account (@ProfKurt). While teaching at Georgetown University between 2009 and 2017, Professor Carlson was director of the Georgetown Institute for Consumer Research and co-director of the McDonough School of Business Behavioral Research Lab, and he received the MSB Dean's Distinguished Faculty Research Award and the Decision Analysis Society's Publication Award.
Â
)Ms. Kindler has worked on a variety of engagements, including intellectual property (IP) disputes, contract disputes, litigation matters related to securities and finance, false advertising allegations, and antitrust matters. In litigation matters, she has testified in deposition and at trial, and assisted in all phases of the litigation process, including discovery, expert reports, deposition, and trial preparation. In patent infringement matters, Ms. Kindler has analyzed claimed lost sales, claimed lost profits, and claimed reasonable royalty damages. In antitrust matters, she has assessed the competitive consequences of mergers, analyzed the competitive behavior of market participants, and estimated the impact of market power. Her work has also included the development of complex damages models, the analysis of statistical data, and the analysis of stock price movements. Ms. Kindler has been recognized as among the top economic experts for IP matters by Intellectual Asset Management (IAM) in the IAM Patent 1000, which identifies leading patent professionals around the globe. Prior to joining Analysis Group, she held positions with two economics consulting firms.
)Professor Klausner teaches courses on corporate law, corporate governance, business transactions, and regulation of financial institutions. In recent years, most of his writing has been on corporate governance. He maintains a database on securities class actions and SEC enforcement actions, and has written papers and blog posts based on that database. In addition, Professor Klausner is currently writing a book and producing an online course called Deals: The Economic Foundations of Business Transactions.
Before beginning his academic career, Professor Klausner practiced law in Washington, DC, and Hong Kong. He was a White House fellow from 1989 to 1990, a law clerk for Judge David Bazelon on the United States Court of Appeals for the District of Columbia Circuit in 1981-82, and a law clerk for Justice William Brennan on the United States Supreme Court.
)Professor Hochberg specializes in entrepreneurship, innovation, venture capital, and private equity, focusing on venture capital networks, entrepreneurial finance, seed accelerators, and corporate governance and compensation. Her research covers topics such as venture capital investment performance, the effects of networks and syndication on venture capital firms, and investment selection. Professor Hochberg has also explored the private equity investment choices of pension funds and other institutional investors, as well as broad-based option compensation in firms. She is the managing director of the Seed Accelerator Rankings Project, which publishes annual rankings of accelerator programs in the US. Prior to joining the Rice faculty, she held positions at the Kellogg School of Management at Northwestern University and the Samuel Curtis Johnson Graduate School of Management at Cornell University. She has taught courses on entrepreneurial finance and health care innovation, and has served as an associate editor of several finance journals, including the Journal of Empirical Finance and the Journal of Banking and Finance. Professor Hochberg is a recipient of the Ewing Marion Kauffman Prize Medal for Distinguished Research in Entrepreneurship, and a research associate at the National Bureau of Economic Research. Prior to joining academia, she was a software engineer at both established and startup technology companies, and co-founded a startup. Professor Hochberg is an active angel investor and advisor to startups, and a Landmark Fellow with Landmark Partners, a large private equity investor in secondary markets. She is a co-founder of Flywheel Innovation, a corporate innovation advisory firm.
)Mr. Davis specializes in applying financial economics and data analysis to major litigation matters, with a focus on agricultural markets and pharmaceutical products. He has experience managing case teams, supporting academic affiliates and industry experts, and assisting clients through all phases of complex business litigation, including fact discovery, class certification, merits, trial, and settlement. Mr. Davis’s agricultural experience includes antitrust matters involving allegations of market power in animal protein markets, matters involving the presence of genetically modified products in US grain supplies, and matters involving international trade in agricultural products. His pharmaceutical work includes antitrust matters involving allegations of delayed generic entry, False Claims Act matters involving allegations related to the promotion of pharmaceuticals, and disputes pertaining to the commercial reasonableness of firm conduct.
Mr. Davis also has experience conducting economic research across a variety of industries, including financial services, agriculture, and pharmaceuticals, and analyzing issues related to commodity markets, futures prices, intellectual property and patents, industrial organization and antitrust law, and financial market infrastructure. He is a CFA charterholder.
)Dr. Schatzki has a broad range of expertise in energy, environment, finance, and competition matters. He supports clients in a range of contexts, including strategic and financial advice, policy analysis, regulatory and rulemaking proceedings, and litigation.
Dr. Schatzki has deep experience in electricity, natural gas, petroleum, and renewable energy. His expertise in the electricity sector includes wholesale energy and capacity market design; utility regulation and ratemaking; economic impact analysis of new market rules, regulations, and generation and transmission investments; contract analysis and disputes; financial valuation; and options analysis. Dr. Schatzki has testified before US state and federal, as well as Canadian provincial, regulatory commissions. He has supported the analysis of alleged market manipulation and damages in high-profile litigations such as FERC v. Barclays and lawsuits following the California electricity crisis.
Dr. Schatzki works extensively on environmental economics, policy, and regulation. Recently, he has focused on the intersection of climate policy and energy markets, and disputes involving water resources and environmental contamination. His research has been published in distinguished energy- and environment-related publications, and he has provided research for prominent organizations such as the Electric Power Research Institute, the Edison Electric Institute, and the Federal Energy Regulatory Commission.
In finance and competition matters, Dr. Schatzki has worked with clients on litigation and non-litigation projects in many sectors, including energy, financial instruments, foreign exchange, insurance, airlines, and retail products.
)Dr. Koehn specializes in applied microeconomics and finance. He has performed research and given economic testimony in antitrust, regulatory, tax, and other business litigation matters. The author of several publications on topics such as banking and finance, energy economics, and real estate, Dr. Koehn is a former adjunct associate professor of finance at the University of California, Irvine Graduate School of Management.
)Mr. Case is an institutional investment expert with significant expertise in the areas of investment governance, asset allocation, portfolio design and implementation, and portfolio analysis and reporting. As a former institutional investment consultant, he worked with a wide range of global clients, including insurers, health care organizations, corporate and public plan sponsors, family offices, and other large asset pools. Mr. Case was a partner at Mercer Investment Consulting, a practice leader at Evaluation Associates, and a senior consultant at Rogerscasey. He led client service teams for large clients, including defined-benefit and defined-contribution plans, insurers and mutual fund families, and registered investment advisors and foundations. As an expert, Mr. Case has evaluated various process-related issues, including the process used to monitor an ERISA plan’s investment advisor and delegated fiduciary. He previously worked as an investment analyst for AT&T’s pension investment team, oversaw the sub-advisory and pension assets of AXA Equitable Life, and managed the strategic relationship team at Putnam Investments. He is a CFA charterholder.
)Ms. Kirk Fair has extensive experience leading the development of economic and market analyses, assessing class certification and damages, evaluating consumer behavior, and testifying in a wide range of matters in the US, Canada, and Europe. She has been deeply involved in merger investigations and major antitrust litigation, as well as intellectual property (IP), false advertising, and tax matters. She also is a founder of the Analysis Group’s Surveys & Experimental Studies practice.
Ms. Kirk Fair specializes in evaluating competition and substitution patterns to examine potential competitive effects in mergers and “but-for” outcomes in antitrust litigation. She has significant analytical and testifying experience in cartel matters, notably in a number of prominent cases in the technology, consumer products, and financial services industries. She also has evaluated competition, pricing, and outputs in connection with merger investigations in the US, Canada, and the EU. In addition to having served as a compliance monitor for several years, she has supported the US Department of Justice (DOJ), the Federal Trade Commission (FTC), and the Canadian Competition Bureau (CCB) in a variety of merger investigations.
Ms. Kirk Fair also has particular expertise in the development, administration, and analysis of consumer surveys for use in antitrust, false advertising, and IP matters, as well as merger reviews and strategy cases. She has testified in arbitration, deposition, and trial in matters involving the design and implementation of consumer surveys, as well as the evaluation of opposing parties’ surveys and of statistical sampling and analyses. Her work has been used to support and critique damages models and to provide insights into the role of consumer choice in market definition.
Ms. Kirk Fair serves as a Vice-Chair to the American Bar Association (ABA) Antitrust Law Section’s Pricing Conduct Committee. She has received numerous awards for her accomplishments, including the W@ “40 in Their 40s: Notable Women Competition Professionals” and the Concurrences Antitrust Writing Award for her coauthored article “The Tyranny of Market Shares: Incorporating Survey-Based Evidence into Merger Analysis” (Corporate Disputes).
)Professor Riddiough is best known for his work on real options, mortgage pricing and strategy, REITs, and land use regulation. He has served as an expert in numerous real estate-related matters, in which he has testified on appraisal and the value of distressed mortgages. Professor Riddiough has consulted to numerous organizations, including the US Department of Housing and Urban Development, GMAC, Wells Fargo, Coldwell Banker Commercial, The Equitable Life Assurance Society, and the State of Wisconsin Investment Board. He has published more than 40 scholarly articles. He has served on the boards of directors of several organizations, including ArCap REIT, EquiBase Capital Partners, and the American Real Estate and Urban Economics Association. Professor Riddiough is the recipient of best dissertation and best paper awards in real estate economics, and is a fellow at the Real Estate Research Institute and a past fellow at the Homer Hoyt Institute. He teaches courses in real estate finance, real estate capital markets, and microeconomics.
)Professor Howell’s research focuses on entrepreneurship, private equity, fintech, and innovation. She is a research associate at the National Bureau of Economic Research, a fellow at the Asian Bureau of Finance and Economic Research, and a research fellow at the Institute for Private Capital’s Private Equity Research Consortium. She has testified before the US House of Representatives Ways and Means Committee and presented her work before the US Department of Energy, Senate Small Business Committee, Air Force, and Centers for Medicare & Medicaid Services. Professor Howell is the recipient of the AQR Asset Management Institute Young Researcher Award and the Kauffman Foundation Junior Faculty Research Fellowship, among other awards. She also serves as an associate editor of The Review of Financial Studies and a member of the advisory board to the American Female Finance Committee of the American Finance Association. Earlier in her career, Professor Howell was an energy security policy analyst and an energy consultant.
)Mr. Deal leads the economic analyses in the Menlo Park, California office and helps coordinate the firm’s Insurance practice. He combines an economics and risk analysis background with many years of experience in economic, litigation, and management consulting. He serves as a testifying and consulting expert on a wide variety of matters, often involving economic and statistical analysis of large datasets. His work as an expert has covered a variety of practice areas, including antitrust, economic damages, class action matters, and business valuation. Mr. Deal’s experience includes work in health care, insurance, finance, technology, and many other industries. He has coauthored a number of book chapters and studies, including The Economic Effects of Federal Participation in Terrorism Risk with R. Glenn Hubbard, an Analysis Group academic affiliate, former chair of the President’s Council of Economic Advisers, and former dean of the Columbia Business School.
)Professor Savitz focuses his epidemiological research on a wide range of public health issues, from the health effects of environmental agents in the workplace and community to a wide range of reproductive health outcomes. He has served as principal investigator on more than three dozen public health studies, including as one of three epidemiologists to evaluate the probable causal link between exposure to perfluorooctanoic acid and the development of certain diseases. Professor Savitz submitted an expert report on behalf of the plaintiffs at the class certification stage of a litigation matter and has consulted on a wide range of issues related to both environmental and reproductive epidemiology. He is the author of more than 300 journal articles and has edited or authored three books, including Interpreting Epidemiologic Evidence: Connecting Research to Applications. Professor Savitz has served as the editor of Epidemiology and the American Journal of Epidemiology, a member of the Epidemiology and Disease Control Study Section of the National Institutes of Health, president of the Society for Epidemiologic Research and the Society for Pediatric and Perinatal Epidemiologic Research, and North American regional councilor for the International Epidemiological Association. He is a member of the National Academy of Medicine and served as vice president for research at Brown University.
)Dr. Signorovitch advises life sciences companies on data analytics for business critical research and decision making. He has broad experience leading the strategic development and implementation of analytics across the product life cycle, from early-phase clinical studies to market access and real-world evidence generation. Dr. Signorovitch’s practice areas span trial design, multi-stakeholder collaborations, natural history studies, regulatory interactions, health economic modeling, global reimbursement submissions, policy evaluation, real-world evidence development, individualized medicine, predictive analytics, and due diligence for acquisitions. He has particular expertise in developing and applying new methodologies to address health care research challenges, and in designing analytics platforms to enhance collaborative research and decision making. Dr. Signorovitch’s work has been used to inform clinical regulators and health care payers in US and global markets, published in peer-reviewed journals, and presented at clinical and economic research conferences. Prior to joining Analysis Group, Dr. Signorovitch was a research fellow at the Harvard-MIT Division of Health Sciences and Technology.
)Professor Schoar is an expert in corporate finance, entrepreneurship, and organizational economics. Her research interests span from entrepreneurial finance to household finance and financial intermediation. Her research examines returns and capital flows in the venture capital industry, the financing of small and medium-sized enterprises and startup firms, and the role of consumer financial markets. Professor Schoar has served as an expert witness in cases involving commercial litigation and financial services. She is co-organizer of the Corporate Finance Working Group at the National Bureau of Economic Research, a former member of the Consumer Financial Protection Bureau’s Academic Research Council, and co-founder and scientific director of ideas42, a research lab on behavioral social science. She has published numerous articles and papers and received several awards for her research, including the Ewing Marion Kauffman Prize Medal for Distinguished Research in Entrepreneurship and the Brattle Group Prize in Corporate Finance for her paper “The Effects of Corporate Diversification on Productivity.” She has served as an associate editor of The Journal of Finance, the American Economic Journal: Applied Economics, and the Journal of Economic Perspectives. Professor Schoar’s work has been featured in The Economist, the Financial Times, The New York Times, and The Wall Street Journal.
)Professor Chalmers is an expert in securities issues, including the trading behavior of investors and the pricing of securities. He has undertaken extensive research in municipal bonds, mutual funds, and trading costs, much of which has been published in leading peer-reviewed academic journals, including The Journal of Finance, the Journal of Financial Economics, and The Review of Financial Studies. In the area of mutual funds, his research with Professors Roger Edelen and Greg Kadlec discovered and explained the source of perverse incentives exploited by so-called market timers in their trading of mutual funds. He has also written about stale pricing problems in equity mutual funds and mutual fund transaction costs, and has collaborated with other mutual fund experts, such as Professors Daniel Bergstresser and Peter Tufano, on research analyzing fund performance across fund marketing channels. He also has extensive expertise in municipal bond pricing and valuation issues. Professor Chalmers' research has been cited in reports by the General Accounting Office and in several testimonies provided before the House Financial Services Committee, as well as being widely referenced in major media outlets. He has authored several expert reports and provided testimony before the US District Court of Wisconsin.
)Dr. Lehmann specializes in applying microeconomics, econometrics, and statistical methods to complex litigation and regulatory investigations in the areas of antitrust and competition, labor and employment, and health care. In antitrust and competition matters, she has evaluated market definition, market power, and competitive dynamics, and analyzed class certification, liability, and damages issues in cases involving allegations of price-fixing, monopolization, and other anticompetitive conduct. Dr. Lehmann has extensive experience in labor market antitrust matters involving allegations of no-poach and wage-fixing agreements in a variety of industries. In the area of health care, she frequently collaborates with biostatisticians, epidemiologists, scientists, and regulatory experts in evaluating research and development processes and analyzing clinical trial, laboratory testing, registry, claims, and adverse events data in product liability litigations and patent and licensing disputes involving pharmaceuticals, medical devices, and chemical products.
Her employment and antitrust research has been published in the Journal of Economic Literature, The Journal of Human Resources, Labour Economics, Cartel & Joint Conduct Review, and Distribution, and her academic work has been cited in a number of leading media outlets, including Scientific American, Forbes, and BBC News. She serves as vice-chair of the Distribution and Franchising Committee of the American Bar Association (ABA) Antitrust Law Section. Prior to joining Analysis Group, Dr. Lehmann was an assistant professor of economics at the University of Houston, where she taught undergraduate and graduate courses in labor economics.
)Dr. Kupiec’s research interests include quantitative financial risk measurement, systemic risk, deposit insurance, and the regulation of banking and financial services. At the American Enterprise Institute, he has authored several studies on systemic risk measurement and related regulations, bank stress testing, and bank regulations that follow financial crisis, including their impact on the wider economy. Dr. Kupiec was an associate director of the Division of Insurance and Research and director of the Center for Financial Research (CFR) at the Federal Deposit Insurance Corporation. In these roles, he oversaw research on bank risk measurement that contributed to the development and implementation of regulatory policies, including the international Basel III framework. He also served as chairman of the Research Task Force of the Basel Committee on Banking Supervision. Dr. Kupiec has worked at the International Monetary Fund, Freddie Mac, and J.P. Morgan, as well as for the Division of Research and Statistics at the Board of Governors of the Federal Reserve System. Prior to entering the financial services industry, Dr. Kupiec was an assistant professor of finance at North Carolina State University. He has published articles in several academic journals, including The Journal of Finance, the Journal of Financial Intermediation, the Journal of Financial Stability, the Journal of Financial Services Research, The Journal of Risk, and the Journal of Investment Management.
)Mr. Decter specializes in the application of microeconomics, finance, and data analysis to complex securities and antitrust litigation and business strategy cases, most notably in matters related to residential mortgage-backed securities, collateralized debt obligations and credit default swaps, residential mortgage lending, mortgage reinsurance, commercial insurance, private equity, and payment cards. He has conducted damages analyses, and supported multiple experts in the areas of statistical sampling, loan and securities underwriting, damages, and loss causation.
Mr. Decter's business litigation experience focuses on finance matters in which he has managed large case teams and data sets in working with testifying experts. He supported academic affiliates in their examination of class certification issues related to commonality, predominance, and causation in In re Countrywide Financial Corp. Mortgage Marketing and Sales Practices Litigation, a mortgage marketing matter in which the plaintiff's motion for class certification was denied. Mr. Decter also supported an expert in filing a report on behalf of the defendants in New Jersey Carpenters Vacation Fund et al. v. The Royal Bank of Scotland Group plc et al., a case that marked the first major ruling on class certification among the numerous mortgage-backed securities actions pending in courts across the country at the time. He has also conducted damages analyses and worked with experts in numerous securities, antitrust, and intellectual property cases. Mr. Decter's business strategy engagements related to strategic pricing, portfolio management, and economic cost studies have spanned multiple industries, including pharmaceuticals, telecommunications, information technology, and manufacturing.
Prior to joining Analysis Group, Mr. Decter was a management consultant in the telecommunications industry. He also has several years of telecommunications industry experience in strategic planning, business development, and product management.
Professor Savoldelli is a finance and investment expert with over 25 years of experience analyzing and advising on a wide range of hedge fund-focused issues, including fund performance, portfolio construction, fund administration, due diligence, capital raising, and asset allocation. He served as a chief investment officer for four different institutions: Optima Fund Management, Merrill Lynch, Swiss Bank Corp. Asset Management, and Chase Manhattan Private Bank. In these roles, he oversaw over $80 billion in assets.
Over the course of his investment career, Professor Savoldelli’s responsibilities included selecting hedge funds for the allocation of investor assets, making asset allocation decisions, managing investment portfolios, developing investment policies, and overseeing investment manager adherence to investment strategy and policy. He has deep experience related to the challenging issues hedge fund managers may face, including those related to fiduciary duty, disclosure, liquidation, side-pockets accounts, and valuation of complex and illiquid assets. Additionally, he is knowledgeable about the roles and responsibilities of hedge fund service providers such as prime brokers, marketers, administrators, and auditors.
At Columbia Business School, Professor Savoldelli teaches a course in the M.B.A. program on the investment strategies employed by hedge funds and best practices for the operational aspects of hedge fund management, including fund administration selection, operational risk evaluation, and leverage risk. In addition, he is a contributing editor on Bloomberg Television, commenting on developments from a hedge fund perspective.
)Professor Slottje has deep experience in both academia and economic consulting. An emeritus professor of economics at Southern Methodist University, he has been working in litigation consulting for more than three decades in senior positions with several international firms. He has worked with many leading law firms, testifying at deposition and trial in hundreds of prominent matters.
An economist and a statistician, Professor Slottje is an expert in the fields of labor economics, consumer demand, industrial organization, and statistics and econometrics, allowing him to bring a unique perspective and skill set to his consulting assignments. He has published more than 150 journal articles and more than a dozen books, and has been ranked among the world’s top three scholars in applied econometrics based on his publishing record in the field. Professor Slottje is a member of the American Economic Association, the American Statistical Association, and The Econometric Society.
)Professor Kahn’s research interests include brand management and loyalty, consumer choice and decision making, price promotions, and retailing. She has served as an expert witness and testified at deposition in numerous matters. Professor Kahn is the author of Global Brand Power: Leveraging Branding for Long-Term Growth and The Shopping Revolution: How Retailers Succeed in an Era of Endless Disruption Accelerated by COVID-19, and coauthor of Grocery Revolution: The New Focus on the Customer. She has published more than 70 articles in leading academic journals. She is a former area editor of Marketing Science, the Journal of Consumer Research, the Journal of Consumer Psychology, and the Journal of Marketing, and has served on the editorial boards of the Journal of Marketing, the Journal of Marketing Research, Marketing Science, the Journal of Consumer Research, the Journal of Behavioral Decision Making, and Marketing Letters. Prior to joining The Wharton School, Professor Kahn was on the faculty of the UCLA Anderson School of Management. She also served as dean of the Miami Herbert Business School.
)Professor Hart is a leading expert in contract theory, the theory of the firm, and corporate finance. In 2016, he and Professor Bengt Holmström were awarded the Nobel Prize in Economics for their work in contract theory. Professor Hart’s research centers on the roles that ownership structure and contractual arrangements play in the governance and boundaries of corporations. His recent work involves determining how parties can write better contracts, as well as how a new model of corporate governance can better incorporate the importance shareholders place on nonfinancial criteria.
Professor Hart has consulted to businesses and government entities, and provided expert testimony on contract and governance disputes in which he has evaluated the business purpose and economic substance of special purpose entities. As an expert on behalf of Qualcomm in Apple v. Qualcomm, he provided guidance on the optimal structure of contracts, and why and when they should be enforced. His book Firms, Contracts, and Financial Structure is a leading work in the fields of contract theory and corporate finance. He has published widely in peer-reviewed journals and contributed to the Financial Times and The Wall Street Journal. Professor Hart is a member of the IGM (Initiative on Global Markets) Economics Experts Panel of The University of Chicago Booth School of Business, and is affiliated with the Program on Corporate Governance at Harvard Law School’s John M. Olin Center for Law, Economics, and Business. He is a past president of the American Law and Economics Association.
Professor Baker is an expert in health care economics, including the effects of regulation on health care markets, physician market structure, the effects of managed care and insurance market competition on health care delivery and spending, and the determinants and impact of medical technology adoption. He has served as a consultant and advisor to health plans, government programs and public initiatives, and firms providing health care services and developing new health care products. Professor Baker’s research has been published in leading academic journals, including JAMA, The New England Journal of Medicine, American Economic Review, and the Journal of Health Economics. He is an elected member of the National Academy of Medicine and the recipient of the American Society of Health Economists’ ASHEcon Medal, which recognizes the top American health economists age 40 or under. Professor Baker’s studies of the relationships between area characteristics and health care delivery have twice won the NIHCM Foundation Health Care Research Award.
Ms. Comeaux specializes in the application of finance and economics to complex business litigation and damages estimation. She has led teams across a broad range of matters involving commercial disputes, antitrust and competition, and securities and finance. Her clients include leading media and technology companies, financial institutions, global manufacturers, and life sciences companies. Ms. Comeaux has provided assistance through all phases of pretrial and trial practice, including expert search, fact discovery, class certification, quantification and rebuttal of damages, expert testimony, trial preparation, and settlement negotiations. She has also assisted clients in mass arbitration proceedings, regulatory investigations, and strategy engagements.
Ms. Comeaux has experience with a wide range of empirical methodologies, particularly within the context of damages analyses. Her work regularly involves critical examination of theories of liability, development of models to quantify damages, and both quantitative and qualitative analyses in response to allegations of negligence or punitive damages. She has worked with a wide variety of academic and industry experts to assess organizational, industry, and market conditions in order to contextualize analyses of damages. Ms. Comeaux has particular expertise in organizational assessments that address theories of liability, including reviewing and responding to the results of assessments conducted by regulators and third parties.
Professor Reuter specializes in examining the behavior of individual investors and financial institutions, including mutual fund families, investment banks, rating agencies, financial advisors, and the financial media. His work focuses on the value of financial advice, the strategic behavior of target-date retirement funds, and portfolio management outsourcing in the mutual fund industry. In addition to his academic experience, Professor Reuter has served as an expert in a mutual fund fee litigation, filing an expert report and testifying at deposition. He has also provided testimony to the US Department of Labor (DOL), which summarized his research on the behavior of brokers and broker-sold mutual funds.
Professor Reuter has published a number of articles on topics such as mutual fund performance, the effect of pension design on employer costs and employee retirement choices, and the effect of advertising on product reviews. This research has been published in leading academic journals, including The Journal of Finance and The Quarterly Journal of Economics; mentioned in media outlets such as The New York Times and The Wall Street Journal; and cited by the President’s Council of Economic Advisers and the DOL. Professor Reuter also serves as an editorial board member of the Journal of Pension Economics and Finance. He is a research associate at the National Bureau of Economic Research (NBER) and a fellow at the TIAA Institute.
Dr. Chapsal is an economist who specializes in empirical and theoretical industrial organization. He has provided economic expertise in a large number of high-profile cases involving mergers, cartels, information exchanges, abuses of dominant positions, regulation, intellectual property matters, and damages quantifications. Recent examples include the Lafarge/Holcim and Fnac/Darty mergers, as well as airfreight, cathode ray tube, and elevator cartel cases. Dr. Chapsal has also assisted various firms in designing optimized pricing strategies and dealing with policy issues. His reports have been presented to the competition authorities of France, Germany, Austria, and South Africa; the European Commission; the Higher Regional Court of Düsseldorf; and the Court of Appeals, Conseil d’Etat, Conseil constitutionnel, and Tribunal of Commerce of Paris.
Prior to joining Analysis Group, Dr. Chapsal founded MAPP, a Paris- and Brussels-based economic consultancy, which was acquired by KPMG in 2018. Previously, he worked in a US competition economics consultancy. Dr. Chapsal regularly publishes articles on competition economics, on subjects ranging from the econometric analysis of cartels to geographic market delineation and exclusionary strategies. He is an affiliated professor at the Sciences Po Department of Economics and a member of the CESifo academic research network.
Mr. Malinak specializes in financial economics, with particular expertise in damages estimation, applied finance theory, and business and asset valuation. He has provided deposition, arbitration, and trial testimony on economic damages and valuation issues, and has testified on financial integrity, the cost of capital, and economic issues in utility rate hearings and at a Federal Energy Regulatory Commission (FERC) hearing. Mr. Malinak has directed litigation projects in many industries on issues related to securities (including derivative securities), antitrust, breach of contract, taxation, regulatory economics, and intellectual property claims. He has frequently addressed class certification and damages issues in securities fraud cases, as well as the myriad economic, financial, and accounting issues common to most damages calculations, such as cost of capital and prejudgment interest. Mr. Malinak has significant experience in tax-related work, including leading Analysis Group teams in Black & Decker, Inc. v. United States and Chemtech Royalty Associates L.P. v. United States, as well as in financial institutions and risk management, having led consulting teams supporting experts in the Winstar savings and loan litigations. He also completed a major project on the risk of Fannie Mae, resulting in a white paper authored by an academic affiliate. He has served as treasurer, head of the audit and finance committee, and a member of the executive committee and board of directors of the Meridian International Center, an international leadership organization that works with partners in the government, private, NGO, and educational sectors to create lasting international partnerships through leadership programs and cultural exchanges. Prior to joining Analysis Group, Mr. Malinak was a principal at Putnam, Hayes & Bartlett.
Dr. Brackley is board certified in internal medicine and an expert in patient and medical safety. Her deep knowledge of clinical trial management includes clinical events committees and safety event reviews, as well as pharmacovigilance, post-market processes, field actions, and risk management. She has consulted on these issues to medical device, diagnostic, and pharmaceutical companies for over a decade. Dr. Brackley’s expert experience includes providing medical insight, post-market surveillance, and pharmacovigilance expertise in complex legal matters, in which she has submitted expert reports and testified at deposition; supporting legal teams in their review and understanding of complex medical and epidemiological issues; and reviewing medical records, complaints, and regulatory submissions. She has provided safety oversight and medical review expertise in clinical studies, and developed processes for clinical trial adjudication and data safety monitoring boards. In addition, Dr. Brackley has created strategies for developing and optimizing medical safety groups in the medical device, diagnostic, and pharmaceutical industries, including processes, procedures, organizational structure, implementation, and rollout. Earlier in her career, as a vice president and medical safety officer at Boston Scientific, she provided safety oversight and safety vigilance throughout the product life cycle and was involved in strategic decision making across all products worldwide. Prior to her roles in industry, Dr. Brackley completed a residency in internal medicine. She is a member of the American Medical Association, the Massachusetts Medical Society, and the Regulatory Affairs Professionals Society.
Ms. Comstock has extensive experience applying economic and financial analyses to litigation and other complex business situations. She has assisted clients in all phases of the litigation process, including fact and expert discovery, trial preparation, and settlement negotiations. Ms. Comstock’s case work has involved litigation related to the high-profile bankruptcies of several firms. She has provided consulting support and supported experts in cases related to the alleged manipulation of different benchmark rates, including evaluations of the effects of alleged manipulation on the value of different derivatives and securities. She has also provided consulting and expert support in matters involving alleged violations of Rule 10b-5 and Section 11, and on matters related to mortgage-backed securities. Ms. Comstock has supported experts in ERISA-related litigations, alleged breach of contract matters, and other business and valuation disputes.
Mr. Beach has more than 30 years of experience valuing businesses; rendering fairness opinions; and negotiating, structuring, and closing mergers and acquisitions (M&A), financings, strategic alliances, and joint ventures. During his career, he has closed over 100 M&A transactions and over 100 financings for companies in the technology, health care, consumer products, and financial services industries. He has frequently served as an expert witness in complex litigation matters involving shareholder rights and valuation, and has testified several times in Delaware Chancery Court. As founder and president of Business Consulting Group, LLC, Mr. Beach oversees the firm’s valuation and advisory work for corporate transactions. Earlier in his career, Mr. Beach was head of corporate finance for KPMG and head of investment banking at Advest, Inc. In addition, he was president and co-founder of Boston Corporate Finance, a boutique investment banking firm focused on providing M&A, capital-raising, and general advisory services to global companies in the technology sector. He has served on the board of numerous companies and organizations, and has advised many companies on their strategic development and direction. Mr. Beach has been a guest lecturer at Harvard Business School, Cornell University, and Dartmouth College. He has been a certified public accountant and is a registered principal with the Financial Industry Regulatory Authority (FINRA).
Mr. Hille has more than 30 years of experience in investment management. In his former role as chief investment officer at Texas Christian University (TCU), he was responsible for the day-to-day management of its multibillion-dollar investment program, which includes the operation and fiduciary oversight of the university’s endowment assets. His responsibilities also included implementing approved investment policies; developing investment processes and procedures for risk management and asset allocation, monitoring, and evaluation; investment manager selection and termination; and identifying management strategies to improve the program’s investment performance and efficiency. Prior to joining TCU, Mr. Hille was chief investment officer of the Teacher Retirement System of Texas, the state’s largest public pension plan. Earlier in his career, he managed portfolios for the Employees Retirement System of Texas. He currently serves on the investment advisory and trustee boards of the Employees Retirement System of Texas and the Texas Treasury Safekeeping Trust Company, as well as on the board of trustees of the Communities Foundation of Texas. Mr. Hille has served as president of the Austin Society of Financial Analysts and as an adjunct professor of finance at the University of Texas McCombs School of Business. He is a Chartered Financial Analyst (CFA) and Chartered Alternative Investment Analyst (CAIA) charterholder.
Mr. Richard has more than 20 years of experience in institutional money management. He was a founder of Taurus Horizon Fund, where he was a managing partner and fund manager for the strategy. Previously, he served at State Street Global Advisors as a senior fixed-income portfolio manager. The assets under his management exceeded $15 billion dollars. Mr. Richard's investment expertise spans a variety of security types, including unsecured corporate credit and securitized structures (such as ABS, MBS, CMBS, and CDO). Over his career, Mr. Richard has also taken an active role in trading securities and performing due-diligence credit work on underlying collateral.
Mr. Richard has provided expert reports, rebuttal reports, deposition testimony, and trial testimony in a number of securities-related cases, opining on issues related to valuation, portfolio manager due diligence, investment suitability, and market conditions, among others. He has served as an expert witness in securities litigation in which he analyzed structured investment vehicles (SIV) on behalf of a large investment bank, and has opined on issues related to the residential mortgage-backed security (RMBS) market. He has also provided consulting services on matters related to auction-rate securities and embedded swap agreements within structured finance instruments. He is a Chartered Financial Analyst and a member of the Boston Security Analysts Society.
For more than 25 years, Mr. Christensen has worked on high-stakes litigation matters with world-class experts, supporting their testimony at both bench and jury trials. His work has focused on valuation and appraisal matters, private equity disputes, antitrust and consent decree litigations, bankruptcy, and tax and transfer pricing dispute resolutions. Through his extensive experience, he has developed a deep understanding of the high-tech, digital advertising, pharmaceutical, media and entertainment, and finance industries. In addition to his litigation work, Mr. Christensen has also assisted in the preparation of numerous impact studies in the high-tech space on issues such as cloud computing and storage, broadband availability, virtual and augmented reality, artificial intelligence, and the metaverse. His clients have included Meta/Facebook, Google, GSK, AstraZeneca, JAB Holding Company, Bank of America, BNP, and Fidelity. Among his engagements are high-tech antitrust matters, a GSK transfer pricing dispute, the Nortel Networks bankruptcy, Delaware appraisal trial victories involving PetSmart and Panera, and rate-setting trials for BMI. Mr. Christensen is a CFA charterholder.
Professor Christoffersen’s research focuses on mutual funds, hedge funds, and the role of financial institutions in capital markets. She has been retained as an expert in litigation matters to address topics such as mutual fund market timing and trading strategy issues. She has published in a number of finance journals, and her work has been cited in The New York Times, the International Herald Tribune, Bloomberg News, and The Wall Street Journal. Professor Christoffersen has received grants from Canada’s Social Sciences and Humanities Research Council, the Montreal Financial Mathematics Institute, and the Quebec Research Funds, as well as research awards from Q Group, the Bank of Canada, the BSI Gamma Foundation, INQUIRE, and the Swiss Finance Institute. Prior to joining the faculty at the University of Toronto, she held positions at McGill University, Copenhagen Business School, and the Department of Finance Canada.
Mr. McLean specializes in applying finance and economics to problems in complex business litigation, including securities, valuation, tax, and intellectual property (IP) matters. His experience spans several industries, from banking, insurance, and high tech to telecommunications and health care. He has served as an expert witness, and has provided assistance in many phases of litigation, including development, presentation, and review of pretrial discovery; preparation of testimony; and critique of analyses of opposing experts.
Mr. McLean’s case work has included general damages analyses, lost profit and reasonable royalty calculations related to IP misappropriation, and assessments of fiduciary duties and investment management. In addition, he has evaluated the economic characteristics and risk transfer of a range of financial instruments, such as private mortgage insurance, subprime loans, and preferred equity in a new venture. He has led large case teams in a number of high-profile matters, including consulting to the US Department of Justice (DOJ) regarding the financial issues involved in tribal trust fund disputes, and supporting counsel for a large electronics manufacturer in litigation associated with features on smartphones and tablets.
In addition, Mr. McLean has presented on topics related to damages assessment and patents. He has also worked with entrepreneurial companies, helping to develop financial projections, business plans, and marketing strategies.
Professor Hubbard is a leading expert in public economics, corporate and institutional finance, macroeconomics, antitrust, and industrial organization. He has provided trial and deposition testimony in numerous litigation matters, including more than a dozen cases in the Delaware Chancery Court. He has also served as a testifying expert in several high-profile finance- and securities-related cases, as well as on damages issues in antitrust matters. Professor Hubbard has consulted to several government and international agencies, including the US Department of the Treasury, the US International Trade Commission, the US Securities and Exchange Commission, the World Bank, the Board of Governors of the Federal Reserve System, the Federal Reserve Bank of New York, and the Congressional Budget Office. From 2001 to 2003, he served as chairman of the President’s Council of Economic Advisers.
Professor Hubbard has published more than 100 scholarly articles and coauthored several books, including the widely used textbook Money, the Financial System, and the Economy. His commentaries have appeared in Businessweek, The Wall Street Journal, The New York Times, the Financial Times, and The Washington Post, as well as on PBS television and NPR radio business programs. A frequent speaker, Professor Hubbard has presented his research at economic conferences throughout the world.
Ms. Cotton has extensive experience conducting complex quantitative and qualitative analyses of data in both mergers and litigation matters. She has supported experts from leading universities and managed case teams in a broad range of industries on matters related to antitrust, bankruptcy, class certification, intellectual property, securities, survey design, tax, and transfer pricing. Her recent case work has included assessing competitive effects in major antitrust matters and mergers; analyzing Federal Trade Commission (FTC), US Department of Justice (DOJ), and Canadian Competition Bureau (CCB) merger compliance, including assistance with Hart-Scott-Rodino (HSR) filings, second requests, divestiture analysis, advocacy, and merger trial testimony; managing the independent evaluation of large-scale transaction and customer datasets in major antitrust matters; examining damages issues in a data breach context; and determining arm’s-length pricing in a large US transfer pricing matter. Ms. Cotton also has substantial experience evaluating questions of commonality and typicality in the context of privacy, technology, data breach, pharmaceutical, medical device, and overcharge class actions.
Professor Blanchard’s research combines experiments with observational data analyses to study how consumers make complex decisions about finance and technology. He serves as a marketing and research expert in commercial litigation and advises financial services and technology companies on business strategies and research. Professor Blanchard is the director of Georgetown’s M.B.A. Certificate in Consumer Analytics and Insights program, and he teaches courses on research design, surveys, and quantitative analyses to undergraduate, graduate, and executive education program students. He has been named among the best 40 business professors under 40 by Poets&Quants, and a Young Scholar by the Marketing Science Institute.
Professor Blanchard is an associate editor of the Journal of Marketing Research, the Journal of Consumer Research, and the International Journal of Research in Marketing, and he has published articles in a number of prominent marketing journals. Professor Blanchard’s research and perspectives on consumer finances and technology have been featured in media outlets such as Forbes, Fortune, Harvard Business Review, NerdWallet, The New York Times, Marketplace, and NBC News. Prior to joining the Georgetown faculty, he served as a member of the American Marketing Association’s Academic Council, and held visiting positions at Dartmouth College and Columbia University.
Mr. Richardson has more than 30 years of experience as a senior executive at institutional asset management firms, most recently as executive director of client service and business development and member of the global management team at Impax Asset Management Group. Throughout his career, Mr. Richardson has been responsible for overseeing the management of institutional investment portfolios of fixed-income, listed equity, and private securities. During the final decade of his tenure as head of Impax’s North American business, these portfolios were managed with a particular focus on the role of environmental, social, and governance (ESG) factors in investment management decisions. He has consulted to public and private companies in numerous industries, including financial services and insurance, on investment, governance, and compliance matters. Mr. Richardson has had oversight of a full range of investment portfolios offered through different fund vehicles, including 40 Act funds, commingled funds, collective trust funds, limited partnerships, and segregated accounts. He has been responsible for client, asset, and revenue growth, as well as new product initiatives and M&A. Mr. Richardson testified at deposition and trial, and has contributed to articles on sustainable investments for media outlets such as the Financial Times, The New York Times, and CNBC. Prior to his work with Impax, he co-founded Global Energy Investors, a private equity infrastructure firm, and Dwight Asset Management, an institutional fixed-income investment firm that was subsequently acquired by Goldman Sachs. He serves as a member of the Global Leadership Council for the World Resources Institute, and as a member of the President’s Council for Ceres. Mr. Richardson is a CFA charterholder.
Dr. Cliff is a financial economist with expertise in a range of topics, including asset valuation, mergers and acquisitions (M&A), tax shelters, stock analysts’ recommendations, IPOs, REITs, derivatives, and hedge funds. He has extensive experience with large financial datasets, sophisticated econometric models, and simulations. In his consulting engagements, Dr. Cliff has addressed damages modeling, class certification, business and asset valuation, analysis of complex financial structures, analysis of solvency and debt covenants, evaluation of investment strategies, and assessment of due diligence practices. In these assignments, he has managed large case teams, designed and performed analyses in support of expert reports, critiqued opposing expert reports, and assisted with preparation for depositions and trial. Dr. Cliff has also served as an expert on cases involving valuation, damages, and liquidity discounts. Prior to joining Analysis Group, Dr. Cliff was a finance professor for nine years at Purdue University and Virginia Tech, where he taught a variety of courses at the undergraduate, M.B.A., and Ph.D. levels. His academic research has been published in leading journals such as the Journal of Finance, the Journal of Business, and Financial Management.
Professor Eden is an expert on transfer pricing and multinational enterprises (MNEs), with decades of experience consulting to MNEs, governments, and international organizations on transfer pricing and MNE strategies and structures. In transfer pricing matters, she has served as an expert witness – in cases that include Coca-Cola Co. v. Commissioner and In re: Nortel Networks – and filed numerous expert reports. Professor Eden has taught courses on transfer pricing, MNEs, and the economics of international business, and founded the Transfer Pricing Aggies program at Texas A&M University, which has trained hundreds of graduate students. She has extensive research experience in areas such as transfer pricing and MNE strategies in the digital economy, and her work has been widely published in management and international business journals. Professor Eden has authored several books, including Taxing Multinationals: Transfer Pricing and Corporate Income Taxation in North America, Multinationals in North America, The Economics of Transfer Pricing, and Research Methods in International Business. She is a frequent speaker at transfer pricing and tax conferences, as well as dean of the Fellows of the Academy of International Business, where she formerly served as president.
Dr. Mortimer specializes in health economics, industrial organization, microeconomic theory, and econometrics. He has extensive experience with issues involving competition, intellectual property, marketing, pricing, and valuation with a focus on the health care industry. He has evaluated questions of class certification, damages, liability, and market definition in antitrust matters. He also has provided economic analyses and expert testimony on causation and damages in a variety of health care cases, including cases involving allegations of False Claims Act (FCA) and Anti-Kickback Statute (AKS) violations. In addition to his work in litigation, Dr. Mortimer has assisted pharmaceutical and medical device manufacturers on pricing and contracting issues and authored several public policy studies related to legislation establishing a biosimilar approval pathway, biosimilar competition, pharmaceutical pricing, generic drug competition and the role of authorized generic entry, and paragraph IV abbreviated new drug application (ANDA) filings. His research has been published in leading peer-reviewed journals, including Health Affairs, Nature Reviews Drug Discovery, The Journal of Industrial Economics, and the Journal of Medical Economics.
Professor Jena is a health economist, practicing internal medicine physician, and professor of health care policy. His work involves several areas of health economics and policy, including the economics of medical innovation, the economics of physician behavior and the physician workforce, medical malpractice, and the economics of health care productivity. Professor Jena has been retained as an expert in several pharmaceutical and health care industry matters.
A prolific author, Professor Jena has contributed to more than 150 peer-reviewed articles and articles intended to increase patient understanding, published in outlets including the New England Journal of Medicine and The New York Times. He is a faculty research fellow at the National Bureau of Economic Research and serves on Harvard Medical School's Standing Committee on Health Policy. Professor Jena is a recipient of the NIH Director's Early Independence Award to fund research on the physician determinants of health care spending, quality, and patient outcomes, and a recipient of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) New Investigator Award. In 2018, he was listed among 100 great leaders in health care by Becker's Hospital Review.
Dr. Dawson specializes in applying economics and finance to complex problems in business litigation, including intellectual property (IP), false advertising, securities, and finance matters. Her experience spans several industries, from medical devices and high tech to telecommunications and accounting. Dr. Dawson has consulted to counsel in all phases of the litigation process, including understanding complex claims, assisting with fact and expert discovery, and providing trial support. She has served as an expert witness on matters involving false advertising, breach of contract, and copyright infringement. Dr. Dawson’s case work has involved complex data analysis, development of financial models, general damages assessment, evaluation of lost profits, royalty, and other damages remedies in IP and false advertising matters, ascertainment of loss causation and damages in securities fraud matters, and financial statement analyses. She has spoken at various conferences and served as a panelist on the topics of platform economics and IP damages.
Mr. Bodington specializes in the business and finance aspects of the electric power industry. He is the founder of a boutique investment banking firm that has provided M&A, financing, and restructuring advisory services to the energy sector for more than 25 years. Mr. Bodington has played a key role in more than 100 transactions with an aggregate value of more than $7 billion. In these engagements, he has led the purchase and sale of interests in power projects; arranged debt and equity financing for energy projects in development, construction, and operation; and advised owners and lenders on various capitalization, value, repayment, restructuring, and management issues. His clients include industrial companies, independent power companies, equity investors, lenders, utility affiliates, and regulated utilities.
Mr. Bodington is also a seasoned expert witness who has provided testimony for clients on finance and damages issues. Prior to founding Bodington & Company, he spent eight years with Bechtel Group and four years with an international management consulting firm. Mr. Bodington is the author of more than 50 articles on a variety of economic and financial topics relevant to the energy sector. He holds Financial Industry Regulatory Authority (FINRA) Series 7, 24, 63, 79, and 99 licenses.
Dr. Robbins is a pharmaceutical and biotech executive with over 40 years of broad-based industry experience. In his role at Kodiak Strategic Consultants, he consults to a diverse group of pharmaceutical and biotech companies on clinical, regulatory, business development, and licensing issues. Dr. Robbins served as a CEO in residence at the University of Minnesota’s Office for Technology Commercialization and co-founded several biotech ventures. He is actively involved with a number of startups, including GigaMune, Neuropharma Meds, and Diastol Therapeutics. He served as the COO of Bullet Biotechnology, regulatory strategic advisor to GigaGen, and acting CEO of GigaMune, all of which have focused on novel immunotherapies targeting cancer and autoimmune diseases. Dr. Robbins has served as an expert in multiple antitrust matters, intellectual property cases, and contract disputes, and provided testimony at deposition, trial, and arbitration. Prior to his consulting career, he held several senior-level positions at brand and generic pharmaceutical companies, where he was responsible for the development of regulatory and clinical strategies that led to numerous new drug application (NDA), biologics license application (BLA), and abbreviated new drug application (ANDA) approvals by the US Food and Drug Administration (FDA). He has conducted analyses in therapeutic areas that include cardiology, oncology, endocrine/metabolic, women’s health, infectious diseases, radiology, and nuclear medicine and diagnostics. In addition, Dr. Robbins has experience assisting biotech startups with strategy and financing. He holds adjunct professorships in pharmacology at the University of Minnesota Medical School and the University of Minnesota College of Pharmacy, and his work has been published in numerous peer-reviewed scientific journals. Dr. Robbins serves on the Antitrust Council of the Minnesota State Bar Association.
Mr. Cohen has over 30 years’ experience as an expert in international arbitration, valuation, antitrust, intellectual property, and securities, and has testified in arbitration and federal courts on many aspects of economic damages. He specializes in fields that are intensive in intangible assets such as patents, copyrights, trademarks, and trade secrets. He has worked across a wide range of industries, including health care, software and technology, financial services, energy, transportation, and entertainment.
Mr. Cohen has worked with significant corporations including Apple, Microsoft, Oracle, Wells Fargo, State Street, Wachovia, SoundExchange, ASCAP, Liberty Mutual, Allstate Insurance, Johnson & Johnson, AstraZeneca, Astellas, United Airlines, TWA, DaimlerChrysler, Mitsubishi, and Anheuser-Busch. He also has experience in matters related to the US Federal Trade Commission, the US International Trade Commission, the Tax and Antitrust Divisions of the US Department of Justice, the Republic of Uruguay, and the Commonwealth of Australia.
Mr. Cohen is the author of Intangible Assets: Valuation and Economic Benefit and a contributor to the American Bar Association publication Proving Antitrust Damages. He has been a guest lecturer at both Northwestern University and The University of Chicago. He is also a prolific songwriter.
Professor Hylton has over 30 years of experience researching legal issues in antitrust, merger, and intellectual property cases. He is an expert on tort law, labor law, civil procedure, and empirical legal analysis. A prolific author, Professor Hylton has published 5 books and more than 100 scholarly articles on topics such as oligopoly pricing, the intersection of antitrust and intellectual property, and damages in patent infringement cases. He is an associate editor of the International Review of Law and Economics, a former contributing editor of the Antitrust Law Journal, coeditor of Competition Policy International, and editor of the Social Science Research Network’s Torts & Products Liability Law eJournal. Professor Hylton is a past president of the American Law and Economics Association, and previously served as the organization’s secretary-treasurer and vice president. He is a member of the American Law Institute and serves on the board of directors of the Pioneer Institute. Prior to joining Boston University, Professor Hylton was awarded tenure as a faculty member at Northwestern University School of Law and served as a research fellow at the American Bar Foundation.
Professor Knittel’s research focuses on industrial organization, applied econometrics, and energy and environmental economics. He has provided trial and deposition testimony in a number of litigation matters, including valuing product features in smartphones, PCs, and contact lenses. He has also consulted to Delta Airlines, Ford Motor Company, the US Energy Information Administration, and Korea Electric Power Company. Professor Knittel has authored or coauthored numerous articles on topics such as market structure and product pricing, tacit collusion, and challenges in merger simulation analysis. Examples of his research include articles on the spurious correlation between ethanol production and gasoline prices, unilateral market power in the electricity reserves market, and tacit collusion in credit card markets. His research has appeared in the American Economic Review, the American Economic Journal: Macroeconomics, the American Economic Journal: Economic Policy, The Review of Economics and Statistics, The Journal of Industrial Economics, and The Energy Journal, among other academic publications. He is a former coeditor of the Journal of Public Economics and serves or has served as an associate editor for several other scholarly journals, including the American Economic Journal: Economic Policy, The Journal of Industrial Economics, the Journal of Transport Economics and Policy, and The Journal of Energy Markets. Professor Knittel is a research associate at the National Bureau of Economic Research (NBER) in the Productivity, Innovation, and Entrepreneurship and Industrial Organization programs, and he co-directs the Environment and Energy Economics program.
Dr. Duh, Chief Epidemiologist at Analysis Group, specializes in real-world evidence (RWE) generation for product registration, post-approval safety studies, and health economics and outcomes research (HEOR) of pharmaceuticals, vaccines, and regenerative biotherapeutics. She has led multiple projects for new molecular entity approvals and product label expansion applications to the US Food and Drug Administration (FDA) and European Medicines Agency (EMA), as well as health technology assessment (HTA) research for submissions to national payers such as the Centers for Medicare and Medicaid Services (CMS) in the US and the UK’s National Institute for Health and Care Excellence (NICE). Her extensive research has appeared in over 250 peer-reviewed publications.
Her work also extends to pharmaceutical liability litigation and securities fraud litigation related to adverse drug events that allegedly led to product recalls, market withdrawals, black box warnings, and FDA limited access programs.
Dr. Duh is also an adjunct in the biostatistics department at the Harvard T.H. Chan School of Public Health. She served as a chairperson of drug safety and epidemiology for the Drug Information Association (DIA) and was an adjunct assistant professor of pharmacoeconomics and pharmacoepidemiology at Massachusetts College of Pharmacy and Allied Health Sciences. Dr. Duh was appointed to an expert panel convened by the Foundation for the National Institutes of Health’s (FNIH’s) Observational Medical Outcomes Partnership (OMOP). She has served as a peer reviewer for several journals, including PharmacoEconomics, the American Journal of Health-System Pharmacy, Chest, Pharmacoepidemiology and Drug Safety, the American Journal of Kidney Diseases, and Therapeutics and Clinical Risk Management. Dr. Duh is also an elected member of the American Society of Hematology and a member of the American Society of Clinical Oncology, the International Society of Pharmacoepidemiology, and the International Society of Pharmacoeconomics and Outcomes Research (ISPOR).
View Dr. Duh's selected publications on the Harvard Catalyst website
Pierre Cremieux, President of Analysis Group, has a broad range of expertise in health economics, antitrust, statistics, and labor economics. He has consulted to numerous clients in the US and Canada and testified in bench and jury trials, arbitrations, and administrative proceedings.
Dr. Cremieux has served as an expert and supported other experts in both litigation and non-litigation matters on antitrust issues; general commercial claims; contractual disputes; and a number of labor-related matters in a variety of industries, including high tech, pharmaceuticals, biotech, financial products, consumer products, and commodities. He has assessed the evaluation of damages on a class-wide basis in some of the largest class action matters in recent years.
His scientific research in antitrust economics, class certification, health economics, and statistics has been published in numerous peer-reviewed journals including the George Mason Law Review, the American Bar Association Economics Committee Newsletter, The Review of Economics and Statistics, the Journal of Health Economics, Industrial and Labor Relations Review, the Journal of Clinical Oncology, and the American Journal of Managed Care. Dr. Cremieux's research has been cited in leading media outlets including The Wall Street Journal and Forbes.
Dr. Cremieux has frequently presented at leading legal, health care, and economics seminars on topics such as antitrust, class certification, health economics, and statistics, in both the United States and Canada. He has also been invited to teach courses on economics, statistics, health care, and antitrust at various schools including McGill University, Boston University, Harvard Medical School, and Yale's School of Management.
Prior to joining Analysis Group in 1997, Dr. Cremieux spent five years as a professor at the University du Québec à Montréal, and served as an adjunct professor from 1997 to 2018.
Dr. Rice is an economist with a range of expertise in health economics, industrial organization, statistics, and econometrics. He has extensive experience applying economic theory and statistical methods in complex litigation and research settings. Dr. Rice has led analyses related to government investigations and litigation matters, where he has supported counsel and been retained as an expert on alleged Anti-Kickback Statute and False Claims Act violations, as well as on antitrust, cryptocurrency, insider trading, misappropriation of trade secrets, and breach of contract issues. In matters related to liability and damages, he conducts empirical analyses involving large-scale databases on a range of topics, including causal inference, merger simulation, and budget impact. Dr. Rice’s case experience has involved providing assistance in the preparation of expert reports, testimony, and rebuttal analyses and arguments; developing sophisticated interactive models enabling real-time damages assessments under alternative scenarios; and presenting analyses to US Attorney’s Office investigators. In addition to his litigation work, he has provided econometric and statistical consulting on matters such as economic research questions, risk management, fair market valuation, and compliance. Dr. Rice is adjunct faculty in the Harvard University Department of Economics and has taught undergraduate courses on econometrics, health economics, industrial organization, and regulatory economics. He has published extensively in numerous peer-reviewed journals, and presented at conferences and seminars.
Mr. Jenson has extensive experience managing complex high tech capital equipment businesses for public and private equity companies. He has more than 30 years of experience in global manufacturing focusing on general management, marketing, sales, and product development. His experience includes automation systems, robotics, thin-film process equipment, material handling equipment, industrial equipment, and analytical instrumentation. Mr. Jenson has participated in numerous mergers and acquisitions (M&As), as part of both the acquiring firm and the acquired firm. His M&A experience includes investment target identification, valuation, due diligence, integration, and management of acquired companies. In his position as general manager of core technologies for Ocean Insight – a spectroscopy and imaging technology company – Mr. Jenson leads the global sales, marketing, and product development teams. Prior to his work with Ocean Insight, he led the $200 million waterjet cutting systems business segment of SHAPE Technologies Group, managed the $250 million compound semiconductor equipment business unit of Veeco Instruments, and served as a senior leader in automation solutions for the semiconductor and flat panel display industries at Brooks Automation. Mr. Jenson is also a veteran submarine officer of the US Navy.
Ms. Glowka is a chartered accountant who specializes in the assessment of damages and forensic analysis arising in the context of dispute resolution. She has served as an expert and led consulting teams on complex UK and international assignments, including litigation and international arbitration matters before the High Court of Justice in London, the Scottish Court of Session, the UK Competition Appeal Tribunal, and all the major international arbitration forums.
Ms. Glowka has acted on a broad range of litigation and arbitration matters across the automotive, oil and gas, pharmaceutical, telecommunications, software, and consumer products industries, among others. Her litigation and arbitration work has involved the evaluation of damages arising in the context of contractual and shareholder disputes, as well as post-transaction disputes such as breach of warranty claims. Ms. Glowka’s forensic accounting work has spanned analysis and tracing of funds and transactions, as well as evaluation of fraud and accounting irregularities, including allegations of accounts manipulation for inflating performance-related bonuses and purchase consideration. She has also evaluated complex financial reporting issues under a variety of accounting standard-setting regimes, including UK generally accepted accounting principles (GAAP) and International Financial Reporting Standards (IFRS). Ms. Glowka is a member of Chartered Accountants Australia and New Zealand.
Professor Rock is an expert in corporate law and corporate governance. He coauthored the book The Anatomy of Corporate Law: A Comparative and Functional Approach, and has published numerous articles on topics such as poison pills, politics and corporate law, hedge funds, corporate voting, proxy access, corporate federalism, and mergers and acquisitions. Prior to joining the NYU faculty, Professor Rock taught at the University of Pennsylvania Law School, where at various times he served as co-director of the Institute for Law and Economics, associate dean, senior advisor to the president, and provost and director of open course initiatives. He has held visiting professorships at NYU and Columbia University, and was a Fulbright Senior Scholar at Hebrew University. Prior to his academic career, Professor Rock worked as an attorney specializing in complex antitrust, corporate, and securities litigation. In January 2019, the American Law Institute named him Reporter for the Restatement of the Law, Corporate Governance.
Professor Levinsohn is an expert in antitrust, industrial organization, and econometrics. He has provided expert reports and testimony in several landmark antitrust and regulatory matters, including In re: TFT-LCD (Flat Panel) Antitrust Litigation, In re: Vitamins Antitrust Litigation, In re: New Motor Vehicles Canadian Export Antitrust Litigation, and the Tobacco Master Settlement Agreement proceedings. He has also consulted to numerous foreign governments and international organizations.
Professor Levinsohn conducts research in industrial organization, applied econometrics, international economics, and development economics. He has served on the editorial boards of American Economic Review, The Review of Economics and Statistics, the Journal of International Economics, and the Journal of Economic Literature. Prior to joining the Yale faculty, Professor Levinsohn was the J. Ira and Nicki Harris Family Professor of Public Policy at the Gerald R. Ford School of Public Policy at the University of Michigan.
Dr. Garces is an economist with deep public- and private-sector antitrust policy and regulation experience in the US and Europe, including serving in the European Commission’s Directorate-General for Competition (DG COMP) and Directorate-General for Internal Market and Industry. Her consulting and case work experience includes mergers and conduct cases in the telecommunications, media, industrial, consumer staples, and technology sectors. She has corporate experience at a large technology company and is widely recognized as an expert on the economic analysis of new digital business models, as well as on regulation in innovative sectors. Dr. Garces has published extensively on topics such as the antitrust analysis of commercial practices, the assessment of conglomerate mergers, the interaction between antitrust and privacy, value creation processes in platform businesses, and behavioral economics. She is also a coauthor of the widely used book Quantitative Techniques for Competition and Antitrust Analysis.
Professor Keller is an expert on marketing management, branding, and brand equity. His research focuses on improving marketing strategies through an understanding of consumer behavior, as well as on the design, implementation, and evaluation of integrated marketing communication programs. Professor Keller has served as brand advisor to a number of large corporations, including Accenture, American Express, Disney, Ford, Intel, Levi-Strauss, L.L. Bean, Nike, Procter & Gamble, and Samsung. He has published over 120 papers in peer-reviewed journals such as the Journal of Marketing, the Journal of Marketing Research, and the Journal of Consumer Research. He also authored the widely used textbooks Marketing Management (with Philip Kotler) and Strategic Brand Management. Professor Keller has received numerous awards for his research accomplishments, and has conducted marketing seminars for executives in a variety of forums. He previously held faculty positions at the University of California, Berkeley; Stanford University; and the University of North Carolina at Chapel Hill.
A former chief economist at the Federal Communications Commission (FCC), Professor Rogerson focuses his research on applied microeconomic theory, industrial organization, regulation, cost accounting, telecommunications, and defense procurement. He has been an active participant in media transactions before the FCC, including Comcast/NBCUniversal and News Corp./DirecTV, as well as various rulemaking proceedings. Professor Rogerson was also the FCC’s senior economist, supervising its economic analyses of the Comcast/Time Warner Cable, AT&T/DirecTV, and Charter Communications/Time Warner Cable transactions. He has also served as an economic expert for the US Department of Justice, Federal Trade Commission, and the National Association of Attorneys General in various antitrust cases in the telecommunications, media, and defense industries. Professor Rogerson has published a number of articles and book chapters on topics such as vertical mergers in the video programming and distribution industry, and incentives for investment and innovation as related to the regulation of broadband telecommunications. He is a former editor of Economic Inquiry and Defense and Peace Economics, and a former member of the editorial boards of both the Review of Accounting Studies and The Journal of Industrial Economics. He served two terms as chair of Northwestern University’s Department of Economics, and currently holds several leadership roles at Northwestern, including research director of the Program on Antitrust Economics and Competition Policy at the Searle Center on Law, Regulation, and Economic Growth; director of the Center for Business Institutions; and co-director of the Center for the Study of Industrial Organization.
Professor Haas-Wilson is an expert in health care antitrust, including the competitive effects of hospital mergers and commercial health insurer mergers, the effects of vertical consolidation in health care markets, and the implications of physician networks on competition in the health care industry. She recently testified in Federal District Court in Idaho on behalf of plaintiffs, in an antitrust lawsuit alleging competitive harm from St. Luke’s Health System’s acquisition of a large independent physician practice. She has served as a consultant on antitrust issues to the Federal Trade Commission, the Massachusetts Attorney General, the California Department of Corporations, and numerous private entities. She also testified on behalf of the Federal Trade Commission in the matter of Evanston Northwestern Healthcare Corporation. Professor Haas-Wilson is the author of Managed Care and Monopoly Power: The Antitrust Challenge and coeditor of Uncertain Times: Kenneth Arrow and the Changing Economics of Health Care. Her research has appeared in the Journal of Political Economy, the Journal of Economic Perspectives, the Journal of Law and Economics, the Review of Economics and Statistics, and the Journal of Health Economics, among others.
Dr. Rothman specializes in the economic analysis of antitrust and competition issues. He is retained by private parties to present analyses to the US Department of Justice (DOJ) and the US Federal Trade Commission (FTC). He is also retained by and has testified for the FTC as an expert witness in merger litigation. In addition to his merger work, Dr. Rothman has worked on multiple joint conduct and unilateral conduct matters.
Dr. Rothman is a senior editor of the Antitrust Law Journal. He has published research in outlets including Antitrust Law Journal, The Antitrust Source, Journal of Health Economics, Journal of Competition Law & Economics, and Concurrences: Competition Law Journal. Dr. Rothman has taught a course on the economics of merger analysis in the economics department at Harvard University. Prior to joining Analysis Group, he was an assistant professor at Columbia University.
Professor Pindyck is a leading industrial organization economist and testifying witness in the areas of antitrust and intellectual property. His research and writing have covered topics in microeconomics and industrial organization, the behavior of resource and commodity markets, financial markets, and econometric modeling and forecasting. His recent work in economics and finance has examined the determinants of market structure and market power, the dynamics of commodity spot and futures markets, criteria for investing in risky projects, the role of R&D, and the value of patents. He has received many academic honors, including several awards for outstanding teaching, and holds senior editorial positions with a number of publications. Professor Pindyck has consulted to dozens of public and private organizations, including the Federal Trade Commission, IBM, and AT&T, and has been deposed and/or testified in over a dozen cases in diverse industries such as food, energy, software, medical devices, and airlines. He has worked with Analysis Group on many of these cases, including the Lotus v. Borland litigation, in which Professor Pindyck used econometric modeling techniques to identify the economic value of various attributes and isolated the value of the infringing features. He also worked with Analysis Group in a major litigation matter involving price-fixing allegations, in which he examined allegations of accumulation of buying power and the resulting effects on negotiations with suppliers.
Ms. Guérin is an economist who specializes in the application of statistics and econometrics to health economics and outcomes research (HEOR) and epidemiology. Her areas of expertise include retrospective database analyses such as medical claims, electronic health records, and clinical trial data; economic modeling, such as cost-effectiveness and budget impact models; and design of chart review studies, surveys, and other prospective studies. She has participated in the development of large clinical data registries and in the design of real-world evidence (RWE) studies to support regulatory submissions. Ms. Guérin has broad research and analytical experience in areas such as comparative effectiveness and cost effectiveness, development of prediction algorithms, assessment of disease prevalence and incidence, evaluation of burden of illness, productivity loss, treatment patterns, analysis of patient-reported outcomes (PROs), safety/tolerability analyses, discrete choice experiments, and patient experience studies. She has also supported many pharmaceutical companies in the development of HEOR planning and RWE generation plans. Ms. Guérin has conducted health care research across many therapeutic areas, including oncology, hematology, dermatology, gastroenterology, rheumatology, neurology, psychiatry, endocrinology, cardiology and circulatory diseases, and respiratory diseases. She publishes frequently and is the coauthor of over 100 research papers published in numerous peer-reviewed journals and presented at a variety of scientific conferences.
Dr. Cain is an expert in securities litigation, corporate disclosures, M&A litigation, private equity, valuation, insider trading, and corporate governance. He has provided economic analysis, consulting, and expert witness testimony on a variety of finance topics for investigations, settlement negotiations, and trials. He has estimated event studies and trading profits in relation to allegations of insider trading, improper trading behavior, corporate misrepresentations and disclosures, and unregistered stock sales on behalf of the US Securities and Exchange Commission (SEC), US Department of Justice (DOJ), Commodity Futures Trading Commission (CFTC), and other clients. Dr. Cain worked for several years at the SEC, where he was an advisor to Commissioner Jackson and a financial economist in the Office of Litigation Economics. Prior to joining the SEC, Dr. Cain was an assistant professor of finance at the University of Notre Dame Mendoza College of Business. He has published research in numerous journals on topics that include investment banking and fairness opinion valuations, merger contracts and terminations, corporate governance and shareholder activism, hostile takeovers, earnout clauses, merger-related litigation, and management buyouts. Dr. Cain’s research has been cited in forums such as the US Chamber Institute for Legal Reform, amicus briefs to the US Supreme Court, trial verdicts of the Supreme Court of the State of New York and the Delaware Chancery Court, and The International Comparative Legal Guide to Mergers and Acquisitions. His research has also been highlighted in media outlets such as The Wall Street Journal, The New York Times, the Financial Times, and Forbes.
Professor Kinch, a drug development expert specializing in cancer, immunological, and infectious diseases, focuses on combining cutting-edge science and entrepreneurship to improve public health. At Washington University in St. Louis, Professor Kinch founded and directs the Center for Research Innovation in Biotechnology (CRIB), which assesses trends that guide the research and development of novel medicines. He also helped create the Center for Drug Discovery (CDD) to identify and underwrite the university’s most promising drug discovery projects. Professor Kinch has been issued more than a dozen US patents, published more than 100 patent applications, and written several books and book chapters on the commercialization of biopharmaceutical innovation, as well as other aspects of drug development. He has published widely in peer-reviewed journals, including Drug Discovery Today, Science, Cell Chemical Biology, and Biotechnology Law Report, and his research has been profiled in media outlets such as The Wall Street Journal, NPR, CBS News, and The New York Times. Before joining Washington University, he was the managing director of the Yale Center for Molecular Discovery. He has also taught at Johns Hopkins University and Purdue University, and held senior research positions at Functional Genetics and MedImmune. Professor Kinch serves on the board of the American Cancer Society and on scientific advisory boards (SABs) for several biopharmaceutical companies.
Professor Rossiter is an expert in health economics who has testified or served as an expert in the following areas: competition in the financing and delivery of health services; reimbursement economics, especially for Medicare, Medicare Advantage, and Medicaid; managed care organizations; prescription medicines; survey research; and health information analytics. Professor Rossiter is the former secretary of health and human resources for the Commonwealth of Virginia. In that role, he was responsible for over 15,000 employees in 13 agencies (including 10 state mental hospitals), brought major information technology projects in the Secretariat to national prominence, and made major reforms in Virginia Medicaid. He also served as deputy for policy to the Administrator of the Centers for Medicare and Medicaid Services (CMS). As deputy, he created and directed a new payment system for US hospitals under Medicare, was responsible for the CMS strategic plan, and formulated all agency policy initiatives through the federal legislative process.
Prior to joining the William & Mary faculty, Professor Rossiter was a professor of health administration at Virginia Commonwealth University. He served on the board of regents of the National Library of Medicine, National Institutes of Health; on the board of directors of AcademyHealth; and as chair of the board of directors of the Coalition for Health Services Research, the lobbying arm of AcademyHealth, during the passage of the Affordable Care Act. He has also served on numerous advisory groups, including the National Advisory Council for Healthcare Research and Quality, and is currently a trustee and chair of the Williamsburg Health Foundation. Professor Rossiter is the author or editor of 15 books, and the author of over 50 journal articles on health economics and the role of competition in the financing and delivery of health services.
Mr. Darling consults to clients and provides expert testimony to address litigation, strategy, regulatory, and policy questions in a wide range of antitrust and competition, class certification, health care, energy, and environmental matters. He has submitted and supported expert testimony before US district and appellate courts, state utility commissions, siting boards, and federal agencies. He has also assisted clients with responses to government investigations and presented findings before US Attorneys’ Offices, state attorneys general, and the US Drug Enforcement Administration.
In the areas of health care and antitrust, Mr. Darling has extensive experience supporting clients on issues related to discovery and data production, class certification, patent infringement, market definition and market power, and competitive effects in pharmaceutical and life sciences matters involving patent infringement issues, reverse payment settlements, and product hop allegations. He has also designed and implemented customized suspicious order monitoring (SOM) and loss prevention programs for controlled substances, and has experience in False Claims Act and Anti-Kickback Statute litigation cases, including analyses of causation and damages calculations.
Mr. Darling is also an expert on electricity, oil, and natural gas pricing, markets, and infrastructure. His consulting work on behalf of utilities, state and regional organizations, and global companies includes projects related to cost/benefit analyses of new plant construction and retirements; ratepayer and bill impacts; environmental effects of emissions and pollution controls; economic impacts of energy projects, mergers, and policies; natural gas, biomass, and other market studies; and climate change matters including decarbonization policy proposals and quantification of the impacts of greenhouse gas emissions. He has conducted and overseen numerous economic and bill impact assessments in support of projects and policy proposals, ranging from new power plants and transportation facilities to electric, petroleum, and natural gas transmission infrastructure.
Ms. Hitscherich specializes in corporate acquisitions, leveraged buyouts, exclusive sales and divestitures, takeover defenses, and restructurings. She has served as an expert witness in several complex securities litigations, including matters involving deal structure, valuation, due diligence, custom and usage in the finance industry, and financing alternatives.
Ms. Hitscherich has extensive experience in investment banking and corporate law practice, including as a managing director in mergers and acquisitions with Banc of America Securities, where she was secretary of the Fairness Opinion Review Committee; vice president in mergers and acquisitions with J.P. Morgan & Co., where she was a founding member of the takeover defense team and a senior member of the acquisitions fairness Advisory Review Committee; and as a mergers and acquisitions attorney with Skadden, Arps, Slate, Meagher & Flom.
At Columbia Business School, Ms. Hitscherich teaches corporate finance, advanced corporate finance, business law, and mergers and acquisitions in the M.B.A. and Executive M.B.A. programs.Dr. Royer applies a broad range of quantitative tools to address client needs in data science, statistics, HEOR, finance, intellectual property, competition policy, and antitrust cases in the United States, Canada, and the EU. His recent work includes predicting the potential future onset of rare or undiagnosed conditions with machine learning models; predicting whether patents would be considered essential to technological standards if challenged in courts; valuing patents in the communications industry; evaluating damages related to product defects; analyzing investment guidelines in securities lending suits; addressing allegations of monopolization in major antitrust cases involving high tech firms; and supporting many academic experts on mutual fund market timing and excess fee cases. In addition, Dr. Royer has conducted extensive academic research and coauthored books and papers on topics such as using new AI advances in HEOR; predicting treatment resistance in tuberculosis, using machine learning algorithms in propensity score models; measuring the impact of ESO backdating on shareholders’ wealth; analyzing mutual fund pricing; analyzing antitrust limit pricing; valuing private investments for hospitals in Canada; determining the impact of hypertension therapies on mortality; and comparing unemployment compensation in different countries.
Professor Reibstein’s research focuses on competitive marketing strategies, metrics, and product line decisions, among other topics. He has provided marketing management education and consulting research to companies in the consumer goods, pharmaceutical, and oil and gas industries, among others. His consulting activities have included numerous applications of conjoint analysis and other survey techniques in engagements spanning a wide range of products. Professor Reibstein has submitted expert reports and provided testimony on marketing and marketing research in several litigation matters, including analyses of smartphone features in a patent dispute, health claims in a false advertising dispute, and pharmaceutical detailing in a co-marketing dispute.
His recent work includes assessing strategies to address competitors’ reactions to marketing actions and developing metrics that link marketing decisions to financial consequences, which was published in his book, Marketing Metrics: The Definitive Guide to Measuring Marketing Performance. Professor Reibstein is also the author or coauthor of numerous books and chapters in books on subjects including competitive marketing strategy, global branding, and marketing performance measurement. Professor Reibstein has also written several papers on conjoint analysis and its validity and reliability. His research has been published in leading academic journals, including Marketing Science, the Journal of Marketing Research, and the International Journal of Research in Marketing. Â
Professor Reibstein has been honored with more than 30 teaching and publishing awards, including the John S. Day Distinguished Alumni Academic Service Award from Purdue University’s Krannert School of Management. He has served as the chairman of the American Marketing Association board of directors and as the executive director of the Marketing Science Institute.
Professor Carlson specializes in the marketing management implications of consumer decision-making processes, including the development of brand preferences and the influence of emerging preferences on the decision making process. Though much of Professor Carlson's research explores consumer decision making, he also studies how voters, jurors, and managers make decisions. Over the last 20 years, he has run thousands of surveys, sampling U.S. and international populations.
Professor Carlson has served as an expert in evaluating a survey in a class action matter, consulted on a high profile class action settlement involving consumer deception, and testified before the SEC in an equity trust matter. Professor Carlson's published research can be found in top marketing, psychology, and management journals. He is also the coauthor of Contemporary Brand Management. He blogs for Psychology Today and Forbes, and maintains an active Twitter account (@ProfKurt). While teaching at Georgetown University between 2009 and 2017, Professor Carlson was director of the Georgetown Institute for Consumer Research and co-director of the McDonough School of Business Behavioral Research Lab, and he received the MSB Dean's Distinguished Faculty Research Award and the Decision Analysis Society's Publication Award.
Â
Ms. Kindler has worked on a variety of engagements, including intellectual property (IP) disputes, contract disputes, litigation matters related to securities and finance, false advertising allegations, and antitrust matters. In litigation matters, she has testified in deposition and at trial, and assisted in all phases of the litigation process, including discovery, expert reports, deposition, and trial preparation. In patent infringement matters, Ms. Kindler has analyzed claimed lost sales, claimed lost profits, and claimed reasonable royalty damages. In antitrust matters, she has assessed the competitive consequences of mergers, analyzed the competitive behavior of market participants, and estimated the impact of market power. Her work has also included the development of complex damages models, the analysis of statistical data, and the analysis of stock price movements. Ms. Kindler has been recognized as among the top economic experts for IP matters by Intellectual Asset Management (IAM) in the IAM Patent 1000, which identifies leading patent professionals around the globe. Prior to joining Analysis Group, she held positions with two economics consulting firms.
Professor Klausner teaches courses on corporate law, corporate governance, business transactions, and regulation of financial institutions. In recent years, most of his writing has been on corporate governance. He maintains a database on securities class actions and SEC enforcement actions, and has written papers and blog posts based on that database. In addition, Professor Klausner is currently writing a book and producing an online course called Deals: The Economic Foundations of Business Transactions.
Before beginning his academic career, Professor Klausner practiced law in Washington, DC, and Hong Kong. He was a White House fellow from 1989 to 1990, a law clerk for Judge David Bazelon on the United States Court of Appeals for the District of Columbia Circuit in 1981-82, and a law clerk for Justice William Brennan on the United States Supreme Court.
Professor Hochberg specializes in entrepreneurship, innovation, venture capital, and private equity, focusing on venture capital networks, entrepreneurial finance, seed accelerators, and corporate governance and compensation. Her research covers topics such as venture capital investment performance, the effects of networks and syndication on venture capital firms, and investment selection. Professor Hochberg has also explored the private equity investment choices of pension funds and other institutional investors, as well as broad-based option compensation in firms. She is the managing director of the Seed Accelerator Rankings Project, which publishes annual rankings of accelerator programs in the US. Prior to joining the Rice faculty, she held positions at the Kellogg School of Management at Northwestern University and the Samuel Curtis Johnson Graduate School of Management at Cornell University. She has taught courses on entrepreneurial finance and health care innovation, and has served as an associate editor of several finance journals, including the Journal of Empirical Finance and the Journal of Banking and Finance. Professor Hochberg is a recipient of the Ewing Marion Kauffman Prize Medal for Distinguished Research in Entrepreneurship, and a research associate at the National Bureau of Economic Research. Prior to joining academia, she was a software engineer at both established and startup technology companies, and co-founded a startup. Professor Hochberg is an active angel investor and advisor to startups, and a Landmark Fellow with Landmark Partners, a large private equity investor in secondary markets. She is a co-founder of Flywheel Innovation, a corporate innovation advisory firm.
Mr. Davis specializes in applying financial economics and data analysis to major litigation matters, with a focus on agricultural markets and pharmaceutical products. He has experience managing case teams, supporting academic affiliates and industry experts, and assisting clients through all phases of complex business litigation, including fact discovery, class certification, merits, trial, and settlement. Mr. Davis’s agricultural experience includes antitrust matters involving allegations of market power in animal protein markets, matters involving the presence of genetically modified products in US grain supplies, and matters involving international trade in agricultural products. His pharmaceutical work includes antitrust matters involving allegations of delayed generic entry, False Claims Act matters involving allegations related to the promotion of pharmaceuticals, and disputes pertaining to the commercial reasonableness of firm conduct.
Mr. Davis also has experience conducting economic research across a variety of industries, including financial services, agriculture, and pharmaceuticals, and analyzing issues related to commodity markets, futures prices, intellectual property and patents, industrial organization and antitrust law, and financial market infrastructure. He is a CFA charterholder.
Dr. Schatzki has a broad range of expertise in energy, environment, finance, and competition matters. He supports clients in a range of contexts, including strategic and financial advice, policy analysis, regulatory and rulemaking proceedings, and litigation.
Dr. Schatzki has deep experience in electricity, natural gas, petroleum, and renewable energy. His expertise in the electricity sector includes wholesale energy and capacity market design; utility regulation and ratemaking; economic impact analysis of new market rules, regulations, and generation and transmission investments; contract analysis and disputes; financial valuation; and options analysis. Dr. Schatzki has testified before US state and federal, as well as Canadian provincial, regulatory commissions. He has supported the analysis of alleged market manipulation and damages in high-profile litigations such as FERC v. Barclays and lawsuits following the California electricity crisis.
Dr. Schatzki works extensively on environmental economics, policy, and regulation. Recently, he has focused on the intersection of climate policy and energy markets, and disputes involving water resources and environmental contamination. His research has been published in distinguished energy- and environment-related publications, and he has provided research for prominent organizations such as the Electric Power Research Institute, the Edison Electric Institute, and the Federal Energy Regulatory Commission.
In finance and competition matters, Dr. Schatzki has worked with clients on litigation and non-litigation projects in many sectors, including energy, financial instruments, foreign exchange, insurance, airlines, and retail products.
Dr. Koehn specializes in applied microeconomics and finance. He has performed research and given economic testimony in antitrust, regulatory, tax, and other business litigation matters. The author of several publications on topics such as banking and finance, energy economics, and real estate, Dr. Koehn is a former adjunct associate professor of finance at the University of California, Irvine Graduate School of Management.
Mr. Case is an institutional investment expert with significant expertise in the areas of investment governance, asset allocation, portfolio design and implementation, and portfolio analysis and reporting. As a former institutional investment consultant, he worked with a wide range of global clients, including insurers, health care organizations, corporate and public plan sponsors, family offices, and other large asset pools. Mr. Case was a partner at Mercer Investment Consulting, a practice leader at Evaluation Associates, and a senior consultant at Rogerscasey. He led client service teams for large clients, including defined-benefit and defined-contribution plans, insurers and mutual fund families, and registered investment advisors and foundations. As an expert, Mr. Case has evaluated various process-related issues, including the process used to monitor an ERISA plan’s investment advisor and delegated fiduciary. He previously worked as an investment analyst for AT&T’s pension investment team, oversaw the sub-advisory and pension assets of AXA Equitable Life, and managed the strategic relationship team at Putnam Investments. He is a CFA charterholder.
Ms. Kirk Fair has extensive experience leading the development of economic and market analyses, assessing class certification and damages, evaluating consumer behavior, and testifying in a wide range of matters in the US, Canada, and Europe. She has been deeply involved in merger investigations and major antitrust litigation, as well as intellectual property (IP), false advertising, and tax matters. She also is a founder of the Analysis Group’s Surveys & Experimental Studies practice.
Ms. Kirk Fair specializes in evaluating competition and substitution patterns to examine potential competitive effects in mergers and “but-for” outcomes in antitrust litigation. She has significant analytical and testifying experience in cartel matters, notably in a number of prominent cases in the technology, consumer products, and financial services industries. She also has evaluated competition, pricing, and outputs in connection with merger investigations in the US, Canada, and the EU. In addition to having served as a compliance monitor for several years, she has supported the US Department of Justice (DOJ), the Federal Trade Commission (FTC), and the Canadian Competition Bureau (CCB) in a variety of merger investigations.
Ms. Kirk Fair also has particular expertise in the development, administration, and analysis of consumer surveys for use in antitrust, false advertising, and IP matters, as well as merger reviews and strategy cases. She has testified in arbitration, deposition, and trial in matters involving the design and implementation of consumer surveys, as well as the evaluation of opposing parties’ surveys and of statistical sampling and analyses. Her work has been used to support and critique damages models and to provide insights into the role of consumer choice in market definition.
Ms. Kirk Fair serves as a Vice-Chair to the American Bar Association (ABA) Antitrust Law Section’s Pricing Conduct Committee. She has received numerous awards for her accomplishments, including the W@ “40 in Their 40s: Notable Women Competition Professionals” and the Concurrences Antitrust Writing Award for her coauthored article “The Tyranny of Market Shares: Incorporating Survey-Based Evidence into Merger Analysis” (Corporate Disputes).
Professor Riddiough is best known for his work on real options, mortgage pricing and strategy, REITs, and land use regulation. He has served as an expert in numerous real estate-related matters, in which he has testified on appraisal and the value of distressed mortgages. Professor Riddiough has consulted to numerous organizations, including the US Department of Housing and Urban Development, GMAC, Wells Fargo, Coldwell Banker Commercial, The Equitable Life Assurance Society, and the State of Wisconsin Investment Board. He has published more than 40 scholarly articles. He has served on the boards of directors of several organizations, including ArCap REIT, EquiBase Capital Partners, and the American Real Estate and Urban Economics Association. Professor Riddiough is the recipient of best dissertation and best paper awards in real estate economics, and is a fellow at the Real Estate Research Institute and a past fellow at the Homer Hoyt Institute. He teaches courses in real estate finance, real estate capital markets, and microeconomics.
Professor Howell’s research focuses on entrepreneurship, private equity, fintech, and innovation. She is a research associate at the National Bureau of Economic Research, a fellow at the Asian Bureau of Finance and Economic Research, and a research fellow at the Institute for Private Capital’s Private Equity Research Consortium. She has testified before the US House of Representatives Ways and Means Committee and presented her work before the US Department of Energy, Senate Small Business Committee, Air Force, and Centers for Medicare & Medicaid Services. Professor Howell is the recipient of the AQR Asset Management Institute Young Researcher Award and the Kauffman Foundation Junior Faculty Research Fellowship, among other awards. She also serves as an associate editor of The Review of Financial Studies and a member of the advisory board to the American Female Finance Committee of the American Finance Association. Earlier in her career, Professor Howell was an energy security policy analyst and an energy consultant.
Mr. Deal leads the economic analyses in the Menlo Park, California office and helps coordinate the firm’s Insurance practice. He combines an economics and risk analysis background with many years of experience in economic, litigation, and management consulting. He serves as a testifying and consulting expert on a wide variety of matters, often involving economic and statistical analysis of large datasets. His work as an expert has covered a variety of practice areas, including antitrust, economic damages, class action matters, and business valuation. Mr. Deal’s experience includes work in health care, insurance, finance, technology, and many other industries. He has coauthored a number of book chapters and studies, including The Economic Effects of Federal Participation in Terrorism Risk with R. Glenn Hubbard, an Analysis Group academic affiliate, former chair of the President’s Council of Economic Advisers, and former dean of the Columbia Business School.
Professor Savitz focuses his epidemiological research on a wide range of public health issues, from the health effects of environmental agents in the workplace and community to a wide range of reproductive health outcomes. He has served as principal investigator on more than three dozen public health studies, including as one of three epidemiologists to evaluate the probable causal link between exposure to perfluorooctanoic acid and the development of certain diseases. Professor Savitz submitted an expert report on behalf of the plaintiffs at the class certification stage of a litigation matter and has consulted on a wide range of issues related to both environmental and reproductive epidemiology. He is the author of more than 300 journal articles and has edited or authored three books, including Interpreting Epidemiologic Evidence: Connecting Research to Applications. Professor Savitz has served as the editor of Epidemiology and the American Journal of Epidemiology, a member of the Epidemiology and Disease Control Study Section of the National Institutes of Health, president of the Society for Epidemiologic Research and the Society for Pediatric and Perinatal Epidemiologic Research, and North American regional councilor for the International Epidemiological Association. He is a member of the National Academy of Medicine and served as vice president for research at Brown University.
Dr. Signorovitch advises life sciences companies on data analytics for business critical research and decision making. He has broad experience leading the strategic development and implementation of analytics across the product life cycle, from early-phase clinical studies to market access and real-world evidence generation. Dr. Signorovitch’s practice areas span trial design, multi-stakeholder collaborations, natural history studies, regulatory interactions, health economic modeling, global reimbursement submissions, policy evaluation, real-world evidence development, individualized medicine, predictive analytics, and due diligence for acquisitions. He has particular expertise in developing and applying new methodologies to address health care research challenges, and in designing analytics platforms to enhance collaborative research and decision making. Dr. Signorovitch’s work has been used to inform clinical regulators and health care payers in US and global markets, published in peer-reviewed journals, and presented at clinical and economic research conferences. Prior to joining Analysis Group, Dr. Signorovitch was a research fellow at the Harvard-MIT Division of Health Sciences and Technology.
Professor Schoar is an expert in corporate finance, entrepreneurship, and organizational economics. Her research interests span from entrepreneurial finance to household finance and financial intermediation. Her research examines returns and capital flows in the venture capital industry, the financing of small and medium-sized enterprises and startup firms, and the role of consumer financial markets. Professor Schoar has served as an expert witness in cases involving commercial litigation and financial services. She is co-organizer of the Corporate Finance Working Group at the National Bureau of Economic Research, a former member of the Consumer Financial Protection Bureau’s Academic Research Council, and co-founder and scientific director of ideas42, a research lab on behavioral social science. She has published numerous articles and papers and received several awards for her research, including the Ewing Marion Kauffman Prize Medal for Distinguished Research in Entrepreneurship and the Brattle Group Prize in Corporate Finance for her paper “The Effects of Corporate Diversification on Productivity.” She has served as an associate editor of The Journal of Finance, the American Economic Journal: Applied Economics, and the Journal of Economic Perspectives. Professor Schoar’s work has been featured in The Economist, the Financial Times, The New York Times, and The Wall Street Journal.
Professor Chalmers is an expert in securities issues, including the trading behavior of investors and the pricing of securities. He has undertaken extensive research in municipal bonds, mutual funds, and trading costs, much of which has been published in leading peer-reviewed academic journals, including The Journal of Finance, the Journal of Financial Economics, and The Review of Financial Studies. In the area of mutual funds, his research with Professors Roger Edelen and Greg Kadlec discovered and explained the source of perverse incentives exploited by so-called market timers in their trading of mutual funds. He has also written about stale pricing problems in equity mutual funds and mutual fund transaction costs, and has collaborated with other mutual fund experts, such as Professors Daniel Bergstresser and Peter Tufano, on research analyzing fund performance across fund marketing channels. He also has extensive expertise in municipal bond pricing and valuation issues. Professor Chalmers' research has been cited in reports by the General Accounting Office and in several testimonies provided before the House Financial Services Committee, as well as being widely referenced in major media outlets. He has authored several expert reports and provided testimony before the US District Court of Wisconsin.
Dr. Lehmann specializes in applying microeconomics, econometrics, and statistical methods to complex litigation and regulatory investigations in the areas of antitrust and competition, labor and employment, and health care. In antitrust and competition matters, she has evaluated market definition, market power, and competitive dynamics, and analyzed class certification, liability, and damages issues in cases involving allegations of price-fixing, monopolization, and other anticompetitive conduct. Dr. Lehmann has extensive experience in labor market antitrust matters involving allegations of no-poach and wage-fixing agreements in a variety of industries. In the area of health care, she frequently collaborates with biostatisticians, epidemiologists, scientists, and regulatory experts in evaluating research and development processes and analyzing clinical trial, laboratory testing, registry, claims, and adverse events data in product liability litigations and patent and licensing disputes involving pharmaceuticals, medical devices, and chemical products.
Her employment and antitrust research has been published in the Journal of Economic Literature, The Journal of Human Resources, Labour Economics, Cartel & Joint Conduct Review, and Distribution, and her academic work has been cited in a number of leading media outlets, including Scientific American, Forbes, and BBC News. She serves as vice-chair of the Distribution and Franchising Committee of the American Bar Association (ABA) Antitrust Law Section. Prior to joining Analysis Group, Dr. Lehmann was an assistant professor of economics at the University of Houston, where she taught undergraduate and graduate courses in labor economics.
Dr. Kupiec’s research interests include quantitative financial risk measurement, systemic risk, deposit insurance, and the regulation of banking and financial services. At the American Enterprise Institute, he has authored several studies on systemic risk measurement and related regulations, bank stress testing, and bank regulations that follow financial crisis, including their impact on the wider economy. Dr. Kupiec was an associate director of the Division of Insurance and Research and director of the Center for Financial Research (CFR) at the Federal Deposit Insurance Corporation. In these roles, he oversaw research on bank risk measurement that contributed to the development and implementation of regulatory policies, including the international Basel III framework. He also served as chairman of the Research Task Force of the Basel Committee on Banking Supervision. Dr. Kupiec has worked at the International Monetary Fund, Freddie Mac, and J.P. Morgan, as well as for the Division of Research and Statistics at the Board of Governors of the Federal Reserve System. Prior to entering the financial services industry, Dr. Kupiec was an assistant professor of finance at North Carolina State University. He has published articles in several academic journals, including The Journal of Finance, the Journal of Financial Intermediation, the Journal of Financial Stability, the Journal of Financial Services Research, The Journal of Risk, and the Journal of Investment Management.
Mr. Decter specializes in the application of microeconomics, finance, and data analysis to complex securities and antitrust litigation and business strategy cases, most notably in matters related to residential mortgage-backed securities, collateralized debt obligations and credit default swaps, residential mortgage lending, mortgage reinsurance, commercial insurance, private equity, and payment cards. He has conducted damages analyses, and supported multiple experts in the areas of statistical sampling, loan and securities underwriting, damages, and loss causation.
Mr. Decter's business litigation experience focuses on finance matters in which he has managed large case teams and data sets in working with testifying experts. He supported academic affiliates in their examination of class certification issues related to commonality, predominance, and causation in In re Countrywide Financial Corp. Mortgage Marketing and Sales Practices Litigation, a mortgage marketing matter in which the plaintiff's motion for class certification was denied. Mr. Decter also supported an expert in filing a report on behalf of the defendants in New Jersey Carpenters Vacation Fund et al. v. The Royal Bank of Scotland Group plc et al., a case that marked the first major ruling on class certification among the numerous mortgage-backed securities actions pending in courts across the country at the time. He has also conducted damages analyses and worked with experts in numerous securities, antitrust, and intellectual property cases. Mr. Decter's business strategy engagements related to strategic pricing, portfolio management, and economic cost studies have spanned multiple industries, including pharmaceuticals, telecommunications, information technology, and manufacturing.
Prior to joining Analysis Group, Mr. Decter was a management consultant in the telecommunications industry. He also has several years of telecommunications industry experience in strategic planning, business development, and product management.
Professor Savoldelli is a finance and investment expert with over 25 years of experience analyzing and advising on a wide range of hedge fund-focused issues, including fund performance, portfolio construction, fund administration, due diligence, capital raising, and asset allocation. He served as a chief investment officer for four different institutions: Optima Fund Management, Merrill Lynch, Swiss Bank Corp. Asset Management, and Chase Manhattan Private Bank. In these roles, he oversaw over $80 billion in assets.
Over the course of his investment career, Professor Savoldelli’s responsibilities included selecting hedge funds for the allocation of investor assets, making asset allocation decisions, managing investment portfolios, developing investment policies, and overseeing investment manager adherence to investment strategy and policy. He has deep experience related to the challenging issues hedge fund managers may face, including those related to fiduciary duty, disclosure, liquidation, side-pockets accounts, and valuation of complex and illiquid assets. Additionally, he is knowledgeable about the roles and responsibilities of hedge fund service providers such as prime brokers, marketers, administrators, and auditors.
At Columbia Business School, Professor Savoldelli teaches a course in the M.B.A. program on the investment strategies employed by hedge funds and best practices for the operational aspects of hedge fund management, including fund administration selection, operational risk evaluation, and leverage risk. In addition, he is a contributing editor on Bloomberg Television, commenting on developments from a hedge fund perspective.
Professor Slottje has deep experience in both academia and economic consulting. An emeritus professor of economics at Southern Methodist University, he has been working in litigation consulting for more than three decades in senior positions with several international firms. He has worked with many leading law firms, testifying at deposition and trial in hundreds of prominent matters.
An economist and a statistician, Professor Slottje is an expert in the fields of labor economics, consumer demand, industrial organization, and statistics and econometrics, allowing him to bring a unique perspective and skill set to his consulting assignments. He has published more than 150 journal articles and more than a dozen books, and has been ranked among the world’s top three scholars in applied econometrics based on his publishing record in the field. Professor Slottje is a member of the American Economic Association, the American Statistical Association, and The Econometric Society.
Professor Kahn’s research interests include brand management and loyalty, consumer choice and decision making, price promotions, and retailing. She has served as an expert witness and testified at deposition in numerous matters. Professor Kahn is the author of Global Brand Power: Leveraging Branding for Long-Term Growth and The Shopping Revolution: How Retailers Succeed in an Era of Endless Disruption Accelerated by COVID-19, and coauthor of Grocery Revolution: The New Focus on the Customer. She has published more than 70 articles in leading academic journals. She is a former area editor of Marketing Science, the Journal of Consumer Research, the Journal of Consumer Psychology, and the Journal of Marketing, and has served on the editorial boards of the Journal of Marketing, the Journal of Marketing Research, Marketing Science, the Journal of Consumer Research, the Journal of Behavioral Decision Making, and Marketing Letters. Prior to joining The Wharton School, Professor Kahn was on the faculty of the UCLA Anderson School of Management. She also served as dean of the Miami Herbert Business School.
Professor Hart is a leading expert in contract theory, the theory of the firm, and corporate finance. In 2016, he and Professor Bengt Holmström were awarded the Nobel Prize in Economics for their work in contract theory. Professor Hart’s research centers on the roles that ownership structure and contractual arrangements play in the governance and boundaries of corporations. His recent work involves determining how parties can write better contracts, as well as how a new model of corporate governance can better incorporate the importance shareholders place on nonfinancial criteria.
Professor Hart has consulted to businesses and government entities, and provided expert testimony on contract and governance disputes in which he has evaluated the business purpose and economic substance of special purpose entities. As an expert on behalf of Qualcomm in Apple v. Qualcomm, he provided guidance on the optimal structure of contracts, and why and when they should be enforced. His book Firms, Contracts, and Financial Structure is a leading work in the fields of contract theory and corporate finance. He has published widely in peer-reviewed journals and contributed to the Financial Times and The Wall Street Journal. Professor Hart is a member of the IGM (Initiative on Global Markets) Economics Experts Panel of The University of Chicago Booth School of Business, and is affiliated with the Program on Corporate Governance at Harvard Law School’s John M. Olin Center for Law, Economics, and Business. He is a past president of the American Law and Economics Association.
Professor Baker is an expert in health care economics, including the effects of regulation on health care markets, physician market structure, the effects of managed care and insurance market competition on health care delivery and spending, and the determinants and impact of medical technology adoption. He has served as a consultant and advisor to health plans, government programs and public initiatives, and firms providing health care services and developing new health care products. Professor Baker’s research has been published in leading academic journals, including JAMA, The New England Journal of Medicine, American Economic Review, and the Journal of Health Economics. He is an elected member of the National Academy of Medicine and the recipient of the American Society of Health Economists’ ASHEcon Medal, which recognizes the top American health economists age 40 or under. Professor Baker’s studies of the relationships between area characteristics and health care delivery have twice won the NIHCM Foundation Health Care Research Award.
Ms. Comeaux specializes in the application of finance and economics to complex business litigation and damages estimation. She has led teams across a broad range of matters involving commercial disputes, antitrust and competition, and securities and finance. Her clients include leading media and technology companies, financial institutions, global manufacturers, and life sciences companies. Ms. Comeaux has provided assistance through all phases of pretrial and trial practice, including expert search, fact discovery, class certification, quantification and rebuttal of damages, expert testimony, trial preparation, and settlement negotiations. She has also assisted clients in mass arbitration proceedings, regulatory investigations, and strategy engagements.
Ms. Comeaux has experience with a wide range of empirical methodologies, particularly within the context of damages analyses. Her work regularly involves critical examination of theories of liability, development of models to quantify damages, and both quantitative and qualitative analyses in response to allegations of negligence or punitive damages. She has worked with a wide variety of academic and industry experts to assess organizational, industry, and market conditions in order to contextualize analyses of damages. Ms. Comeaux has particular expertise in organizational assessments that address theories of liability, including reviewing and responding to the results of assessments conducted by regulators and third parties.
Professor Reuter specializes in examining the behavior of individual investors and financial institutions, including mutual fund families, investment banks, rating agencies, financial advisors, and the financial media. His work focuses on the value of financial advice, the strategic behavior of target-date retirement funds, and portfolio management outsourcing in the mutual fund industry. In addition to his academic experience, Professor Reuter has served as an expert in a mutual fund fee litigation, filing an expert report and testifying at deposition. He has also provided testimony to the US Department of Labor (DOL), which summarized his research on the behavior of brokers and broker-sold mutual funds.
Professor Reuter has published a number of articles on topics such as mutual fund performance, the effect of pension design on employer costs and employee retirement choices, and the effect of advertising on product reviews. This research has been published in leading academic journals, including The Journal of Finance and The Quarterly Journal of Economics; mentioned in media outlets such as The New York Times and The Wall Street Journal; and cited by the President’s Council of Economic Advisers and the DOL. Professor Reuter also serves as an editorial board member of the Journal of Pension Economics and Finance. He is a research associate at the National Bureau of Economic Research (NBER) and a fellow at the TIAA Institute.
Dr. Chapsal is an economist who specializes in empirical and theoretical industrial organization. He has provided economic expertise in a large number of high-profile cases involving mergers, cartels, information exchanges, abuses of dominant positions, regulation, intellectual property matters, and damages quantifications. Recent examples include the Lafarge/Holcim and Fnac/Darty mergers, as well as airfreight, cathode ray tube, and elevator cartel cases. Dr. Chapsal has also assisted various firms in designing optimized pricing strategies and dealing with policy issues. His reports have been presented to the competition authorities of France, Germany, Austria, and South Africa; the European Commission; the Higher Regional Court of Düsseldorf; and the Court of Appeals, Conseil d’Etat, Conseil constitutionnel, and Tribunal of Commerce of Paris.
Prior to joining Analysis Group, Dr. Chapsal founded MAPP, a Paris- and Brussels-based economic consultancy, which was acquired by KPMG in 2018. Previously, he worked in a US competition economics consultancy. Dr. Chapsal regularly publishes articles on competition economics, on subjects ranging from the econometric analysis of cartels to geographic market delineation and exclusionary strategies. He is an affiliated professor at the Sciences Po Department of Economics and a member of the CESifo academic research network.
Mr. Malinak specializes in financial economics, with particular expertise in damages estimation, applied finance theory, and business and asset valuation. He has provided deposition, arbitration, and trial testimony on economic damages and valuation issues, and has testified on financial integrity, the cost of capital, and economic issues in utility rate hearings and at a Federal Energy Regulatory Commission (FERC) hearing. Mr. Malinak has directed litigation projects in many industries on issues related to securities (including derivative securities), antitrust, breach of contract, taxation, regulatory economics, and intellectual property claims. He has frequently addressed class certification and damages issues in securities fraud cases, as well as the myriad economic, financial, and accounting issues common to most damages calculations, such as cost of capital and prejudgment interest. Mr. Malinak has significant experience in tax-related work, including leading Analysis Group teams in Black & Decker, Inc. v. United States and Chemtech Royalty Associates L.P. v. United States, as well as in financial institutions and risk management, having led consulting teams supporting experts in the Winstar savings and loan litigations. He also completed a major project on the risk of Fannie Mae, resulting in a white paper authored by an academic affiliate. He has served as treasurer, head of the audit and finance committee, and a member of the executive committee and board of directors of the Meridian International Center, an international leadership organization that works with partners in the government, private, NGO, and educational sectors to create lasting international partnerships through leadership programs and cultural exchanges. Prior to joining Analysis Group, Mr. Malinak was a principal at Putnam, Hayes & Bartlett.
Dr. Brackley is board certified in internal medicine and an expert in patient and medical safety. Her deep knowledge of clinical trial management includes clinical events committees and safety event reviews, as well as pharmacovigilance, post-market processes, field actions, and risk management. She has consulted on these issues to medical device, diagnostic, and pharmaceutical companies for over a decade. Dr. Brackley’s expert experience includes providing medical insight, post-market surveillance, and pharmacovigilance expertise in complex legal matters, in which she has submitted expert reports and testified at deposition; supporting legal teams in their review and understanding of complex medical and epidemiological issues; and reviewing medical records, complaints, and regulatory submissions. She has provided safety oversight and medical review expertise in clinical studies, and developed processes for clinical trial adjudication and data safety monitoring boards. In addition, Dr. Brackley has created strategies for developing and optimizing medical safety groups in the medical device, diagnostic, and pharmaceutical industries, including processes, procedures, organizational structure, implementation, and rollout. Earlier in her career, as a vice president and medical safety officer at Boston Scientific, she provided safety oversight and safety vigilance throughout the product life cycle and was involved in strategic decision making across all products worldwide. Prior to her roles in industry, Dr. Brackley completed a residency in internal medicine. She is a member of the American Medical Association, the Massachusetts Medical Society, and the Regulatory Affairs Professionals Society.
Ms. Comstock has extensive experience applying economic and financial analyses to litigation and other complex business situations. She has assisted clients in all phases of the litigation process, including fact and expert discovery, trial preparation, and settlement negotiations. Ms. Comstock’s case work has involved litigation related to the high-profile bankruptcies of several firms. She has provided consulting support and supported experts in cases related to the alleged manipulation of different benchmark rates, including evaluations of the effects of alleged manipulation on the value of different derivatives and securities. She has also provided consulting and expert support in matters involving alleged violations of Rule 10b-5 and Section 11, and on matters related to mortgage-backed securities. Ms. Comstock has supported experts in ERISA-related litigations, alleged breach of contract matters, and other business and valuation disputes.
Mr. Beach has more than 30 years of experience valuing businesses; rendering fairness opinions; and negotiating, structuring, and closing mergers and acquisitions (M&A), financings, strategic alliances, and joint ventures. During his career, he has closed over 100 M&A transactions and over 100 financings for companies in the technology, health care, consumer products, and financial services industries. He has frequently served as an expert witness in complex litigation matters involving shareholder rights and valuation, and has testified several times in Delaware Chancery Court. As founder and president of Business Consulting Group, LLC, Mr. Beach oversees the firm’s valuation and advisory work for corporate transactions. Earlier in his career, Mr. Beach was head of corporate finance for KPMG and head of investment banking at Advest, Inc. In addition, he was president and co-founder of Boston Corporate Finance, a boutique investment banking firm focused on providing M&A, capital-raising, and general advisory services to global companies in the technology sector. He has served on the board of numerous companies and organizations, and has advised many companies on their strategic development and direction. Mr. Beach has been a guest lecturer at Harvard Business School, Cornell University, and Dartmouth College. He has been a certified public accountant and is a registered principal with the Financial Industry Regulatory Authority (FINRA).
Mr. Hille has more than 30 years of experience in investment management. In his former role as chief investment officer at Texas Christian University (TCU), he was responsible for the day-to-day management of its multibillion-dollar investment program, which includes the operation and fiduciary oversight of the university’s endowment assets. His responsibilities also included implementing approved investment policies; developing investment processes and procedures for risk management and asset allocation, monitoring, and evaluation; investment manager selection and termination; and identifying management strategies to improve the program’s investment performance and efficiency. Prior to joining TCU, Mr. Hille was chief investment officer of the Teacher Retirement System of Texas, the state’s largest public pension plan. Earlier in his career, he managed portfolios for the Employees Retirement System of Texas. He currently serves on the investment advisory and trustee boards of the Employees Retirement System of Texas and the Texas Treasury Safekeeping Trust Company, as well as on the board of trustees of the Communities Foundation of Texas. Mr. Hille has served as president of the Austin Society of Financial Analysts and as an adjunct professor of finance at the University of Texas McCombs School of Business. He is a Chartered Financial Analyst (CFA) and Chartered Alternative Investment Analyst (CAIA) charterholder.
Mr. Richard has more than 20 years of experience in institutional money management. He was a founder of Taurus Horizon Fund, where he was a managing partner and fund manager for the strategy. Previously, he served at State Street Global Advisors as a senior fixed-income portfolio manager. The assets under his management exceeded $15 billion dollars. Mr. Richard's investment expertise spans a variety of security types, including unsecured corporate credit and securitized structures (such as ABS, MBS, CMBS, and CDO). Over his career, Mr. Richard has also taken an active role in trading securities and performing due-diligence credit work on underlying collateral.
Mr. Richard has provided expert reports, rebuttal reports, deposition testimony, and trial testimony in a number of securities-related cases, opining on issues related to valuation, portfolio manager due diligence, investment suitability, and market conditions, among others. He has served as an expert witness in securities litigation in which he analyzed structured investment vehicles (SIV) on behalf of a large investment bank, and has opined on issues related to the residential mortgage-backed security (RMBS) market. He has also provided consulting services on matters related to auction-rate securities and embedded swap agreements within structured finance instruments. He is a Chartered Financial Analyst and a member of the Boston Security Analysts Society.
For more than 25 years, Mr. Christensen has worked on high-stakes litigation matters with world-class experts, supporting their testimony at both bench and jury trials. His work has focused on valuation and appraisal matters, private equity disputes, antitrust and consent decree litigations, bankruptcy, and tax and transfer pricing dispute resolutions. Through his extensive experience, he has developed a deep understanding of the high-tech, digital advertising, pharmaceutical, media and entertainment, and finance industries. In addition to his litigation work, Mr. Christensen has also assisted in the preparation of numerous impact studies in the high-tech space on issues such as cloud computing and storage, broadband availability, virtual and augmented reality, artificial intelligence, and the metaverse. His clients have included Meta/Facebook, Google, GSK, AstraZeneca, JAB Holding Company, Bank of America, BNP, and Fidelity. Among his engagements are high-tech antitrust matters, a GSK transfer pricing dispute, the Nortel Networks bankruptcy, Delaware appraisal trial victories involving PetSmart and Panera, and rate-setting trials for BMI. Mr. Christensen is a CFA charterholder.
Professor Christoffersen’s research focuses on mutual funds, hedge funds, and the role of financial institutions in capital markets. She has been retained as an expert in litigation matters to address topics such as mutual fund market timing and trading strategy issues. She has published in a number of finance journals, and her work has been cited in The New York Times, the International Herald Tribune, Bloomberg News, and The Wall Street Journal. Professor Christoffersen has received grants from Canada’s Social Sciences and Humanities Research Council, the Montreal Financial Mathematics Institute, and the Quebec Research Funds, as well as research awards from Q Group, the Bank of Canada, the BSI Gamma Foundation, INQUIRE, and the Swiss Finance Institute. Prior to joining the faculty at the University of Toronto, she held positions at McGill University, Copenhagen Business School, and the Department of Finance Canada.
Mr. McLean specializes in applying finance and economics to problems in complex business litigation, including securities, valuation, tax, and intellectual property (IP) matters. His experience spans several industries, from banking, insurance, and high tech to telecommunications and health care. He has served as an expert witness, and has provided assistance in many phases of litigation, including development, presentation, and review of pretrial discovery; preparation of testimony; and critique of analyses of opposing experts.
Mr. McLean’s case work has included general damages analyses, lost profit and reasonable royalty calculations related to IP misappropriation, and assessments of fiduciary duties and investment management. In addition, he has evaluated the economic characteristics and risk transfer of a range of financial instruments, such as private mortgage insurance, subprime loans, and preferred equity in a new venture. He has led large case teams in a number of high-profile matters, including consulting to the US Department of Justice (DOJ) regarding the financial issues involved in tribal trust fund disputes, and supporting counsel for a large electronics manufacturer in litigation associated with features on smartphones and tablets.
In addition, Mr. McLean has presented on topics related to damages assessment and patents. He has also worked with entrepreneurial companies, helping to develop financial projections, business plans, and marketing strategies.
Professor Hubbard is a leading expert in public economics, corporate and institutional finance, macroeconomics, antitrust, and industrial organization. He has provided trial and deposition testimony in numerous litigation matters, including more than a dozen cases in the Delaware Chancery Court. He has also served as a testifying expert in several high-profile finance- and securities-related cases, as well as on damages issues in antitrust matters. Professor Hubbard has consulted to several government and international agencies, including the US Department of the Treasury, the US International Trade Commission, the US Securities and Exchange Commission, the World Bank, the Board of Governors of the Federal Reserve System, the Federal Reserve Bank of New York, and the Congressional Budget Office. From 2001 to 2003, he served as chairman of the President’s Council of Economic Advisers.
Professor Hubbard has published more than 100 scholarly articles and coauthored several books, including the widely used textbook Money, the Financial System, and the Economy. His commentaries have appeared in Businessweek, The Wall Street Journal, The New York Times, the Financial Times, and The Washington Post, as well as on PBS television and NPR radio business programs. A frequent speaker, Professor Hubbard has presented his research at economic conferences throughout the world.
Ms. Cotton has extensive experience conducting complex quantitative and qualitative analyses of data in both mergers and litigation matters. She has supported experts from leading universities and managed case teams in a broad range of industries on matters related to antitrust, bankruptcy, class certification, intellectual property, securities, survey design, tax, and transfer pricing. Her recent case work has included assessing competitive effects in major antitrust matters and mergers; analyzing Federal Trade Commission (FTC), US Department of Justice (DOJ), and Canadian Competition Bureau (CCB) merger compliance, including assistance with Hart-Scott-Rodino (HSR) filings, second requests, divestiture analysis, advocacy, and merger trial testimony; managing the independent evaluation of large-scale transaction and customer datasets in major antitrust matters; examining damages issues in a data breach context; and determining arm’s-length pricing in a large US transfer pricing matter. Ms. Cotton also has substantial experience evaluating questions of commonality and typicality in the context of privacy, technology, data breach, pharmaceutical, medical device, and overcharge class actions.
Professor Blanchard’s research combines experiments with observational data analyses to study how consumers make complex decisions about finance and technology. He serves as a marketing and research expert in commercial litigation and advises financial services and technology companies on business strategies and research. Professor Blanchard is the director of Georgetown’s M.B.A. Certificate in Consumer Analytics and Insights program, and he teaches courses on research design, surveys, and quantitative analyses to undergraduate, graduate, and executive education program students. He has been named among the best 40 business professors under 40 by Poets&Quants, and a Young Scholar by the Marketing Science Institute.
Professor Blanchard is an associate editor of the Journal of Marketing Research, the Journal of Consumer Research, and the International Journal of Research in Marketing, and he has published articles in a number of prominent marketing journals. Professor Blanchard’s research and perspectives on consumer finances and technology have been featured in media outlets such as Forbes, Fortune, Harvard Business Review, NerdWallet, The New York Times, Marketplace, and NBC News. Prior to joining the Georgetown faculty, he served as a member of the American Marketing Association’s Academic Council, and held visiting positions at Dartmouth College and Columbia University.
Mr. Richardson has more than 30 years of experience as a senior executive at institutional asset management firms, most recently as executive director of client service and business development and member of the global management team at Impax Asset Management Group. Throughout his career, Mr. Richardson has been responsible for overseeing the management of institutional investment portfolios of fixed-income, listed equity, and private securities. During the final decade of his tenure as head of Impax’s North American business, these portfolios were managed with a particular focus on the role of environmental, social, and governance (ESG) factors in investment management decisions. He has consulted to public and private companies in numerous industries, including financial services and insurance, on investment, governance, and compliance matters. Mr. Richardson has had oversight of a full range of investment portfolios offered through different fund vehicles, including 40 Act funds, commingled funds, collective trust funds, limited partnerships, and segregated accounts. He has been responsible for client, asset, and revenue growth, as well as new product initiatives and M&A. Mr. Richardson testified at deposition and trial, and has contributed to articles on sustainable investments for media outlets such as the Financial Times, The New York Times, and CNBC. Prior to his work with Impax, he co-founded Global Energy Investors, a private equity infrastructure firm, and Dwight Asset Management, an institutional fixed-income investment firm that was subsequently acquired by Goldman Sachs. He serves as a member of the Global Leadership Council for the World Resources Institute, and as a member of the President’s Council for Ceres. Mr. Richardson is a CFA charterholder.
Dr. Cliff is a financial economist with expertise in a range of topics, including asset valuation, mergers and acquisitions (M&A), tax shelters, stock analysts’ recommendations, IPOs, REITs, derivatives, and hedge funds. He has extensive experience with large financial datasets, sophisticated econometric models, and simulations. In his consulting engagements, Dr. Cliff has addressed damages modeling, class certification, business and asset valuation, analysis of complex financial structures, analysis of solvency and debt covenants, evaluation of investment strategies, and assessment of due diligence practices. In these assignments, he has managed large case teams, designed and performed analyses in support of expert reports, critiqued opposing expert reports, and assisted with preparation for depositions and trial. Dr. Cliff has also served as an expert on cases involving valuation, damages, and liquidity discounts. Prior to joining Analysis Group, Dr. Cliff was a finance professor for nine years at Purdue University and Virginia Tech, where he taught a variety of courses at the undergraduate, M.B.A., and Ph.D. levels. His academic research has been published in leading journals such as the Journal of Finance, the Journal of Business, and Financial Management.
Professor Eden is an expert on transfer pricing and multinational enterprises (MNEs), with decades of experience consulting to MNEs, governments, and international organizations on transfer pricing and MNE strategies and structures. In transfer pricing matters, she has served as an expert witness – in cases that include Coca-Cola Co. v. Commissioner and In re: Nortel Networks – and filed numerous expert reports. Professor Eden has taught courses on transfer pricing, MNEs, and the economics of international business, and founded the Transfer Pricing Aggies program at Texas A&M University, which has trained hundreds of graduate students. She has extensive research experience in areas such as transfer pricing and MNE strategies in the digital economy, and her work has been widely published in management and international business journals. Professor Eden has authored several books, including Taxing Multinationals: Transfer Pricing and Corporate Income Taxation in North America, Multinationals in North America, The Economics of Transfer Pricing, and Research Methods in International Business. She is a frequent speaker at transfer pricing and tax conferences, as well as dean of the Fellows of the Academy of International Business, where she formerly served as president.
Dr. Mortimer specializes in health economics, industrial organization, microeconomic theory, and econometrics. He has extensive experience with issues involving competition, intellectual property, marketing, pricing, and valuation with a focus on the health care industry. He has evaluated questions of class certification, damages, liability, and market definition in antitrust matters. He also has provided economic analyses and expert testimony on causation and damages in a variety of health care cases, including cases involving allegations of False Claims Act (FCA) and Anti-Kickback Statute (AKS) violations. In addition to his work in litigation, Dr. Mortimer has assisted pharmaceutical and medical device manufacturers on pricing and contracting issues and authored several public policy studies related to legislation establishing a biosimilar approval pathway, biosimilar competition, pharmaceutical pricing, generic drug competition and the role of authorized generic entry, and paragraph IV abbreviated new drug application (ANDA) filings. His research has been published in leading peer-reviewed journals, including Health Affairs, Nature Reviews Drug Discovery, The Journal of Industrial Economics, and the Journal of Medical Economics.
Professor Jena is a health economist, practicing internal medicine physician, and professor of health care policy. His work involves several areas of health economics and policy, including the economics of medical innovation, the economics of physician behavior and the physician workforce, medical malpractice, and the economics of health care productivity. Professor Jena has been retained as an expert in several pharmaceutical and health care industry matters.
A prolific author, Professor Jena has contributed to more than 150 peer-reviewed articles and articles intended to increase patient understanding, published in outlets including the New England Journal of Medicine and The New York Times. He is a faculty research fellow at the National Bureau of Economic Research and serves on Harvard Medical School's Standing Committee on Health Policy. Professor Jena is a recipient of the NIH Director's Early Independence Award to fund research on the physician determinants of health care spending, quality, and patient outcomes, and a recipient of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) New Investigator Award. In 2018, he was listed among 100 great leaders in health care by Becker's Hospital Review.
Dr. Dawson specializes in applying economics and finance to complex problems in business litigation, including intellectual property (IP), false advertising, securities, and finance matters. Her experience spans several industries, from medical devices and high tech to telecommunications and accounting. Dr. Dawson has consulted to counsel in all phases of the litigation process, including understanding complex claims, assisting with fact and expert discovery, and providing trial support. She has served as an expert witness on matters involving false advertising, breach of contract, and copyright infringement. Dr. Dawson’s case work has involved complex data analysis, development of financial models, general damages assessment, evaluation of lost profits, royalty, and other damages remedies in IP and false advertising matters, ascertainment of loss causation and damages in securities fraud matters, and financial statement analyses. She has spoken at various conferences and served as a panelist on the topics of platform economics and IP damages.
Mr. Bodington specializes in the business and finance aspects of the electric power industry. He is the founder of a boutique investment banking firm that has provided M&A, financing, and restructuring advisory services to the energy sector for more than 25 years. Mr. Bodington has played a key role in more than 100 transactions with an aggregate value of more than $7 billion. In these engagements, he has led the purchase and sale of interests in power projects; arranged debt and equity financing for energy projects in development, construction, and operation; and advised owners and lenders on various capitalization, value, repayment, restructuring, and management issues. His clients include industrial companies, independent power companies, equity investors, lenders, utility affiliates, and regulated utilities.
Mr. Bodington is also a seasoned expert witness who has provided testimony for clients on finance and damages issues. Prior to founding Bodington & Company, he spent eight years with Bechtel Group and four years with an international management consulting firm. Mr. Bodington is the author of more than 50 articles on a variety of economic and financial topics relevant to the energy sector. He holds Financial Industry Regulatory Authority (FINRA) Series 7, 24, 63, 79, and 99 licenses.
Dr. Robbins is a pharmaceutical and biotech executive with over 40 years of broad-based industry experience. In his role at Kodiak Strategic Consultants, he consults to a diverse group of pharmaceutical and biotech companies on clinical, regulatory, business development, and licensing issues. Dr. Robbins served as a CEO in residence at the University of Minnesota’s Office for Technology Commercialization and co-founded several biotech ventures. He is actively involved with a number of startups, including GigaMune, Neuropharma Meds, and Diastol Therapeutics. He served as the COO of Bullet Biotechnology, regulatory strategic advisor to GigaGen, and acting CEO of GigaMune, all of which have focused on novel immunotherapies targeting cancer and autoimmune diseases. Dr. Robbins has served as an expert in multiple antitrust matters, intellectual property cases, and contract disputes, and provided testimony at deposition, trial, and arbitration. Prior to his consulting career, he held several senior-level positions at brand and generic pharmaceutical companies, where he was responsible for the development of regulatory and clinical strategies that led to numerous new drug application (NDA), biologics license application (BLA), and abbreviated new drug application (ANDA) approvals by the US Food and Drug Administration (FDA). He has conducted analyses in therapeutic areas that include cardiology, oncology, endocrine/metabolic, women’s health, infectious diseases, radiology, and nuclear medicine and diagnostics. In addition, Dr. Robbins has experience assisting biotech startups with strategy and financing. He holds adjunct professorships in pharmacology at the University of Minnesota Medical School and the University of Minnesota College of Pharmacy, and his work has been published in numerous peer-reviewed scientific journals. Dr. Robbins serves on the Antitrust Council of the Minnesota State Bar Association.
Mr. Cohen has over 30 years’ experience as an expert in international arbitration, valuation, antitrust, intellectual property, and securities, and has testified in arbitration and federal courts on many aspects of economic damages. He specializes in fields that are intensive in intangible assets such as patents, copyrights, trademarks, and trade secrets. He has worked across a wide range of industries, including health care, software and technology, financial services, energy, transportation, and entertainment.
Mr. Cohen has worked with significant corporations including Apple, Microsoft, Oracle, Wells Fargo, State Street, Wachovia, SoundExchange, ASCAP, Liberty Mutual, Allstate Insurance, Johnson & Johnson, AstraZeneca, Astellas, United Airlines, TWA, DaimlerChrysler, Mitsubishi, and Anheuser-Busch. He also has experience in matters related to the US Federal Trade Commission, the US International Trade Commission, the Tax and Antitrust Divisions of the US Department of Justice, the Republic of Uruguay, and the Commonwealth of Australia.
Mr. Cohen is the author of Intangible Assets: Valuation and Economic Benefit and a contributor to the American Bar Association publication Proving Antitrust Damages. He has been a guest lecturer at both Northwestern University and The University of Chicago. He is also a prolific songwriter.
Professor Hylton has over 30 years of experience researching legal issues in antitrust, merger, and intellectual property cases. He is an expert on tort law, labor law, civil procedure, and empirical legal analysis. A prolific author, Professor Hylton has published 5 books and more than 100 scholarly articles on topics such as oligopoly pricing, the intersection of antitrust and intellectual property, and damages in patent infringement cases. He is an associate editor of the International Review of Law and Economics, a former contributing editor of the Antitrust Law Journal, coeditor of Competition Policy International, and editor of the Social Science Research Network’s Torts & Products Liability Law eJournal. Professor Hylton is a past president of the American Law and Economics Association, and previously served as the organization’s secretary-treasurer and vice president. He is a member of the American Law Institute and serves on the board of directors of the Pioneer Institute. Prior to joining Boston University, Professor Hylton was awarded tenure as a faculty member at Northwestern University School of Law and served as a research fellow at the American Bar Foundation.
Professor Knittel’s research focuses on industrial organization, applied econometrics, and energy and environmental economics. He has provided trial and deposition testimony in a number of litigation matters, including valuing product features in smartphones, PCs, and contact lenses. He has also consulted to Delta Airlines, Ford Motor Company, the US Energy Information Administration, and Korea Electric Power Company. Professor Knittel has authored or coauthored numerous articles on topics such as market structure and product pricing, tacit collusion, and challenges in merger simulation analysis. Examples of his research include articles on the spurious correlation between ethanol production and gasoline prices, unilateral market power in the electricity reserves market, and tacit collusion in credit card markets. His research has appeared in the American Economic Review, the American Economic Journal: Macroeconomics, the American Economic Journal: Economic Policy, The Review of Economics and Statistics, The Journal of Industrial Economics, and The Energy Journal, among other academic publications. He is a former coeditor of the Journal of Public Economics and serves or has served as an associate editor for several other scholarly journals, including the American Economic Journal: Economic Policy, The Journal of Industrial Economics, the Journal of Transport Economics and Policy, and The Journal of Energy Markets. Professor Knittel is a research associate at the National Bureau of Economic Research (NBER) in the Productivity, Innovation, and Entrepreneurship and Industrial Organization programs, and he co-directs the Environment and Energy Economics program.
Dr. Duh, Chief Epidemiologist at Analysis Group, specializes in real-world evidence (RWE) generation for product registration, post-approval safety studies, and health economics and outcomes research (HEOR) of pharmaceuticals, vaccines, and regenerative biotherapeutics. She has led multiple projects for new molecular entity approvals and product label expansion applications to the US Food and Drug Administration (FDA) and European Medicines Agency (EMA), as well as health technology assessment (HTA) research for submissions to national payers such as the Centers for Medicare and Medicaid Services (CMS) in the US and the UK’s National Institute for Health and Care Excellence (NICE). Her extensive research has appeared in over 250 peer-reviewed publications.
Her work also extends to pharmaceutical liability litigation and securities fraud litigation related to adverse drug events that allegedly led to product recalls, market withdrawals, black box warnings, and FDA limited access programs.
Dr. Duh is also an adjunct in the biostatistics department at the Harvard T.H. Chan School of Public Health. She served as a chairperson of drug safety and epidemiology for the Drug Information Association (DIA) and was an adjunct assistant professor of pharmacoeconomics and pharmacoepidemiology at Massachusetts College of Pharmacy and Allied Health Sciences. Dr. Duh was appointed to an expert panel convened by the Foundation for the National Institutes of Health’s (FNIH’s) Observational Medical Outcomes Partnership (OMOP). She has served as a peer reviewer for several journals, including PharmacoEconomics, the American Journal of Health-System Pharmacy, Chest, Pharmacoepidemiology and Drug Safety, the American Journal of Kidney Diseases, and Therapeutics and Clinical Risk Management. Dr. Duh is also an elected member of the American Society of Hematology and a member of the American Society of Clinical Oncology, the International Society of Pharmacoepidemiology, and the International Society of Pharmacoeconomics and Outcomes Research (ISPOR).
View Dr. Duh's selected publications on the Harvard Catalyst website
Pierre Cremieux, President of Analysis Group, has a broad range of expertise in health economics, antitrust, statistics, and labor economics. He has consulted to numerous clients in the US and Canada and testified in bench and jury trials, arbitrations, and administrative proceedings.
Dr. Cremieux has served as an expert and supported other experts in both litigation and non-litigation matters on antitrust issues; general commercial claims; contractual disputes; and a number of labor-related matters in a variety of industries, including high tech, pharmaceuticals, biotech, financial products, consumer products, and commodities. He has assessed the evaluation of damages on a class-wide basis in some of the largest class action matters in recent years.
His scientific research in antitrust economics, class certification, health economics, and statistics has been published in numerous peer-reviewed journals including the George Mason Law Review, the American Bar Association Economics Committee Newsletter, The Review of Economics and Statistics, the Journal of Health Economics, Industrial and Labor Relations Review, the Journal of Clinical Oncology, and the American Journal of Managed Care. Dr. Cremieux's research has been cited in leading media outlets including The Wall Street Journal and Forbes.
Dr. Cremieux has frequently presented at leading legal, health care, and economics seminars on topics such as antitrust, class certification, health economics, and statistics, in both the United States and Canada. He has also been invited to teach courses on economics, statistics, health care, and antitrust at various schools including McGill University, Boston University, Harvard Medical School, and Yale's School of Management.
Prior to joining Analysis Group in 1997, Dr. Cremieux spent five years as a professor at the University du Québec à Montréal, and served as an adjunct professor from 1997 to 2018.
Dr. Rice is an economist with a range of expertise in health economics, industrial organization, statistics, and econometrics. He has extensive experience applying economic theory and statistical methods in complex litigation and research settings. Dr. Rice has led analyses related to government investigations and litigation matters, where he has supported counsel and been retained as an expert on alleged Anti-Kickback Statute and False Claims Act violations, as well as on antitrust, cryptocurrency, insider trading, misappropriation of trade secrets, and breach of contract issues. In matters related to liability and damages, he conducts empirical analyses involving large-scale databases on a range of topics, including causal inference, merger simulation, and budget impact. Dr. Rice’s case experience has involved providing assistance in the preparation of expert reports, testimony, and rebuttal analyses and arguments; developing sophisticated interactive models enabling real-time damages assessments under alternative scenarios; and presenting analyses to US Attorney’s Office investigators. In addition to his litigation work, he has provided econometric and statistical consulting on matters such as economic research questions, risk management, fair market valuation, and compliance. Dr. Rice is adjunct faculty in the Harvard University Department of Economics and has taught undergraduate courses on econometrics, health economics, industrial organization, and regulatory economics. He has published extensively in numerous peer-reviewed journals, and presented at conferences and seminars.
Mr. Jenson has extensive experience managing complex high tech capital equipment businesses for public and private equity companies. He has more than 30 years of experience in global manufacturing focusing on general management, marketing, sales, and product development. His experience includes automation systems, robotics, thin-film process equipment, material handling equipment, industrial equipment, and analytical instrumentation. Mr. Jenson has participated in numerous mergers and acquisitions (M&As), as part of both the acquiring firm and the acquired firm. His M&A experience includes investment target identification, valuation, due diligence, integration, and management of acquired companies. In his position as general manager of core technologies for Ocean Insight – a spectroscopy and imaging technology company – Mr. Jenson leads the global sales, marketing, and product development teams. Prior to his work with Ocean Insight, he led the $200 million waterjet cutting systems business segment of SHAPE Technologies Group, managed the $250 million compound semiconductor equipment business unit of Veeco Instruments, and served as a senior leader in automation solutions for the semiconductor and flat panel display industries at Brooks Automation. Mr. Jenson is also a veteran submarine officer of the US Navy.
Ms. Glowka is a chartered accountant who specializes in the assessment of damages and forensic analysis arising in the context of dispute resolution. She has served as an expert and led consulting teams on complex UK and international assignments, including litigation and international arbitration matters before the High Court of Justice in London, the Scottish Court of Session, the UK Competition Appeal Tribunal, and all the major international arbitration forums.
Ms. Glowka has acted on a broad range of litigation and arbitration matters across the automotive, oil and gas, pharmaceutical, telecommunications, software, and consumer products industries, among others. Her litigation and arbitration work has involved the evaluation of damages arising in the context of contractual and shareholder disputes, as well as post-transaction disputes such as breach of warranty claims. Ms. Glowka’s forensic accounting work has spanned analysis and tracing of funds and transactions, as well as evaluation of fraud and accounting irregularities, including allegations of accounts manipulation for inflating performance-related bonuses and purchase consideration. She has also evaluated complex financial reporting issues under a variety of accounting standard-setting regimes, including UK generally accepted accounting principles (GAAP) and International Financial Reporting Standards (IFRS). Ms. Glowka is a member of Chartered Accountants Australia and New Zealand.
Professor Rock is an expert in corporate law and corporate governance. He coauthored the book The Anatomy of Corporate Law: A Comparative and Functional Approach, and has published numerous articles on topics such as poison pills, politics and corporate law, hedge funds, corporate voting, proxy access, corporate federalism, and mergers and acquisitions. Prior to joining the NYU faculty, Professor Rock taught at the University of Pennsylvania Law School, where at various times he served as co-director of the Institute for Law and Economics, associate dean, senior advisor to the president, and provost and director of open course initiatives. He has held visiting professorships at NYU and Columbia University, and was a Fulbright Senior Scholar at Hebrew University. Prior to his academic career, Professor Rock worked as an attorney specializing in complex antitrust, corporate, and securities litigation. In January 2019, the American Law Institute named him Reporter for the Restatement of the Law, Corporate Governance.
Professor Levinsohn is an expert in antitrust, industrial organization, and econometrics. He has provided expert reports and testimony in several landmark antitrust and regulatory matters, including In re: TFT-LCD (Flat Panel) Antitrust Litigation, In re: Vitamins Antitrust Litigation, In re: New Motor Vehicles Canadian Export Antitrust Litigation, and the Tobacco Master Settlement Agreement proceedings. He has also consulted to numerous foreign governments and international organizations.
Professor Levinsohn conducts research in industrial organization, applied econometrics, international economics, and development economics. He has served on the editorial boards of American Economic Review, The Review of Economics and Statistics, the Journal of International Economics, and the Journal of Economic Literature. Prior to joining the Yale faculty, Professor Levinsohn was the J. Ira and Nicki Harris Family Professor of Public Policy at the Gerald R. Ford School of Public Policy at the University of Michigan.
Dr. Garces is an economist with deep public- and private-sector antitrust policy and regulation experience in the US and Europe, including serving in the European Commission’s Directorate-General for Competition (DG COMP) and Directorate-General for Internal Market and Industry. Her consulting and case work experience includes mergers and conduct cases in the telecommunications, media, industrial, consumer staples, and technology sectors. She has corporate experience at a large technology company and is widely recognized as an expert on the economic analysis of new digital business models, as well as on regulation in innovative sectors. Dr. Garces has published extensively on topics such as the antitrust analysis of commercial practices, the assessment of conglomerate mergers, the interaction between antitrust and privacy, value creation processes in platform businesses, and behavioral economics. She is also a coauthor of the widely used book Quantitative Techniques for Competition and Antitrust Analysis.
Professor Keller is an expert on marketing management, branding, and brand equity. His research focuses on improving marketing strategies through an understanding of consumer behavior, as well as on the design, implementation, and evaluation of integrated marketing communication programs. Professor Keller has served as brand advisor to a number of large corporations, including Accenture, American Express, Disney, Ford, Intel, Levi-Strauss, L.L. Bean, Nike, Procter & Gamble, and Samsung. He has published over 120 papers in peer-reviewed journals such as the Journal of Marketing, the Journal of Marketing Research, and the Journal of Consumer Research. He also authored the widely used textbooks Marketing Management (with Philip Kotler) and Strategic Brand Management. Professor Keller has received numerous awards for his research accomplishments, and has conducted marketing seminars for executives in a variety of forums. He previously held faculty positions at the University of California, Berkeley; Stanford University; and the University of North Carolina at Chapel Hill.
A former chief economist at the Federal Communications Commission (FCC), Professor Rogerson focuses his research on applied microeconomic theory, industrial organization, regulation, cost accounting, telecommunications, and defense procurement. He has been an active participant in media transactions before the FCC, including Comcast/NBCUniversal and News Corp./DirecTV, as well as various rulemaking proceedings. Professor Rogerson was also the FCC’s senior economist, supervising its economic analyses of the Comcast/Time Warner Cable, AT&T/DirecTV, and Charter Communications/Time Warner Cable transactions. He has also served as an economic expert for the US Department of Justice, Federal Trade Commission, and the National Association of Attorneys General in various antitrust cases in the telecommunications, media, and defense industries. Professor Rogerson has published a number of articles and book chapters on topics such as vertical mergers in the video programming and distribution industry, and incentives for investment and innovation as related to the regulation of broadband telecommunications. He is a former editor of Economic Inquiry and Defense and Peace Economics, and a former member of the editorial boards of both the Review of Accounting Studies and The Journal of Industrial Economics. He served two terms as chair of Northwestern University’s Department of Economics, and currently holds several leadership roles at Northwestern, including research director of the Program on Antitrust Economics and Competition Policy at the Searle Center on Law, Regulation, and Economic Growth; director of the Center for Business Institutions; and co-director of the Center for the Study of Industrial Organization.
Professor Haas-Wilson is an expert in health care antitrust, including the competitive effects of hospital mergers and commercial health insurer mergers, the effects of vertical consolidation in health care markets, and the implications of physician networks on competition in the health care industry. She recently testified in Federal District Court in Idaho on behalf of plaintiffs, in an antitrust lawsuit alleging competitive harm from St. Luke’s Health System’s acquisition of a large independent physician practice. She has served as a consultant on antitrust issues to the Federal Trade Commission, the Massachusetts Attorney General, the California Department of Corporations, and numerous private entities. She also testified on behalf of the Federal Trade Commission in the matter of Evanston Northwestern Healthcare Corporation. Professor Haas-Wilson is the author of Managed Care and Monopoly Power: The Antitrust Challenge and coeditor of Uncertain Times: Kenneth Arrow and the Changing Economics of Health Care. Her research has appeared in the Journal of Political Economy, the Journal of Economic Perspectives, the Journal of Law and Economics, the Review of Economics and Statistics, and the Journal of Health Economics, among others.
Dr. Rothman specializes in the economic analysis of antitrust and competition issues. He is retained by private parties to present analyses to the US Department of Justice (DOJ) and the US Federal Trade Commission (FTC). He is also retained by and has testified for the FTC as an expert witness in merger litigation. In addition to his merger work, Dr. Rothman has worked on multiple joint conduct and unilateral conduct matters.
Dr. Rothman is a senior editor of the Antitrust Law Journal. He has published research in outlets including Antitrust Law Journal, The Antitrust Source, Journal of Health Economics, Journal of Competition Law & Economics, and Concurrences: Competition Law Journal. Dr. Rothman has taught a course on the economics of merger analysis in the economics department at Harvard University. Prior to joining Analysis Group, he was an assistant professor at Columbia University.
Professor Pindyck is a leading industrial organization economist and testifying witness in the areas of antitrust and intellectual property. His research and writing have covered topics in microeconomics and industrial organization, the behavior of resource and commodity markets, financial markets, and econometric modeling and forecasting. His recent work in economics and finance has examined the determinants of market structure and market power, the dynamics of commodity spot and futures markets, criteria for investing in risky projects, the role of R&D, and the value of patents. He has received many academic honors, including several awards for outstanding teaching, and holds senior editorial positions with a number of publications. Professor Pindyck has consulted to dozens of public and private organizations, including the Federal Trade Commission, IBM, and AT&T, and has been deposed and/or testified in over a dozen cases in diverse industries such as food, energy, software, medical devices, and airlines. He has worked with Analysis Group on many of these cases, including the Lotus v. Borland litigation, in which Professor Pindyck used econometric modeling techniques to identify the economic value of various attributes and isolated the value of the infringing features. He also worked with Analysis Group in a major litigation matter involving price-fixing allegations, in which he examined allegations of accumulation of buying power and the resulting effects on negotiations with suppliers.
Ms. Guérin is an economist who specializes in the application of statistics and econometrics to health economics and outcomes research (HEOR) and epidemiology. Her areas of expertise include retrospective database analyses such as medical claims, electronic health records, and clinical trial data; economic modeling, such as cost-effectiveness and budget impact models; and design of chart review studies, surveys, and other prospective studies. She has participated in the development of large clinical data registries and in the design of real-world evidence (RWE) studies to support regulatory submissions. Ms. Guérin has broad research and analytical experience in areas such as comparative effectiveness and cost effectiveness, development of prediction algorithms, assessment of disease prevalence and incidence, evaluation of burden of illness, productivity loss, treatment patterns, analysis of patient-reported outcomes (PROs), safety/tolerability analyses, discrete choice experiments, and patient experience studies. She has also supported many pharmaceutical companies in the development of HEOR planning and RWE generation plans. Ms. Guérin has conducted health care research across many therapeutic areas, including oncology, hematology, dermatology, gastroenterology, rheumatology, neurology, psychiatry, endocrinology, cardiology and circulatory diseases, and respiratory diseases. She publishes frequently and is the coauthor of over 100 research papers published in numerous peer-reviewed journals and presented at a variety of scientific conferences.
Dr. Cain is an expert in securities litigation, corporate disclosures, M&A litigation, private equity, valuation, insider trading, and corporate governance. He has provided economic analysis, consulting, and expert witness testimony on a variety of finance topics for investigations, settlement negotiations, and trials. He has estimated event studies and trading profits in relation to allegations of insider trading, improper trading behavior, corporate misrepresentations and disclosures, and unregistered stock sales on behalf of the US Securities and Exchange Commission (SEC), US Department of Justice (DOJ), Commodity Futures Trading Commission (CFTC), and other clients. Dr. Cain worked for several years at the SEC, where he was an advisor to Commissioner Jackson and a financial economist in the Office of Litigation Economics. Prior to joining the SEC, Dr. Cain was an assistant professor of finance at the University of Notre Dame Mendoza College of Business. He has published research in numerous journals on topics that include investment banking and fairness opinion valuations, merger contracts and terminations, corporate governance and shareholder activism, hostile takeovers, earnout clauses, merger-related litigation, and management buyouts. Dr. Cain’s research has been cited in forums such as the US Chamber Institute for Legal Reform, amicus briefs to the US Supreme Court, trial verdicts of the Supreme Court of the State of New York and the Delaware Chancery Court, and The International Comparative Legal Guide to Mergers and Acquisitions. His research has also been highlighted in media outlets such as The Wall Street Journal, The New York Times, the Financial Times, and Forbes.
Professor Kinch, a drug development expert specializing in cancer, immunological, and infectious diseases, focuses on combining cutting-edge science and entrepreneurship to improve public health. At Washington University in St. Louis, Professor Kinch founded and directs the Center for Research Innovation in Biotechnology (CRIB), which assesses trends that guide the research and development of novel medicines. He also helped create the Center for Drug Discovery (CDD) to identify and underwrite the university’s most promising drug discovery projects. Professor Kinch has been issued more than a dozen US patents, published more than 100 patent applications, and written several books and book chapters on the commercialization of biopharmaceutical innovation, as well as other aspects of drug development. He has published widely in peer-reviewed journals, including Drug Discovery Today, Science, Cell Chemical Biology, and Biotechnology Law Report, and his research has been profiled in media outlets such as The Wall Street Journal, NPR, CBS News, and The New York Times. Before joining Washington University, he was the managing director of the Yale Center for Molecular Discovery. He has also taught at Johns Hopkins University and Purdue University, and held senior research positions at Functional Genetics and MedImmune. Professor Kinch serves on the board of the American Cancer Society and on scientific advisory boards (SABs) for several biopharmaceutical companies.
Professor Rossiter is an expert in health economics who has testified or served as an expert in the following areas: competition in the financing and delivery of health services; reimbursement economics, especially for Medicare, Medicare Advantage, and Medicaid; managed care organizations; prescription medicines; survey research; and health information analytics. Professor Rossiter is the former secretary of health and human resources for the Commonwealth of Virginia. In that role, he was responsible for over 15,000 employees in 13 agencies (including 10 state mental hospitals), brought major information technology projects in the Secretariat to national prominence, and made major reforms in Virginia Medicaid. He also served as deputy for policy to the Administrator of the Centers for Medicare and Medicaid Services (CMS). As deputy, he created and directed a new payment system for US hospitals under Medicare, was responsible for the CMS strategic plan, and formulated all agency policy initiatives through the federal legislative process.
Prior to joining the William & Mary faculty, Professor Rossiter was a professor of health administration at Virginia Commonwealth University. He served on the board of regents of the National Library of Medicine, National Institutes of Health; on the board of directors of AcademyHealth; and as chair of the board of directors of the Coalition for Health Services Research, the lobbying arm of AcademyHealth, during the passage of the Affordable Care Act. He has also served on numerous advisory groups, including the National Advisory Council for Healthcare Research and Quality, and is currently a trustee and chair of the Williamsburg Health Foundation. Professor Rossiter is the author or editor of 15 books, and the author of over 50 journal articles on health economics and the role of competition in the financing and delivery of health services.
Mr. Darling consults to clients and provides expert testimony to address litigation, strategy, regulatory, and policy questions in a wide range of antitrust and competition, class certification, health care, energy, and environmental matters. He has submitted and supported expert testimony before US district and appellate courts, state utility commissions, siting boards, and federal agencies. He has also assisted clients with responses to government investigations and presented findings before US Attorneys’ Offices, state attorneys general, and the US Drug Enforcement Administration.
In the areas of health care and antitrust, Mr. Darling has extensive experience supporting clients on issues related to discovery and data production, class certification, patent infringement, market definition and market power, and competitive effects in pharmaceutical and life sciences matters involving patent infringement issues, reverse payment settlements, and product hop allegations. He has also designed and implemented customized suspicious order monitoring (SOM) and loss prevention programs for controlled substances, and has experience in False Claims Act and Anti-Kickback Statute litigation cases, including analyses of causation and damages calculations.
Mr. Darling is also an expert on electricity, oil, and natural gas pricing, markets, and infrastructure. His consulting work on behalf of utilities, state and regional organizations, and global companies includes projects related to cost/benefit analyses of new plant construction and retirements; ratepayer and bill impacts; environmental effects of emissions and pollution controls; economic impacts of energy projects, mergers, and policies; natural gas, biomass, and other market studies; and climate change matters including decarbonization policy proposals and quantification of the impacts of greenhouse gas emissions. He has conducted and overseen numerous economic and bill impact assessments in support of projects and policy proposals, ranging from new power plants and transportation facilities to electric, petroleum, and natural gas transmission infrastructure.
Ms. Hitscherich specializes in corporate acquisitions, leveraged buyouts, exclusive sales and divestitures, takeover defenses, and restructurings. She has served as an expert witness in several complex securities litigations, including matters involving deal structure, valuation, due diligence, custom and usage in the finance industry, and financing alternatives.
Ms. Hitscherich has extensive experience in investment banking and corporate law practice, including as a managing director in mergers and acquisitions with Banc of America Securities, where she was secretary of the Fairness Opinion Review Committee; vice president in mergers and acquisitions with J.P. Morgan & Co., where she was a founding member of the takeover defense team and a senior member of the acquisitions fairness Advisory Review Committee; and as a mergers and acquisitions attorney with Skadden, Arps, Slate, Meagher & Flom.
At Columbia Business School, Ms. Hitscherich teaches corporate finance, advanced corporate finance, business law, and mergers and acquisitions in the M.B.A. and Executive M.B.A. programs.Dr. Royer applies a broad range of quantitative tools to address client needs in data science, statistics, HEOR, finance, intellectual property, competition policy, and antitrust cases in the United States, Canada, and the EU. His recent work includes predicting the potential future onset of rare or undiagnosed conditions with machine learning models; predicting whether patents would be considered essential to technological standards if challenged in courts; valuing patents in the communications industry; evaluating damages related to product defects; analyzing investment guidelines in securities lending suits; addressing allegations of monopolization in major antitrust cases involving high tech firms; and supporting many academic experts on mutual fund market timing and excess fee cases. In addition, Dr. Royer has conducted extensive academic research and coauthored books and papers on topics such as using new AI advances in HEOR; predicting treatment resistance in tuberculosis, using machine learning algorithms in propensity score models; measuring the impact of ESO backdating on shareholders’ wealth; analyzing mutual fund pricing; analyzing antitrust limit pricing; valuing private investments for hospitals in Canada; determining the impact of hypertension therapies on mortality; and comparing unemployment compensation in different countries.
Professor Reibstein’s research focuses on competitive marketing strategies, metrics, and product line decisions, among other topics. He has provided marketing management education and consulting research to companies in the consumer goods, pharmaceutical, and oil and gas industries, among others. His consulting activities have included numerous applications of conjoint analysis and other survey techniques in engagements spanning a wide range of products. Professor Reibstein has submitted expert reports and provided testimony on marketing and marketing research in several litigation matters, including analyses of smartphone features in a patent dispute, health claims in a false advertising dispute, and pharmaceutical detailing in a co-marketing dispute.
His recent work includes assessing strategies to address competitors’ reactions to marketing actions and developing metrics that link marketing decisions to financial consequences, which was published in his book, Marketing Metrics: The Definitive Guide to Measuring Marketing Performance. Professor Reibstein is also the author or coauthor of numerous books and chapters in books on subjects including competitive marketing strategy, global branding, and marketing performance measurement. Professor Reibstein has also written several papers on conjoint analysis and its validity and reliability. His research has been published in leading academic journals, including Marketing Science, the Journal of Marketing Research, and the International Journal of Research in Marketing. Â
Professor Reibstein has been honored with more than 30 teaching and publishing awards, including the John S. Day Distinguished Alumni Academic Service Award from Purdue University’s Krannert School of Management. He has served as the chairman of the American Marketing Association board of directors and as the executive director of the Marketing Science Institute.
Professor Carlson specializes in the marketing management implications of consumer decision-making processes, including the development of brand preferences and the influence of emerging preferences on the decision making process. Though much of Professor Carlson's research explores consumer decision making, he also studies how voters, jurors, and managers make decisions. Over the last 20 years, he has run thousands of surveys, sampling U.S. and international populations.
Professor Carlson has served as an expert in evaluating a survey in a class action matter, consulted on a high profile class action settlement involving consumer deception, and testified before the SEC in an equity trust matter. Professor Carlson's published research can be found in top marketing, psychology, and management journals. He is also the coauthor of Contemporary Brand Management. He blogs for Psychology Today and Forbes, and maintains an active Twitter account (@ProfKurt). While teaching at Georgetown University between 2009 and 2017, Professor Carlson was director of the Georgetown Institute for Consumer Research and co-director of the McDonough School of Business Behavioral Research Lab, and he received the MSB Dean's Distinguished Faculty Research Award and the Decision Analysis Society's Publication Award.
Â
Ms. Kindler has worked on a variety of engagements, including intellectual property (IP) disputes, contract disputes, litigation matters related to securities and finance, false advertising allegations, and antitrust matters. In litigation matters, she has testified in deposition and at trial, and assisted in all phases of the litigation process, including discovery, expert reports, deposition, and trial preparation. In patent infringement matters, Ms. Kindler has analyzed claimed lost sales, claimed lost profits, and claimed reasonable royalty damages. In antitrust matters, she has assessed the competitive consequences of mergers, analyzed the competitive behavior of market participants, and estimated the impact of market power. Her work has also included the development of complex damages models, the analysis of statistical data, and the analysis of stock price movements. Ms. Kindler has been recognized as among the top economic experts for IP matters by Intellectual Asset Management (IAM) in the IAM Patent 1000, which identifies leading patent professionals around the globe. Prior to joining Analysis Group, she held positions with two economics consulting firms.
Professor Klausner teaches courses on corporate law, corporate governance, business transactions, and regulation of financial institutions. In recent years, most of his writing has been on corporate governance. He maintains a database on securities class actions and SEC enforcement actions, and has written papers and blog posts based on that database. In addition, Professor Klausner is currently writing a book and producing an online course called Deals: The Economic Foundations of Business Transactions.
Before beginning his academic career, Professor Klausner practiced law in Washington, DC, and Hong Kong. He was a White House fellow from 1989 to 1990, a law clerk for Judge David Bazelon on the United States Court of Appeals for the District of Columbia Circuit in 1981-82, and a law clerk for Justice William Brennan on the United States Supreme Court.
Professor Hochberg specializes in entrepreneurship, innovation, venture capital, and private equity, focusing on venture capital networks, entrepreneurial finance, seed accelerators, and corporate governance and compensation. Her research covers topics such as venture capital investment performance, the effects of networks and syndication on venture capital firms, and investment selection. Professor Hochberg has also explored the private equity investment choices of pension funds and other institutional investors, as well as broad-based option compensation in firms. She is the managing director of the Seed Accelerator Rankings Project, which publishes annual rankings of accelerator programs in the US. Prior to joining the Rice faculty, she held positions at the Kellogg School of Management at Northwestern University and the Samuel Curtis Johnson Graduate School of Management at Cornell University. She has taught courses on entrepreneurial finance and health care innovation, and has served as an associate editor of several finance journals, including the Journal of Empirical Finance and the Journal of Banking and Finance. Professor Hochberg is a recipient of the Ewing Marion Kauffman Prize Medal for Distinguished Research in Entrepreneurship, and a research associate at the National Bureau of Economic Research. Prior to joining academia, she was a software engineer at both established and startup technology companies, and co-founded a startup. Professor Hochberg is an active angel investor and advisor to startups, and a Landmark Fellow with Landmark Partners, a large private equity investor in secondary markets. She is a co-founder of Flywheel Innovation, a corporate innovation advisory firm.
Mr. Davis specializes in applying financial economics and data analysis to major litigation matters, with a focus on agricultural markets and pharmaceutical products. He has experience managing case teams, supporting academic affiliates and industry experts, and assisting clients through all phases of complex business litigation, including fact discovery, class certification, merits, trial, and settlement. Mr. Davis’s agricultural experience includes antitrust matters involving allegations of market power in animal protein markets, matters involving the presence of genetically modified products in US grain supplies, and matters involving international trade in agricultural products. His pharmaceutical work includes antitrust matters involving allegations of delayed generic entry, False Claims Act matters involving allegations related to the promotion of pharmaceuticals, and disputes pertaining to the commercial reasonableness of firm conduct.
Mr. Davis also has experience conducting economic research across a variety of industries, including financial services, agriculture, and pharmaceuticals, and analyzing issues related to commodity markets, futures prices, intellectual property and patents, industrial organization and antitrust law, and financial market infrastructure. He is a CFA charterholder.
Dr. Schatzki has a broad range of expertise in energy, environment, finance, and competition matters. He supports clients in a range of contexts, including strategic and financial advice, policy analysis, regulatory and rulemaking proceedings, and litigation.
Dr. Schatzki has deep experience in electricity, natural gas, petroleum, and renewable energy. His expertise in the electricity sector includes wholesale energy and capacity market design; utility regulation and ratemaking; economic impact analysis of new market rules, regulations, and generation and transmission investments; contract analysis and disputes; financial valuation; and options analysis. Dr. Schatzki has testified before US state and federal, as well as Canadian provincial, regulatory commissions. He has supported the analysis of alleged market manipulation and damages in high-profile litigations such as FERC v. Barclays and lawsuits following the California electricity crisis.
Dr. Schatzki works extensively on environmental economics, policy, and regulation. Recently, he has focused on the intersection of climate policy and energy markets, and disputes involving water resources and environmental contamination. His research has been published in distinguished energy- and environment-related publications, and he has provided research for prominent organizations such as the Electric Power Research Institute, the Edison Electric Institute, and the Federal Energy Regulatory Commission.
In finance and competition matters, Dr. Schatzki has worked with clients on litigation and non-litigation projects in many sectors, including energy, financial instruments, foreign exchange, insurance, airlines, and retail products.
Dr. Koehn specializes in applied microeconomics and finance. He has performed research and given economic testimony in antitrust, regulatory, tax, and other business litigation matters. The author of several publications on topics such as banking and finance, energy economics, and real estate, Dr. Koehn is a former adjunct associate professor of finance at the University of California, Irvine Graduate School of Management.
Mr. Case is an institutional investment expert with significant expertise in the areas of investment governance, asset allocation, portfolio design and implementation, and portfolio analysis and reporting. As a former institutional investment consultant, he worked with a wide range of global clients, including insurers, health care organizations, corporate and public plan sponsors, family offices, and other large asset pools. Mr. Case was a partner at Mercer Investment Consulting, a practice leader at Evaluation Associates, and a senior consultant at Rogerscasey. He led client service teams for large clients, including defined-benefit and defined-contribution plans, insurers and mutual fund families, and registered investment advisors and foundations. As an expert, Mr. Case has evaluated various process-related issues, including the process used to monitor an ERISA plan’s investment advisor and delegated fiduciary. He previously worked as an investment analyst for AT&T’s pension investment team, oversaw the sub-advisory and pension assets of AXA Equitable Life, and managed the strategic relationship team at Putnam Investments. He is a CFA charterholder.
Ms. Kirk Fair has extensive experience leading the development of economic and market analyses, assessing class certification and damages, evaluating consumer behavior, and testifying in a wide range of matters in the US, Canada, and Europe. She has been deeply involved in merger investigations and major antitrust litigation, as well as intellectual property (IP), false advertising, and tax matters. She also is a founder of the Analysis Group’s Surveys & Experimental Studies practice.
Ms. Kirk Fair specializes in evaluating competition and substitution patterns to examine potential competitive effects in mergers and “but-for” outcomes in antitrust litigation. She has significant analytical and testifying experience in cartel matters, notably in a number of prominent cases in the technology, consumer products, and financial services industries. She also has evaluated competition, pricing, and outputs in connection with merger investigations in the US, Canada, and the EU. In addition to having served as a compliance monitor for several years, she has supported the US Department of Justice (DOJ), the Federal Trade Commission (FTC), and the Canadian Competition Bureau (CCB) in a variety of merger investigations.
Ms. Kirk Fair also has particular expertise in the development, administration, and analysis of consumer surveys for use in antitrust, false advertising, and IP matters, as well as merger reviews and strategy cases. She has testified in arbitration, deposition, and trial in matters involving the design and implementation of consumer surveys, as well as the evaluation of opposing parties’ surveys and of statistical sampling and analyses. Her work has been used to support and critique damages models and to provide insights into the role of consumer choice in market definition.
Ms. Kirk Fair serves as a Vice-Chair to the American Bar Association (ABA) Antitrust Law Section’s Pricing Conduct Committee. She has received numerous awards for her accomplishments, including the W@ “40 in Their 40s: Notable Women Competition Professionals” and the Concurrences Antitrust Writing Award for her coauthored article “The Tyranny of Market Shares: Incorporating Survey-Based Evidence into Merger Analysis” (Corporate Disputes).
Professor Riddiough is best known for his work on real options, mortgage pricing and strategy, REITs, and land use regulation. He has served as an expert in numerous real estate-related matters, in which he has testified on appraisal and the value of distressed mortgages. Professor Riddiough has consulted to numerous organizations, including the US Department of Housing and Urban Development, GMAC, Wells Fargo, Coldwell Banker Commercial, The Equitable Life Assurance Society, and the State of Wisconsin Investment Board. He has published more than 40 scholarly articles. He has served on the boards of directors of several organizations, including ArCap REIT, EquiBase Capital Partners, and the American Real Estate and Urban Economics Association. Professor Riddiough is the recipient of best dissertation and best paper awards in real estate economics, and is a fellow at the Real Estate Research Institute and a past fellow at the Homer Hoyt Institute. He teaches courses in real estate finance, real estate capital markets, and microeconomics.
Professor Howell’s research focuses on entrepreneurship, private equity, fintech, and innovation. She is a research associate at the National Bureau of Economic Research, a fellow at the Asian Bureau of Finance and Economic Research, and a research fellow at the Institute for Private Capital’s Private Equity Research Consortium. She has testified before the US House of Representatives Ways and Means Committee and presented her work before the US Department of Energy, Senate Small Business Committee, Air Force, and Centers for Medicare & Medicaid Services. Professor Howell is the recipient of the AQR Asset Management Institute Young Researcher Award and the Kauffman Foundation Junior Faculty Research Fellowship, among other awards. She also serves as an associate editor of The Review of Financial Studies and a member of the advisory board to the American Female Finance Committee of the American Finance Association. Earlier in her career, Professor Howell was an energy security policy analyst and an energy consultant.
Mr. Deal leads the economic analyses in the Menlo Park, California office and helps coordinate the firm’s Insurance practice. He combines an economics and risk analysis background with many years of experience in economic, litigation, and management consulting. He serves as a testifying and consulting expert on a wide variety of matters, often involving economic and statistical analysis of large datasets. His work as an expert has covered a variety of practice areas, including antitrust, economic damages, class action matters, and business valuation. Mr. Deal’s experience includes work in health care, insurance, finance, technology, and many other industries. He has coauthored a number of book chapters and studies, including The Economic Effects of Federal Participation in Terrorism Risk with R. Glenn Hubbard, an Analysis Group academic affiliate, former chair of the President’s Council of Economic Advisers, and former dean of the Columbia Business School.
Professor Savitz focuses his epidemiological research on a wide range of public health issues, from the health effects of environmental agents in the workplace and community to a wide range of reproductive health outcomes. He has served as principal investigator on more than three dozen public health studies, including as one of three epidemiologists to evaluate the probable causal link between exposure to perfluorooctanoic acid and the development of certain diseases. Professor Savitz submitted an expert report on behalf of the plaintiffs at the class certification stage of a litigation matter and has consulted on a wide range of issues related to both environmental and reproductive epidemiology. He is the author of more than 300 journal articles and has edited or authored three books, including Interpreting Epidemiologic Evidence: Connecting Research to Applications. Professor Savitz has served as the editor of Epidemiology and the American Journal of Epidemiology, a member of the Epidemiology and Disease Control Study Section of the National Institutes of Health, president of the Society for Epidemiologic Research and the Society for Pediatric and Perinatal Epidemiologic Research, and North American regional councilor for the International Epidemiological Association. He is a member of the National Academy of Medicine and served as vice president for research at Brown University.
Dr. Signorovitch advises life sciences companies on data analytics for business critical research and decision making. He has broad experience leading the strategic development and implementation of analytics across the product life cycle, from early-phase clinical studies to market access and real-world evidence generation. Dr. Signorovitch’s practice areas span trial design, multi-stakeholder collaborations, natural history studies, regulatory interactions, health economic modeling, global reimbursement submissions, policy evaluation, real-world evidence development, individualized medicine, predictive analytics, and due diligence for acquisitions. He has particular expertise in developing and applying new methodologies to address health care research challenges, and in designing analytics platforms to enhance collaborative research and decision making. Dr. Signorovitch’s work has been used to inform clinical regulators and health care payers in US and global markets, published in peer-reviewed journals, and presented at clinical and economic research conferences. Prior to joining Analysis Group, Dr. Signorovitch was a research fellow at the Harvard-MIT Division of Health Sciences and Technology.
Professor Schoar is an expert in corporate finance, entrepreneurship, and organizational economics. Her research interests span from entrepreneurial finance to household finance and financial intermediation. Her research examines returns and capital flows in the venture capital industry, the financing of small and medium-sized enterprises and startup firms, and the role of consumer financial markets. Professor Schoar has served as an expert witness in cases involving commercial litigation and financial services. She is co-organizer of the Corporate Finance Working Group at the National Bureau of Economic Research, a former member of the Consumer Financial Protection Bureau’s Academic Research Council, and co-founder and scientific director of ideas42, a research lab on behavioral social science. She has published numerous articles and papers and received several awards for her research, including the Ewing Marion Kauffman Prize Medal for Distinguished Research in Entrepreneurship and the Brattle Group Prize in Corporate Finance for her paper “The Effects of Corporate Diversification on Productivity.” She has served as an associate editor of The Journal of Finance, the American Economic Journal: Applied Economics, and the Journal of Economic Perspectives. Professor Schoar’s work has been featured in The Economist, the Financial Times, The New York Times, and The Wall Street Journal.
Professor Chalmers is an expert in securities issues, including the trading behavior of investors and the pricing of securities. He has undertaken extensive research in municipal bonds, mutual funds, and trading costs, much of which has been published in leading peer-reviewed academic journals, including The Journal of Finance, the Journal of Financial Economics, and The Review of Financial Studies. In the area of mutual funds, his research with Professors Roger Edelen and Greg Kadlec discovered and explained the source of perverse incentives exploited by so-called market timers in their trading of mutual funds. He has also written about stale pricing problems in equity mutual funds and mutual fund transaction costs, and has collaborated with other mutual fund experts, such as Professors Daniel Bergstresser and Peter Tufano, on research analyzing fund performance across fund marketing channels. He also has extensive expertise in municipal bond pricing and valuation issues. Professor Chalmers' research has been cited in reports by the General Accounting Office and in several testimonies provided before the House Financial Services Committee, as well as being widely referenced in major media outlets. He has authored several expert reports and provided testimony before the US District Court of Wisconsin.
Dr. Lehmann specializes in applying microeconomics, econometrics, and statistical methods to complex litigation and regulatory investigations in the areas of antitrust and competition, labor and employment, and health care. In antitrust and competition matters, she has evaluated market definition, market power, and competitive dynamics, and analyzed class certification, liability, and damages issues in cases involving allegations of price-fixing, monopolization, and other anticompetitive conduct. Dr. Lehmann has extensive experience in labor market antitrust matters involving allegations of no-poach and wage-fixing agreements in a variety of industries. In the area of health care, she frequently collaborates with biostatisticians, epidemiologists, scientists, and regulatory experts in evaluating research and development processes and analyzing clinical trial, laboratory testing, registry, claims, and adverse events data in product liability litigations and patent and licensing disputes involving pharmaceuticals, medical devices, and chemical products.
Her employment and antitrust research has been published in the Journal of Economic Literature, The Journal of Human Resources, Labour Economics, Cartel & Joint Conduct Review, and Distribution, and her academic work has been cited in a number of leading media outlets, including Scientific American, Forbes, and BBC News. She serves as vice-chair of the Distribution and Franchising Committee of the American Bar Association (ABA) Antitrust Law Section. Prior to joining Analysis Group, Dr. Lehmann was an assistant professor of economics at the University of Houston, where she taught undergraduate and graduate courses in labor economics.
Dr. Kupiec’s research interests include quantitative financial risk measurement, systemic risk, deposit insurance, and the regulation of banking and financial services. At the American Enterprise Institute, he has authored several studies on systemic risk measurement and related regulations, bank stress testing, and bank regulations that follow financial crisis, including their impact on the wider economy. Dr. Kupiec was an associate director of the Division of Insurance and Research and director of the Center for Financial Research (CFR) at the Federal Deposit Insurance Corporation. In these roles, he oversaw research on bank risk measurement that contributed to the development and implementation of regulatory policies, including the international Basel III framework. He also served as chairman of the Research Task Force of the Basel Committee on Banking Supervision. Dr. Kupiec has worked at the International Monetary Fund, Freddie Mac, and J.P. Morgan, as well as for the Division of Research and Statistics at the Board of Governors of the Federal Reserve System. Prior to entering the financial services industry, Dr. Kupiec was an assistant professor of finance at North Carolina State University. He has published articles in several academic journals, including The Journal of Finance, the Journal of Financial Intermediation, the Journal of Financial Stability, the Journal of Financial Services Research, The Journal of Risk, and the Journal of Investment Management.
Mr. Decter specializes in the application of microeconomics, finance, and data analysis to complex securities and antitrust litigation and business strategy cases, most notably in matters related to residential mortgage-backed securities, collateralized debt obligations and credit default swaps, residential mortgage lending, mortgage reinsurance, commercial insurance, private equity, and payment cards. He has conducted damages analyses, and supported multiple experts in the areas of statistical sampling, loan and securities underwriting, damages, and loss causation.
Mr. Decter's business litigation experience focuses on finance matters in which he has managed large case teams and data sets in working with testifying experts. He supported academic affiliates in their examination of class certification issues related to commonality, predominance, and causation in In re Countrywide Financial Corp. Mortgage Marketing and Sales Practices Litigation, a mortgage marketing matter in which the plaintiff's motion for class certification was denied. Mr. Decter also supported an expert in filing a report on behalf of the defendants in New Jersey Carpenters Vacation Fund et al. v. The Royal Bank of Scotland Group plc et al., a case that marked the first major ruling on class certification among the numerous mortgage-backed securities actions pending in courts across the country at the time. He has also conducted damages analyses and worked with experts in numerous securities, antitrust, and intellectual property cases. Mr. Decter's business strategy engagements related to strategic pricing, portfolio management, and economic cost studies have spanned multiple industries, including pharmaceuticals, telecommunications, information technology, and manufacturing.
Prior to joining Analysis Group, Mr. Decter was a management consultant in the telecommunications industry. He also has several years of telecommunications industry experience in strategic planning, business development, and product management.
Professor Savoldelli is a finance and investment expert with over 25 years of experience analyzing and advising on a wide range of hedge fund-focused issues, including fund performance, portfolio construction, fund administration, due diligence, capital raising, and asset allocation. He served as a chief investment officer for four different institutions: Optima Fund Management, Merrill Lynch, Swiss Bank Corp. Asset Management, and Chase Manhattan Private Bank. In these roles, he oversaw over $80 billion in assets.
Over the course of his investment career, Professor Savoldelli’s responsibilities included selecting hedge funds for the allocation of investor assets, making asset allocation decisions, managing investment portfolios, developing investment policies, and overseeing investment manager adherence to investment strategy and policy. He has deep experience related to the challenging issues hedge fund managers may face, including those related to fiduciary duty, disclosure, liquidation, side-pockets accounts, and valuation of complex and illiquid assets. Additionally, he is knowledgeable about the roles and responsibilities of hedge fund service providers such as prime brokers, marketers, administrators, and auditors.
At Columbia Business School, Professor Savoldelli teaches a course in the M.B.A. program on the investment strategies employed by hedge funds and best practices for the operational aspects of hedge fund management, including fund administration selection, operational risk evaluation, and leverage risk. In addition, he is a contributing editor on Bloomberg Television, commenting on developments from a hedge fund perspective.
Professor Slottje has deep experience in both academia and economic consulting. An emeritus professor of economics at Southern Methodist University, he has been working in litigation consulting for more than three decades in senior positions with several international firms. He has worked with many leading law firms, testifying at deposition and trial in hundreds of prominent matters.
An economist and a statistician, Professor Slottje is an expert in the fields of labor economics, consumer demand, industrial organization, and statistics and econometrics, allowing him to bring a unique perspective and skill set to his consulting assignments. He has published more than 150 journal articles and more than a dozen books, and has been ranked among the world’s top three scholars in applied econometrics based on his publishing record in the field. Professor Slottje is a member of the American Economic Association, the American Statistical Association, and The Econometric Society.
Professor Kahn’s research interests include brand management and loyalty, consumer choice and decision making, price promotions, and retailing. She has served as an expert witness and testified at deposition in numerous matters. Professor Kahn is the author of Global Brand Power: Leveraging Branding for Long-Term Growth and The Shopping Revolution: How Retailers Succeed in an Era of Endless Disruption Accelerated by COVID-19, and coauthor of Grocery Revolution: The New Focus on the Customer. She has published more than 70 articles in leading academic journals. She is a former area editor of Marketing Science, the Journal of Consumer Research, the Journal of Consumer Psychology, and the Journal of Marketing, and has served on the editorial boards of the Journal of Marketing, the Journal of Marketing Research, Marketing Science, the Journal of Consumer Research, the Journal of Behavioral Decision Making, and Marketing Letters. Prior to joining The Wharton School, Professor Kahn was on the faculty of the UCLA Anderson School of Management. She also served as dean of the Miami Herbert Business School.